

**SYNTHETIC STUDIES ON SIPHONARIID POLYPROPIONATES:
THE TOTAL SYNTHESIS OF SIPHONARIN B, BACONIPYRONE A,
BACONIPYRONE C, AND THEIR PUTATIVE COMMON PRECURSOR**

A Thesis Submitted to the
College of Graduate Studies and Research
In Partial Fulfillment of the Requirements
For the Degree of Doctor of Philosophy
In the Department of Chemistry
University of Saskatchewan

by
Garrison Eduard Beye

PERMISSION TO USE

In presenting this thesis in partial fulfillment of the requirements for a Postgraduate degree from the University of Saskatchewan, I agree that the Libraries of the University may make this thesis freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised the thesis work, or in their absence, by the Head of the Department, or the Dean of the College in which the thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition will be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in this thesis.

Requests for permission to copy or to make other use of material in this thesis in whole or in part should be addressed to:

**The Head
Department of Chemistry
University of Saskatchewan
110 Science Place
Saskatoon, SK, S7N 5C9
CANADA**

ACKNOWLEDGEMENTS

I would like to Prof. Dale Ward for being my mentor and teacher. Your support, constant encouragement, and total engagement in my education and project made this thesis possible. I truly appreciate all of the time you spent with me discussing reactions I performed, problems I encountered and overcame, and pouring over countless NMR spectra with me. Words cannot express my gratitude.

A big thank you is due to former Ward group members: Drs. Mike Souweha, Jianhang Shen, and Sandip Pardeshi and Ms. Idralyn Alarcon. You took it upon yourselves to teach me the basics of being a graduate student and conduct my orientation and indoctrination into the group. Drs. Martin Gillis and Vishal Jheengut are acknowledged for valuable discussions and never hesitating to provide expert opinion and suggestions. Drs. Clinton Lund, Edwige Otero, Jörg Schachner made my stay enjoyable – the end of the week has not been the same since the three of you left Saskatoon. My junior colleagues and lab mates: Mr. Mohammed (Pooyan) M. Zahedi, Ms. Fabiola Becerril-Jiménez, and Mr. Athanasios (Thano) Karagiannis are acknowledged for our many conversations, your friendship, and making the lab a great place to learn and work. I wish you all luck and success.

Dr. Dev Singh, Dr. Nancy Boman, and Mrs. Jamie Robinson are also acknowledged for their encouragement to pursue my goals and dreams. You gave me the tools to succeed. The years we spent together will continue to be fondly remembered. Thank you!


My parents: Ed, Susan, Glenn, and Mary Ellen are thanked for their support and encouragement.

Last, but certainly not least, without the love and support of my wife, Debbie, and my daughter, Hannah, none of this would have been possible. Thank you for your understanding, commitment, and your unwavering belief in me. Papa is done now – let's go play.

“Always finish what you start.” – A father to his son.

ABSTRACT

Siphonaria zelandica, a pulmonate mollusk, has been the subject of many natural product isolation studies by several, independent research groups. These studies have yielded several polypropionate structures (e.g. **4**, **6**, **8**, and **10**), which, upon careful inspection, were proposed to be related. There has been speculation that none of these isolated structures (**4**, **6**, **8**, and **10**) are biosynthetic products, but are artifacts of isolation. Instead, it has been proposed that an unstable, acyclic precursor, such as **14/15** is the biosynthetic product produced by this mollusk; the putative acyclic precursor has not been isolated or synthesized. None of the synthetic studies on this series of compounds have attempted to address the potential relationships between these structures or speak to their status as natural products.



This work describes the enantioselective synthesis of the putative acyclic precursor **14/15** and its isomerization to siphonarin B (**4**). This was the first enantioselective synthesis of siphonarin B (**4**). Siphonarin B (**4**) was shown to readily undergo a retro-Claisen rearrangement to afford baconipyronone C (**6**) and concurrently undergo a retro-Claisen rearrangement/aldol cascade to provide baconipyronone A (**6**). This was the first total synthesis of baconipyronone A (**6**) through an unprecedented retro-Claisen rearrangement/aldol cascade and the first total synthesis of baconipyronone C (**8**) by a “biomimetic” route versus the classical esterification route. The fourth compound in this series of potentially related compounds, caloundrin B (**10**), was never observed despite a careful search of each reaction crude where it may have been present.

The relationships between these compounds were probed and it was found, that under the conditions examined, the putative acyclic precursor **14/15** is not a biosynthetic product. Instead, siphonarin B (**4**) or perhaps caloundrin B (**10**), are the most likely biosynthetic products of the mollusk. Baconipyronone C (**8**) is not a precursor of baconipyronone A (**6**). The processes responsible for baconipyrones A (**6**) and C (**8**) are irreversible. As had been previously hypothesized, baconipyrones A (**6**) and C (**8**) are most likely artifacts of isolation (i.e., not natural products). The missing link in this series of compounds is caloundrin B (**10**) and its isomerization and rearrangement behavior.

TABLE OF CONTENTS

LIST OF TABLES	ix
LIST OF FIGURES	x
LIST OF SCHEMES.....	xii
LIST OF ABBREVIATIONS.....	xv
INTRODUCTION	1
1.1 Introduction to structures, relationships, isolation, and biosynthesis	1
1.1.1 Siphonariid mollusks and examples of isolated structures	1
1.1.2 Proposed relationships between siphonariid polypropionates	3
1.1.3 Isolation and structure determination.....	8
1.1.4 Siphonariid polypropionate biosynthesis	9
1.2 Synthetic studies on these related siphonariid polypropionates	13
1.2.1 Synthetic studies on baconipyrone C (6): establishment of absolute configuration	13
1.2.2 Total syntheses of baconipyrone C (8)	15
1.2.2.1 Paterson's synthesis	16
1.2.2.2 Hoveyda's synthesis.....	19
1.2.2.3 Yadav's synthesis.....	24
1.2.2.4 Synthetic comparison and summary	27
1.2.3 Synthetic studies on baconipyrone A (6)	29
1.2.3.1 Vogel's synthetic study on the cyclohexanone subunit (87)	30
1.2.3.2 Plumet's synthetic study towards the cyclohexanone subunit (87)	31

1.2.4 Synthetic studies on siphonarin B (4)	33
1.3 Conclusions	36
RESULTS AND DISCUSSION	38
2.1 Research objectives	38
2.2. Target selection and synthetic considerations	39
2.3 The Thiopyran Route to Polypropionates	41
2.4 Trioxaadamantane ring system synthesis and isomerization: model study	45
2.4.1 Muamvatin's trioxaadamantane ring system and isomerization	49
2.4.1.1 Structure determination of (\pm)- 143 , (\pm)- 153 , (\pm)- 156 , and (\pm)- 168	53
2.4.2 Caloundrin B's trioxaadamantane ring system and isomerization	54
2.4.2.1 Structure determination of 138 , 142 , 150 , 152 , 154 , 156 , and 167	58
2.4.3 Trioxaadamantane ring system comparison and conclusions	63
2.5 γ -Pyrone formation model study	66
2.5.1 γ -Pyrone model study conclusions	71
2.6 Retrosynthetic analysis	72
2.7 Synthesis of key aldehyde	73
2.7.1 γ -Pyrone formation	73
2.7.2 Hydration of pyrone-dihydropyrone 202	81
2.7.3 Formal synthesis of baconipyrone C (8)	90
2.7.4 Aldehyde 218 synthesis	93
2.8 Total synthesis of siphonarin B (4) and baconipyrone A (6) and C (8)	96
2.8.1 Carbon skeleton completion: total synthesis of the putative common precursor ..	96
2.8.2 Attempted trioxadithiapentacycle formation	98

2.8.3 Alternative avenues of investigation.....	99
2.8.4 Synthesis and isomerization of the putative common precursor.....	103
2.4.8.1 Conclusions on the synthesis and isomerization of the putative common precursor 14/15	113
2.8.5 Investigation of alternative conditions	114
2.8.5.1 Conclusion of the investigations into alternative conditions	127
2.9 Conclusions	127
2.10 Suggestions for future research.....	130
EXPERIMENTAL	132
3.1 General methods	132
3.2 Spectral data.....	133
3.3 Materials	134
3.4 Computational procedures	134
REFERENCES	220

LIST OF TABLES

Table 2.1 Isomerization studies on (\pm)- 143	52
Table 2.2 Isomerization studies on 142	57
Table 2.3 γ -Pyrone 177 optimization studies	70
Table 2.4 Dehydration and deprotection of 199	80
Table 2.5 Pyrone-dihydropyrone 202 optimization studies	81
Table 2.6 ^1H NMR (CDCl_3) comparison of 213 , 214 and 39	86
Table 2.7 ^{13}C NMR (CDCl_3) comparison of 213 , 214 and 39	87
Table 2.8 Hydration of 210	88
Table 2.9 Key baconipyrone C (8) intermediates synthesis comparison	93
Table 2.10. ^1H NMR (CDCl_3) comparison of natural and synthetic siphonarin B (4).....	108
Table 2.11. ^{13}C NMR (CDCl_3) comparison of natural and synthetic siphonarin B (4)	109
Table 2.12. ^{13}C NMR (CDCl_3) comparison of baconipyrone C (8),	112
14- <i>epi</i> -baconipyrone C (235), and 10- <i>epi</i> -baconipyrone C (236)	112
Table 2.13. ^1H NMR (CDCl_3) comparison of natural and synthetic baconipyrone C (8)....	122
Table 2.14. Comparison of ^{13}C NMR spectra of natural and synthetic baconipyrone C (8)	123
Table 2.15. ^1H NMR (CDCl_3) comparison of natural and synthetic baconipyrone A (6) ...	124
Table 2.16. ^{13}C NMR (CDCl_3) comparison of natural and synthetic baconipyrone A (6) ..	125

LIST OF FIGURES

Figure 1.1 Siphonariid polypropionate classification	2
Figure 1.2 Potentially related siphonariid decapropionates	3
Figure 1.3 Proposed formation of baconipyrones A (8) and C (8)	4
Figure 1.4 Alternative contiguous carbon skeleton cyclization modes	5
Figure 1.5 Destabilizing <i>syn</i> -pentane interactions	6
Figure 1.6 Biosynthetic possibilities	9
Figure 1.7 Biosynthetic studies on denticulatin (1)	10
Figure 1.8 Biosynthetic studies on the siphonarins.....	11
Figure 1.9 Biosynthetic model	12
Figure 1.10 Baconipyrene C (8) synthetic strategy	16
Figure 1.11 Baconipyrene C (8) synthetic comparison	29
Figure 1.12 Disconnection of baconipyrene A (6)	30
Figure 2.1 Research objectives	39
Figure 2.2 Caloundrin B (10) structural features	40
Figure 2.3 The Thiopyran Route to Polypropionates.....	42
Figure 2.4 Model for stereoselectivity in aldol reaction of 129 and 130 with (\pm)- 116	45
Figure 2.5 Natural products containing a trioxaadamantane ring system.....	46
Figure 2.6 ORTEP plot of (\pm)- 143	51
Figure 2.7 Structure determination of (\pm)- 168 , (\pm)- 143 , and (\pm)- 151	53
Figure 2.8 ORTEP plot of 167	54
Figure 2.9 Structure determination of 142 , 150 , and 167	58

Figure 2.10 Structure determination of 138	59
Figure 2.11 Structure determination of 152	60
Figure 2.12 Structure determination of 156	62
Figure 2.13 B3LYP/6-31G** energies (kJ/mol) relative to 151	64
Figure 2.14 Illustrations of the preferred conformations of 140 , 141 , and 149 , as determined by computational studies	65
Figure 2.15 Retrosynthetic analysis of caloundrin B (10)	72
Figure 2.16 Structure elucidation of β - 199	76
Figure 2.17 Proposed mechanism for the formation of pyrone-dihydropyrone 202	78
Figure 2.18 Electrophile addition to dihydropyran 211	83
Figure 2.19 Considerations for the required aldol coupling of 222 and 218	96
Figure 2.20 NOE results for 228	102
Figure 2.21 ^1H NMR spectrum of the putative common precursor	106
Figure 2.22 Structure determination of 237	117
Figure 2.23 Proposed retro-Claisen rearrangement and retro-Claisen rearrangement/aldol cascade pathways	120
Figure 2.24 Synthetic summary	128
Figure 2.25 Proposed continuation of this research	131

LIST OF SCHEMES

Scheme 1.1	14
Scheme 1.2	17
Scheme 1.3	18
Scheme 1.4	19
Scheme 1.5	20
Scheme 1.6	22
Scheme 1.7	23
Scheme 1.8	25
Scheme 1.9	26
Scheme 1.10	27
Scheme 1.11	31
Scheme 1.12	32
Scheme 1.13	34
Scheme 1.14	35
Scheme 2.1	44
Scheme 2.2	47
Scheme 2.3	48
Scheme 2.4	49
Scheme 2.5	50
Scheme 2.6	55
Scheme 2.7	66

Scheme 2.8	68
Scheme 2.9	74
Scheme 2.10	75
Scheme 2.11	77
Scheme 2.12	82
Scheme 2.13	84
Scheme 2.14	84
Scheme 2.15	90
Scheme 2.16	91
Scheme 2.17	92
Scheme 2.18	94
Scheme 2.19	95
Scheme 2.20	95
Scheme 2.21	98
Scheme 2.22	99
Scheme 2.23	100
Scheme 2.24	101
Scheme 2.25	104
Scheme 2.26	107
Scheme 2.27	111
Scheme 2.28	116
Scheme 2.29	117
Scheme 2.30	118

Scheme 2.31	126
--------------------------	-----

LIST OF ABBREVIATIONS

α	observed optical rotation
$[\alpha]_D$	specific rotation (expressed without units; the actual units, (deg·mL)/(g·dm), are understood)
Ac	acetyl
ap	apparent (spectral)
aq	aqueous
Ar	aryl
atm	atmosphere(s)
Bn	benzyl
BORSM	based on recovered starting material
bp	boiling point
br	broad (spectral)
Bu, ⁿ Bu	normal (primary) butyl
^t Bu	<i>tert</i> -butyl
°C	degrees Celsius
calcd	calculated
Chx	cyclohexyl
CI	chemical ionization
cm ⁻¹	wavenumber(s)
CN	nitrile (as in acetonitrile (CH ₃ CN))
concd	concentrated
COSY	correlation spectroscopy

Cp	cyclopentadienyl
CSA	camphorsulfonic acid
δ	chemical shift in parts per million
d	day(s); doublet (spectral); deci
<i>d</i>	density
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
DDQ	2,3-dichloro-5,6-dicyano-1,4-benzoquinone
de	diastereomeric excess
DEPT	distortionless enhancement by polarization transfer
DEIPS	diethylisopropylsilyl ether
dil	dilute
DIBAL-H	diisobutylaluminum hydride
DIPT	diisopropyltartrate
DIPEA	diisopropylethyl amine
DMAP	4-(<i>N,N</i> -dimethylamino)pyridine
DME	1,2-dimethoxyethane
DMF	dimethylformamide
DMP	Dess-Martin periodinane
DMSO	dimethyl sulfoxide
dr	diastereomeric ratio
DRIFT	diffuse reflectance infrared Fourier transform spectroscopy
ee	enantiomeric excess
<i>ent</i>	a prefix used to denote enantiomer of

equiv	equivalents
er	enantiomeric ratio
ESI	electrospray ionization
Et	ethyl
FAB	fast atom bombardment
FCC	flash column chromatography
g	gram(s); prefix to NMR abbreviation denoting gradient-selected (e.g., gCOSY, gHSQC)
h	hour(s)
HMBC	heteronuclear multiple bond correlation
HMDS	hexamethyldisilazane
HMPA	hexamethylphosphoric triamide (hexamethylphosphoramide)
HRMS	high-resolution mass spectrometry
HSQC	heteronuclear single quantum correlation
Hz	hertz
IB	2-iodobenzoic acid
IBA	2-iodosobenzoic acid
IBX	2-iodoxybenzoic acid
Im	Imidazole
IPC	isopinocampheyl
IR	infrared
<i>J</i>	coupling constant (in NMR spectrometry)
J	Joule(s)
k	kilo

K	kelvin (absolute temperature)
L	liter(s)
LDA	lithium diisopropylamide
lit.	literature (abbreviation used with period)
LRMS	low-resolution mass spectrometry
μ	micro
m	multiplet (spectral); meter(s); milli
M	molar (moles per liter); mega
M^+	parent molecular ion
max	maximum
Me	methyl
Mes	mesityl (2,4,6-trimethylphenyl)
MHz	megahertz
min	minute(s); minimum
mM	millimolar (millimoles per liter)
MMFF	Merck Molecular Force Field
MMPP	monoperoxyphthalic acid magnesium salt
mol	mole(s); molecular (as in mol wt)
MOM	methoxymethyl
mp	melting point
MS	mass spectrometry
MW, mol wt	molecular weight
m/z	mass-to-charge ratio

N	normal (equivalents per liter)
nm	nanometer(s)
NMR	nuclear magnetic resonance
NOE	nuclear Overhauser effect
obsd	observed
ORTEP	Oak Ridge Thermal Ellipsoid Plot
Pd/C	palladium on carbon
Ph	phenyl
Piv	pivaloyl
PKS	polyketide synthetase
PMA	phosphomolybdic acid
PMB	p-methoxybenzyl
ppm	part(s) per million
PPTS	pyridinium <i>para</i> -toluenesulfonate
Pr	propyl
ⁱ Pr	isopropyl
pt	point, data point (spectral)
PTLC	preparative thin layer chromatography
q	quartet (spectral)
<i>rac</i>	racemic, racemization
Ref, ref	reference
rel	relative
rt	room temperature

s	singlet (spectral); second(s)
SAM	S-adenosyl methionine
t	triplet (spectral)
TASF	tris(dimethylamino)sulfonium difluorotrimethylsilicate
TBAF	tetrabutylammonium fluoride
TBDMS, TBS	<i>tert</i> -butyldimethylsilyl
temp	temperature
TES	triethylsilyl
Tf	trifluoromethanesulfonyl (triflyl)
THF	tetrahydrofuran
TIPS	triisopropylsilyl
TLC	thin-layer chromatography
TMS	trimethylsilyl
TOF	time-of-flight (in mass spectrometry)
Ts	tosyl ($p\text{-CH}_3\text{C}_6\text{H}_4\text{SO}_2$)
UV	ultraviolet
vis	visible
vol	volume
v/v	volume per unit volume (volume-to-volume ratio)
wt	weight
w/w	weight per unit weight (weight-to-weight ratio)

INTRODUCTION

1.1 Introduction to structures, relationships, isolation, and biosynthesis

1.1.1 Siphonariid mollusks and examples of isolated structures

Siphonariid mollusks are non-descript animals found in temperate and tropical ocean intertidal zones – the area of coastline dry at low tide and underwater at high tide – throughout the world. These limpet-like creatures, sometimes referred to as false limpets, are superbly adapted to their environment with both a primitive lung and gills and may represent an evolutionary link between land and sea mollusks.¹ Of all the pulmonates,ⁱ the siphonariids are considered the most primitive.²

Despite their non-descript outward appearance and primitive evolutionary status, these organisms are credited with being the grand architects of an incredibly diverse array of complex polypropionate natural products.³ The polypropionates produced by siphonariid mollusks have been classified into three groups (**Figure 1**)⁴: simple (cf. denticulatin A (**1**),⁵ and muamvatin (**3**),⁶ α -pyrones (cf. diemenensin (**2**)⁷), and γ -pyrone containing (cf. siphonarins A (**5**)⁸ and B (**4**)⁸ and baconipyrones A - D (**6 - 9**)⁴). Interestingly, these animals produce the same polypropionate secondary metabolite profile regardless of geographical location.⁹

ⁱ A subclass of gastropod, comprising one half of all mollusk species.




Figure 1.1 Siphonariid polypropionate classification

Upon careful inspection and analysis, the rich structural diversity can be attributed to varying intramolecular cyclization events that occur along the heavily oxygenated carbon backbone.^{2, 10} For example, the production of γ -pyrones from 1,3,5-triones, dihydro-4-pyrones and tetrahydro-2-hydroxypyrones from 5-hydroxy-1,3-diones, and spiroacetals from 9-hydroxy-1,5-diones. It has been suggested that some of the polypropionate secondary metabolites produced by the siphonariids may be related through unstable acyclic precursors that undergo different cyclization events. Such a connection was proposed for several

seemingly different γ -pyrone-containing decapropionate metabolites: siphonarin B (**4**), baconipyrones A (**6**) and C (**8**) and caloundrin B (**10**)⁹ (**Figure 1.2**).¹¹




Figure 1.2 Potentially related siphonariid decapropionates

1.1.2 Proposed relationships between siphonariid polypropionates

The baconipyrones A (**8**) and C (**6**) are rare examples of polypropionate natural products containing a non-contiguous carbon skeleton.^{4, 11, 12} Their formation was originally proposed to occur through a rearrangement of the parent decapropionate, most likely siphonarin B (**4**), which was contemporaneously co-isolated (**Figure 1.3**).⁴




Figure 1.3 Proposed formation of baconipyrones A (8) and C (8)

Caloundrin B (10) and siphonarin B (4) were proposed to be related via alternative cyclization modes, attributable to the orientation of the C-8 methyl (C-6,8 *syn* vs. C-6,8 *anti*); C-8 is flanked by two carbonyls and is expected to be readily epimerizable (**Figure 1.4**).^{9, 11}




Figure 1.4 Alternative contiguous carbon skeleton cyclization modes

It was proposed that the configuration at C-8 controls the cyclization preference because of destabilizing syn-pentane interactions between the C-8 and C-10 methyl groups in **13** and the C-6 and C-8 methyl in **16** (i.e., the alternative cyclization modes presented in **Figure 1.4**).¹¹ These destabilizing interactions are highlighted in structures **13a** and **16a** (**Figure 1.5**).




Figure 1.5 Destabilizing *syn*-pentane interactions

These analyses led to a refinement in the hypothesis surrounding the formation and relationships between these compounds (**4**, **6**, **8**, and **10**) and, as a result of this analysis, significant doubt was placed upon their natural product status. It was proposed that siphonarin B (**4**) and caloundrin B (**10**) may be formed non-enzymatically (i.e., formation and abundance governed by each compound's relative stability) from an unstable acyclic precursor, such as **14** and **15**. However, even the unstable acyclic precursors **14** and **15** may not be real natural products because the γ -pyrone moiety was suggested to be a result of isolation.^{ii, 3, 11}

ⁱⁱ Spontaneous formation, during isolation, of the γ -pyrone from a 1,3,5-triketone is unlikely (*vide infra*).

Additional doubt about the natural product status of some of these structures is presented by baconipyrone C (**6**). This structure has been detected numerous times in independent isolation studies,^{4, 12} as would be expected if it were biosynthetically produced by the mollusk. However, a later, “careful”, reexamination of *S. baconi*^{iii, 13} extracts by Garson, based on the notion that these structures may be artifacts of isolation, found no trace of baconipyrone C (**8**); siphonarin B (**4**), as expected, was isolated from this study.¹² It was proposed that a delicate precursor, susceptible to a retro-Claisen rearrangement (cf. **11**, **Figure 1.3**), might be the real natural product and that baconipyrone A (**6**) and C (**8**) might owe their origin to events transpiring outside the organism. Retro-Claisen rearrangements have been shown to occur in similar systems,^{12, 14-17} but a “biomimetic” synthesis of baconipyrone C (**8**) has not been demonstrated and retro-Claisen rearrangement/aldol cascades leading to baconipyrone A (**6**), or even a simple model compound, appears to be unprecedented.

Despite the number of observations supporting the aforementioned hypotheses, there remains a significant, unanswered problem regarding the origin of this series of compounds. If their formation was non-enzymatic (i.e., under thermodynamic control), then it should be expected that siphonarin B (**4**) and caloundrin B (**10**) would be isolated in a ratio reflecting their relative stabilities. Siphonarin B (**4**) has been isolated numerous times in independent studies by several different research groups.^{4, 8, 9} Caloundrin B (**10**), however, has been observed and isolated just once.⁹ Realistically, caloundrin B (**10**) should have been observed on more than just this one occasion given the number of isolation studies that these mollusks have “participated” in.

ⁱⁱⁱ *S. baconi* is synonymous with *S. zelandica*.

The same arguments apply to siphonarins A (**5**) and baconipyrones B (**7**) and D (**9**). These compounds are C-20 desmethyl analogues of **4**, **6**, and **8**, respectively. No C-20 desmethyl compound analogous to caloundrin B (**10**) has been isolated.

1.1.3 Isolation and structure determination

Siphonarins B (**4**) was the first of these related polypropionates to be isolated and characterized.⁸ The sample originated from a collection of *S. zelandica* obtained from New South Wales, Australia in an approximate yield of 0.05 mg/animal. The structure was determined by NMR comparison to siphonarins A (**5**) whose structure and relative configuration was unambiguously determined by X-ray diffraction studies.

Baconipyrones A (**6**) and C (**8**) were later isolated and characterized from a collection of *S. Baconi* obtained near Melbourne, Australia in an approximate yield of 0.05 and 0.016 mg/animal, respectively.⁴ Co-isolated with baconipyrones A (**6**) and C (**8**) were siphonarins A (**5**) and baconipyrones B (**7**), and D (**9**). The structures of baconipyrones A (**6**) and C (**8**) were determined on the basis of NMR comparison and biosynthetic considerations to baconipyrene B (**7**), whose structure and relative configuration was unambiguously determined by X-ray diffraction studies.

Caloundrin B (**10**) was the last of these four related structures to be isolated.⁹ It originated from a sample of *S. zelandica* obtained from Shelley and Kings Beach, Caloundra, Australia in an approximate yield of 0.01 mg/animal and was the only structure in this series of compounds that was not isolated and characterized by Faulkner and co-workers. Expecting to find only siphonarins A (**5**) and B (**4**), Garson and co-workers described the discovery of this new metabolite (co-isolated with **4** and **5**) as surprising. The structure was determined by extensive NMR studies and comparison to related structures. During the course of the NMR

studies to determine the structure, caloundrin B (**10**) decomposed.^{iv} Attempts, under unspecified conditions, to generate more caloundrin B (**10**) from siphonarin B (**4**) were unsuccessful.

1.1.4 Siphonariid polypropionate biosynthesis

There are two conceivable possibilities for the biosynthesis of siphonariid polypropionates: direct condensation of propionate units (pathway A, **Figure 1.6**) or through a polyacetate chain and methylation by S-adenosyl methionine (pathway B, **Figure 1.6**).^{1, 3} Examples of both possibilities are well documented in the literature for other organisms known to produce polypropionates.¹⁸




Figure 1.6 Biosynthetic possibilities

Garson and Faulkner, as part of their long standing investigation into the polypropionates produced by siphonariid mollusks, investigated the biosynthesis of

^{iv} Isolation included aqueous extraction and extensive chromatography. Decomposition occurred in the NMR tube, following isolation.

denticulatin (**1**) (**Figure 1.7**).¹⁸ This investigation was the first reported effort into establishing the biosynthetic origin of the compounds produced by siphonariid mollusks. Through injection of sodium [1-¹⁴C]propionate into the foot muscle of *S. denticulata* and by transdermal uptake of sodium [1-¹⁴C]propionate from inoculated aquarium water, it was shown conclusively that the biosynthesis of denticulatin (**1**) is of propionate origin (i.e., pathway A, **Figure 1.6**).




Figure 1.7 Biosynthetic studies on denticulatin (**1**)

An intriguing problem in the biosynthesis of the siphonariid polypropionates is the direction of chain growth, which cannot be simply determined by inspection due to a decarboxylation event that occurs during biosynthesis. Two modes of chain extension are possible in that chain propagation may proceed from C-1 to C-19 or in the reverse manner. Garson et al. investigated this issue in the siphonarins (**4** and **5**), concurrent to confirming the propionate origin of these molecules (i.e., verification of the previous conclusion regarding siphonariid polypropionate biosynthesis).¹⁹




Figure 1.8 Biosynthetic studies on the siphonarins

Garson reasoned that the problem could be solved by determining the origin of C-19 in siphonarinarin A (**5**) by “feeding” experiments (via injection in the foot muscle of *S. zelandica*) of sodium $[1-{}^{14}\text{C}]$ propionate (**Figure 1.8**). Depending on direction of chain growth, C-19 would either show ${}^{14}\text{C}$ labeling from incorporation of sodium $[1-{}^{14}\text{C}]$ propionate or not; siphonarinarin A (**5**) is constructed through condensation of 9 propionate units and 1 acetate unit.^v In addition to confirming the propionate origin of **4** and **5**, it was definitively shown that there was no incorporation of ${}^{14}\text{C}$ in any of the acetate-related degradation compounds isolated following degradation experiments. Thus, the direction of chain growth was determined to be C-19 to C-1. By analogy, siphonarinarin B (**4**) was also reasoned to grow C-19 to C-1. These studies also confirmed the *de novo* biosynthesis of these compounds as opposed to bioaccumulation from food sources.¹

Garson, Goodman, and Paterson rationalized that the other siphonariid polypropionate metabolites should be assembled in a similar manner on the basis that the

^v Siphonarinarin B (**4**) is constructed from 10 propionate units.

isolated structures are related.¹¹ A comparison of the acyclic structures of the siphonarins B (4), muamvatin (3), and denticulatin (1) all show a common tetrapropionate motif near the terminus of the chain that shares similarity with Cane, Celmer, and Westley's model²⁰ for polyether antibiotic biogenesis (**Figure 1.9**). This observation suggests a genetic commonality between bacteria and the siphonariids, but, to date, no common proteins have been disclosed.^{2, 11, 19}





Figure 1.9 Biosynthetic model

1.2 Synthetic studies on these related siphonariid polypropionates

1.2.1 Synthetic studies on baconipyrone C (**6**): establishment of absolute configuration

A key unresolved issue in the study of baconipyrone C (**6**), and of all these related compounds, was the determination of absolute configuration. Paterson elected to tackle this issue through the synthesis of a known siphonariid polypropionate degradation product, carboxylic acid **40** (the known degradation product is actually *ent*-**40**, *vide infra*) (**Scheme 1.1**).²¹



a) TiCl_4 , $(i\text{Pr})_2\text{EtN}$, Et_2CO b) TBSOTf , 2,6-lutidine c) TiCl_4 , $(i\text{Pr})_2\text{EtN}$, EtCHO d) HF , MeCN e) DMP
 f) $(\text{COCl})_2$, DMSO g) H_2 , Pd/C h) $\text{Sn}(\text{OTf})_2$, Et_3N i) Sml_2 , CH_3CHO j) $\text{PMBOC}(\text{Cl}_3)=\text{NH}$, TfOH
 k) $(t\text{Bu})_4\text{NF}$ l) K_2CO_3 , MeOH m) $(\text{COCl})_2$, DMSO , Et_3N n) NaClO_2 , NaH_2PO_4 , $(\text{CH}_3)_2\text{C}=\text{CCHCH}_3$

Scheme 1.1

The carbon skeleton of the carboxylic acid fragment was constructed via three aldol reactions. Starting from Roche ester derivative **31**,^{vi, 22} two unselective titanium (IV)-mediated aldol reactions produced the carbon skeleton required to access a key intermediate, γ -pyrone aldehyde **35**. Subjection of diol **33** to DMP oxidation followed by Yamamura's γ -pyrone conditions^{23, 24} gave the desired γ -pyrone **34** in moderate yield. Hydrogenolysis, followed by oxidation gave the reportedly sensitive (i.e., prone to racemization) γ -pyrone aldehyde **35**.

To complete the carbon skeleton of the target (**40**), a Sn(II)-mediated aldol reaction²⁵ between γ -pyrone aldehyde **35** and **36**^{vii, 21} was conducted. The oxidation states of the aldol adduct were then reversed in addition to setting the last stereogenic center via a Evans-Tishchenko^{26, 27} reduction. The orthogonal protecting groups were removed and PMB diol **39** was oxidized over a two (2) step sequence to the corresponding keto-acid. Finally, the PMB group was removed via hydrogenolysis to give carboxylic acid **40**.

The carboxylic acid matched the reported spectroscopic data⁸ for this fragment and the corresponding fragment of baconipyronone C (**8**).⁴ However, the optical rotation (synthetic:²¹ $[\alpha]_D +115$ (*c* 0.5, CH₂Cl₂)) was not of the same sign as the isolated material (natural:⁸ $[\alpha]_D -87$ (*c* 0.052, CH₂Cl₂)). This suggested that the siphonariid polypropionates were enantiomeric to carboxylic acid **40** (i.e, *ent-40*).

1.2.2 Total syntheses of baconipyronone C (**8**)

To date, there are two reported syntheses of baconipyronone C (**8**)^{28, 29} and one report on the enantioselective synthesis of the unnatural antipode (*ent-8*).³⁰ All three synthetic efforts

^{vi} Available in 3 steps, 88% overall yield from methyl (*R*)-3-hydroxy-2-methylpropionate.

^{vii} Available in 3 steps, 86% overall yield from methyl (*S*)-3-hydroxy-2-methylpropionate.

were designed around disconnection at the ester linkage, but featured significantly different approaches and methodologies to construct each fragment (**41** and **42**) (**Figure 1.10**). No attempt was made in subsequent syntheses to improve on the coupling strategy and final steps pioneered in the first.²⁸





Figure 1.10 Baconipyrrone C (**8**) synthetic strategy

1.2.2.1 Paterson's synthesis

Paterson approached the total synthesis of baconipyrrone (**8**) based on his earlier work in constructing carboxylic acid **40** (**Scheme 1.1**).²¹ Knowing the required absolute configuration, he began with the opposite enantiomeric series^{viii} from what was used previously (**Scheme 1.2**). The steps pioneered previously were followed without deviation; however, several notable improvements to the efficiency of the process were made. For example, using the alternative Yamamura protocol²⁴ ($\text{CCl}_4/\text{PPh}_3$) to form the Bn-protected pyrone (*ent*-**34**, **Scheme 1.1**) improved the yield from 54% to 88%. Another notable

^{viii} See **Scheme 1.1**. The absolute configurations used in the synthesis of baconipyrrone C (**8**) are, however, opposite to that shown in **Scheme 1.1**. Paterson started the synthesis of baconipyrrone C (**8**) with *ent*-**31**.

improvement was the Sn-mediated aldol reaction²⁵ to form *ent*-**37**: the yield of this transformation was improved from 59%²¹ to 80%²⁸ with the same selectivity. Overall, PMB-protected keto-acid **42** was produced in a longest linear sequence of 18^{ix} steps in an astounding overall yield of 25%.




Scheme 1.2

Attention then turned towards the synthesis of the remaining fragment, hydroxydione **41** (Scheme 1.3). An enantioselective aldol of 3-pentanone (**43**) with (*E*)-2-methyl-2-pentenal (**44**) using previously established conditions³¹ gave the desired aldol adduct in moderate yield and enantioselectivity (57%, 85% ee). Protection as the corresponding *t*-butyldimethylsilyl ether, hydroboration,³² oxidation under Swern conditions, and deprotection finished the synthesis of the desired alcohol **41** over 5 steps in 32% overall yield.

In the same study,²⁸ Paterson also presented an alternative diastereoselective synthesis of **41**, starting from (*R*)-ethyl lactate. The synthesis was slightly longer (9 steps) than the enantioselective synthesis shown in Scheme 1.3, but was very efficient (38% overall yield) and delivered the desired compound (**41**) with excellent ee, as would be expected from a synthesis starting from the chiral pool.

^{ix} 21 steps inclusive of the 3 steps required to make *ent*-**36**.




a) (-)-Ipc₂BOTf, ^tPr₂EtN b) TBSOTf, 2,6-lutidine c) hexylborane, NaOOH
 d) (COCl)₂, DMSO, Et₃N e) HF•pyridine

Scheme 1.3

Completion of the synthesis required what Paterson described as a challenging esterification step due to, what was thought to be, epimerization occurring at C-14 (**Scheme 1.4**); HC-14 is α to a ketone (C-13) and a vinylogous ester (the γ -pyrone moiety), thus HC-14 should be the most acidic proton and the stereocenter most sensitive to epimerization. After much experimentation, a modified Yamaguchi esterification protocol finally gave 73% combined yield of a 10:1 mixture of C-14 diastereomers.^x The remaining protecting group was oxidatively removed and the minor diastereomer chromatographically separated to provide baconipyrone C (**8**) in 67% yield.

^x Epimerization at C-14 was assumed based on sound reasoning, but was not rigorously proven.



Scheme 1.4

From commercially-available starting material, the longest linear sequence was 20^{xi} steps. Despite the length, the described synthesis was extremely efficient giving an overall yield of 11%. This remarkable achievement confirmed the structure proposed for baconipyronone C (**8**), as well as its absolute configuration.


1.2.2.2 Hoveyda's synthesis

Hoveyda's synthesis was the first enantioselective synthesis of the unnatural enantiomer of baconipyronone C (*ent*-**8**).³⁰ The strategy employed was based on the extensive use of chiral metal complexes to enantioselectively access each fragment.

The key catalytic asymmetric allylic alkylation (CAAA) step in the synthesis of the alcohol required diene **53**, which was accessed in 22% yield over 7 steps from commercially-available starting material (**Scheme 1.5**). Subjecting diene **53** to the CAAA protocol developed to support this synthesis, gave the desired doubly alkylated product **55** in 61% yield and >98% ee. Removal of the allyl protecting group,³³ followed by ozonolysis gave the

^{xi} Inclusive of **41**, the synthesis had a total of 28 steps.

desired alcohol fragment (*ent*-**41**). In summary, hydroxydione *ent*-**41** was synthesized in 10 steps with an overall yield of 7% (>98% ee).



a) i. Br₂ ii. DBU b) DIBAL-H c) TBSCl, DMAP, Et₃N d) ^tBuLi, HCO₂Et e) NaH, allyl bromide
 f) (^tBu)₄NF g) DMAP, Et₃N, (OEt)₂POCl h) CuCl₂•2H₂O, (CH₃)₃Al, 7.5 mol% **54** i) Cp₂ZrCl₂, ^tBuLi
 j) ozonolysis

Scheme 1.5


The synthesis of carboxylic acid *ent*-**42** was based on the desymmetrization of oxabicyclic **58**, accessible in 4 steps from commercially available starting materials (**Scheme**

1.6). The first 2 steps in this sequence are known^{xii,34} but later two steps are not reported and, therefore, must be estimated based on analogy.^{xiii,35} Desymmetrization was achieved via a previous established asymmetric ring-opening metathesis/cross metathesis reaction³⁶ that was somewhat optimized in this synthesis to access pyran **61** in moderate yield (62%) and enantioselectivity (88% ee, 15:1 er). Pyran **61** was then opened by dissolving metal reduction. The moderate yield of this step was the result of competitive loss of the PMB group to form the corresponding diol. Nevertheless, **62** was a compound that could be elaborated into the desired compound. This would, however, require the stereoselective addition of another methyl group in addition to the γ -pyrone moiety.

Hoveyda first tackled stereoselective addition of the required methyl group to **62**. Consistent with the theme of this synthetic effort, he extended the carbon skeleton through a catalytic Si-tethered ring-closing metathesis reaction^{37, 38} and then performed a diastereoselective allylic alkylation with Me_2Zn and CuCN .

^{xii} Obtained in 36% overall yield.

^{xiii} Yadav reported the synthesis of the related Bn ether. Yields of the reduction and protection steps are 74 and 94%, respectively.




a) **59**, **63**, styrene, NaI b) Na, NH₃ c) ClMe₂Si(CH₂(H)C=CH₂), imidazole d) *i.* **60**, *ii.* KF, KHCO₃
e) DMAP, Et₃N, (OEt)₂POCl f) Me₂Zn, CuCN

Scheme 1.6

With all the stereogenic centers now correctly installed, attention turned to towards formation of the γ -pyrone moiety (**Scheme 1.7**). Protection of **65**, followed by ozonolysis and reduction in the same pot gave diol **66**. Differentiation of the two primary alcohols was now required to continue the synthesis. Fortunately, experimentation found that the two alcohols reacted at different rates with TBSOTf. By using substoichiometric amounts of reagent, at low temperature, and resubjecting recovered starting material to the reaction

conditions, desired alcohol **67** could be produced in 60% yield.^{xiv} The exposed 1° alcohol was oxidized to give **68** and the stage was now set to install the γ -pyrone and complete the total synthesis.



a) TBSOTf, 2,6-lutidine b) ozonolysis c) DMP d) LDA, then **68** e) DBU

Scheme 1.7

^{xiv} Four runs (four individual experiments) of subjecting starting material to the reaction conditions was required to achieve this modest yield of the protected compound (**67**).

Hoveyda opted to use a novel method of his own design to form the γ -pyrone rather than use any of the more mild methods more recently introduced (**Scheme 1.7**).^{xv,23, 24, 39} Following an aldol reaction of aldehyde **68** with **69** and oxidation of the aldol with DMP, Hoveyda found that a DBU-promoted dehydrative cyclization gave desired pyrone **71** in good yield. Hydrolysis of both TBS-ethers produced the enantiomer of same intermediate used by Paterson²⁸ in the first total synthesis of baconipyrone C (**8**). Repetition of steps pioneered by Paterson (see **Scheme 1.4**) furnished the unnatural enantiomer of baconipyrone C (*ent*-**8**) in yields comparable to those obtained previously.²⁸


1.2.2.3 Yadav's synthesis

Yadav's synthetic strategy, like Hoveyda's, was based on the desymmetrization of oxabicyclic **58** to construct a key section of carboxylic acid fragment **42**.²⁹ This strategy and methodology had been used successfully by Yadav in synthetic studies on several natural products.^{35, 40-48}

Desymmetrization of oxabicyclic **58**^{xvi} by enantioselective hydroboration and its elaboration into lactone **72** has not been described in the open literature; however, a closely-related analogue (Bn vs. PMB) has been partially described (**Scheme 1.8**).³⁵ It can be assumed that similar steps were employed; yields (and selectivities) are expected to be similar, but this is speculation.

^{xv} Few mild methods to form γ -pyrones from 1,3,5-triketone (or protected derivatives) were available to Hoveyda at the time this work was published. More recently, additional investigations into this problem have been published (*vide infra*).

^{xvi} Obtained in four steps in 36% yield.



a) LiAlH_4 , b) $\text{Me}_2\text{C}(\text{OMe})_2$, CSA c) NaH , BnBr , THF d) 2M HCl , THF e) $\text{C}_6\text{H}_5\text{COCl}$, Et_3N , DMAP
f) MOMCl , $i\text{Pr}_2\text{EtN}$, DMAP g) 3M KOH , MeOH h) IBX , DMSO


Scheme 1.8

Reduction of lactone **72**^{xvii} gave triol **73**. In order to isolate C-15-OH (siphonariid numbering), a significant protecting-group game was engaged. Once isolated, the alcohol was oxidized with IBX in DMSO to give aldehyde **76** and the stage was set to install the remaining carbon atoms, form the γ -pyrone, and complete the synthesis of carboxylic acid **42** (Figure 1.10).

Installation of the γ -pyrone proceeded according to methodology developed by Yamamura (Scheme 1.9); the lithium dianion of 4-methyl-3,5-heptanedione (**77**) was reacted with aldehyde **76**, followed by DMP oxidation to give triketone **78**.^{23, 24} The resulting triketone was then subjected to $\text{PPh}_3/\text{CCl}_4$ in THF to form desired γ -pyrone **79**. Deprotection

^{xvii} Accessible in 4 steps from commercially-available material. Like Hoveyda (Section 1.2.2.2), no yields, selectivities, or procedures are given; overall yield is assumed (*vide supra*).

of the MOM and benzyl groups gave *ent*-**39**, the same compound first made by Paterson²⁸ and a key intermediate in the total synthesis of baconipyrone C (**8**). Oxidation, as reported by Paterson, gave the desired carboxylic acid in 23 steps. The overall yield to obtain carboxylic acid **42** was 3.0%.^{xviii}




a) LDA then **76** b) DMP c) PPh_3 , CCl_4 d) TMSBr e) Raney nickel, H_2

Scheme 1.9

Yadav's approach to hydroxydione **41** was significantly longer than both prior reports (Scheme 1.10). He opted for an enzymatic resolution as a means to obtain the product in

^{xviii} Assuming that the 8 unreported steps are as efficient as those reported for the Bn derivative.

enantioenriched form. In total, hydroxydione **41** was accessed in 14 steps in 3% overall yield. The ee of **41** was not stated, but can be inferred from the optical rotation Yadav obtained and comparison to prior reports.^{28, 30}



a) NaH, BnBr b) enzymatic resolution (PS-C enzyme) c) (COCl)₂, DMSO, Et₃N
d) PH₃P=CHCO₂Et e) DIBAL-H f) (+)-DIPT, Ti(OⁱPr)₄, ^tBuOOH g) Me₂CuLi
h) NaIO₄, THF, H₂O i) TBSOTf, 2,6-lutidine j) H₂, Pd/C, MeOH k) EtMgBr, THF
l) HF•pyridine, THF

Scheme 1.10

1.2.2.4 Synthetic comparison and summary

The synthesis of baconipyron C (**8**) presented by Paterson is by far the most efficient, has the least number of steps in the longest linear sequence, and the least number of steps overall (Section 1.2.2.1). Paterson's synthesis is a clear demonstration of just how


powerful the methodology he has developed to efficiently construct polypropionate motifs.⁴⁹ The only weakness of Paterson's synthesis is the use of expensive, enantiopure reagents.

Hoveyda's synthetic approach was interesting from several different perspectives (**Section 1.2.2.2**). Each fragment in the synthesis relied upon an enantioselective reaction based on a chiral metal complex. Carboxylic acid fragment **42** relied upon the desymmetrization of a *meso* compound using an AROM/CM reaction. Hydroxydione **41** used an interesting catalytic asymmetric allylic alkylation (CAAA) protocol that was developed specifically to support the synthesis. However, to be clear, Hoveyda never synthesized baconipyrone C (**8**) because the correct enantiomer was not accessed. It is unclear why catalysts with the appropriate absolute configuration were not utilized in this synthetic effort.

Yadav's synthesis was largely based on methodology previously shown to be effective in synthetic studies of several natural products (**Section 1.2.2.3**). However, in the case of this target, Yadav was forced to make significant use of protecting groups in order to coax his starting material into the final target. These protecting group manipulations detract from the key chemistry employed in this synthesis - desymmetrization of a *meso* compound by enantioselective hydroboration - and as such do not showcase the power of this methodology well. Further, Yadav turned to an enzymatic resolution as a means to enantioselectively access hydroxydione **41**, rather than explore a more modern approach - like the desymmetrization methodology highlighted in this synthesis - to access this fragment.

Despite the innovative and powerful chemistry shown in these three syntheses of baconipyrone C (**8**), none addressed the hypothesis regarding the formation of this compound. Additionally, neither of the two subsequent syntheses improved on any aspect of

Paterson's synthesis, except for the issue of accessing baconipyronone C (**8**) through completely enantioselective routes.



		Paterson 2000 ^a	Hoveyda 2007 ^{b, c}	Yadav 2009 ^d
42	Longest linear sequence	18	22	23
	Total number of steps	21	24	24
	Yield	25%	2.3%	3.0%
	$[\alpha]_D^{25}$ ^e	-96.5 (c 0.4)	+69.1 (c 0.19)	-94.2 (c 0.75)
41	Longest linear sequence	5	10	14
	Total number of steps	5	10	14
	Yield	32%	7%	3.3%
	$[\alpha]_D^{25}$ ^e	-16.4 (c 1.1)	+12 (c 1.0)	-15.6 (c 2.0)

^a Ref 28. ^b Ref 30. ^c Antipodes of **41** and **42** prepared. ^d Ref 29. ^e CHCl₃. ^f Also synthesized diastereoselectively from (*R*)-ethyl lactate (9 steps; 38% overall yield).

^g Not reported.

Figure 1.11 Baconipyronone C (**8**) synthetic comparison

1.2.3 Synthetic studies on baconipyronone A (**6**)

Baconipyronone A (**6**) has never been synthesized, but the cyclohexanone subunit (**87**) has been the subject of two synthetic studies.^{50, 51}





Figure 1.12 Disconnection of baconipyron A (**6**)

1.2.3.1 Vogel's synthetic study on the cyclohexanone subunit (**87**)

Vogel accessed the cyclohexanone subunit (**87**) of baconipyron A (**6**) through a very concise route starting from **88** (Scheme 1.11).⁵¹ An SO₂-induced oxyallylation of **88** followed by retro-ene elimination of SO₂ (the intermediate is shown as **90**) gave **91** in a single pot.⁵² Transesterification of **91** with Bu₃SnOMe⁵³ presumably generated the corresponding Sn-enolate which underwent an efficient intramolecular aldol reaction.⁵⁴ Hydrogenolysis gave the desired cyclohexane subunit (**87**) of baconipyron A (**6**). The cyclohexane subunit (**87**) fortuitously crystallized, which provided the means to unambiguously prove the structure of the compound obtained.




Scheme 1.11

There is no comment in Vogel's report on the synthesis of **87** on whether any effort was made to make carboxylic acid fragment *ent*-**40** and attempt to complete the first total synthesis of baconipyrone A (**6**).

1.2.3.2 Plumet's synthetic study towards the cyclohexanone subunit (**87**)

Plumet was actually the first to report a synthetic effort towards the synthesis of (\pm)-**87**.⁵⁰ However, as unambiguously shown by Vogel in his subsequent synthesis of the cyclohexane subunit (**87**), the compound claimed to be (\pm)-**87** by Plumet was, most likely, a diastereomer of **87**.⁵¹ Vogel showed that the last step in Plumet's synthesis had gone awry; subjection of authentic **87** to the reaction conditions described by Plumet resulted in complete transformation to other compounds, including decomposition. The synthetic

sequence reported by Plumet is shown in **Scheme 12**, noting the failure to produce the desired product.



Scheme 1.12


Lastly, as Vogel pointed out, there was no discussion of structure proof in Plumet's report nor was any data provided that could facilitate a retrospective analysis of the structure.⁵¹

1.2.4 Synthetic studies on siphonarin B (4)

Shortly after completing the first total synthesis of baconipyronone C (**8**), Paterson and coworkers published an elegant synthesis of siphonarin B (**4**).¹⁵ This synthetic effort clearly showed the degree of difficulty that the construction of such natural products present.

In an initial attempt towards siphonarin B (**4**), Paterson utilized key fragment *ent*-**39**, which had been previously used in the synthesis of baconipyronone C (**8**) (**Scheme 1.13**).²⁸ Protecting group manipulation exposed the 1° alcohol towards oxidation by DMP. A Sn-mediated aldol reaction between aldehyde **102** and ketone **103**, again derived from the previous baconipyronone C (**8**) synthesis, afforded aldol **104**.^{28, 49} Hydrolysis of the triethylsilyl group, followed by bis-oxidation of the exposed alcohols provided triketone **105**.

The plan at this stage was to remove the silylidene protecting group of **105** and allow the C-7-OH to form a hemiacetal with the C-9 carbonyl. Unfortunately, the C-3-OH formed a hemiacetal with the C-7 carbonyl instead. Oxidative removal of the PMB group then formed spiroacetal **106** (C-11-OH onto C-7 hemiacetal), which resisted all attempts to undergo ring-chain tautomerism to a form more amenable to the synthesis at hand; a revision in strategy was thus required. This attempt clearly shows that the protecting group strategy employed must work hand-in-hand with the redox strategy to create and unveil functionality at the correct time.




a) Et_3SiOTf , 2,6-lutidine b) AcOH , THF, H_2O c) DMP d) $\text{Sn}(\text{OTf})_2$, Et_3N e) LiBH_4 , Bu_2BOMe , THF
f) Bu_2SiOTf , 2,6-lutidine g) thexylborane , H_2O_2 , NaOH , THF h) PPTS, MeOH i) $(\text{COCl})_2$, DMSO, Et_3N
j) $\text{HF}\cdot\text{pyridine}$ k) DDQ, pH 7 buffer

Scheme 1.13

In the second attempt, Paterson retooled ketone **110**, derived from ketone **109**,^{xix,55} and modified acceptor aldehyde **108** (Scheme 1.14). These changes were made to orthogonally protect C-3 and C-5-OH (siphonariid numbering) in order to control the release of each hydroxyl group and thus establish some level of control over hemiacetal formation that thwarted the previous effort.

^{xix} Available in 3 steps, 62% overall yield from (*S*)-methyl-3-hydroxy-2-methylpropionate



a) TMSOTf, 2,6-lutidine b) K_2CO_3 , MeOH c) DMP d) $\text{Sn}(\text{OTf})_2$, Et_3N e) *i.* $(\text{Chx})_2\text{BCl}$, Et_3N , EtCHO *ii.* LiBH_4 f) DEIPSCl, imidazole g) PPTS, MeOH h) PPTS, MeOH i) $(\text{COCl})_2$, DMSO, Et_3N j) HF•pyridine k) H_2 , Pd/C, EtOH l) $\text{NiCl}_2/\text{CrCl}_2$, $\text{H}_2\text{C=CHI}$

Scheme 1.14

Upon release of the DEIPS protecting group of **112** with HF•pyridine, the desired ring-chain tautomerism of C-5-OH onto C-9 carbonyl occurred and internally protected C-5-OH from further reaction (cf. **113**). Hydrogenolysis of **113** released the benzyl group and the resulting hydroxyl group was oxidized under Swern conditions. The sensitive aldehyde was immediately subjected to the Kishi-Nozaki protocol^{56, 57} with vinyl iodide to give allylic

alcohols **114**. A second Swern oxidation gave the corresponding enone, which was subjected to hydrogenation with palladium on carbon in order to reduce the olefin and hydrogenolyze the PMB group. Extended reaction time (16 hours) was required for hydrogenolysis, which resulted in what was described as significant, competing decomposition. However, a small amount of spirocyclization occurred to afford siphonarin B (**4**) in 8% yield over the final two transformations of the synthesis.

In total, this remarkable diastereoselective synthesis of siphonarin B (**4**) - reportedly described as a sensitive compound - was achieved in a longest linear sequence of 28 steps and 0.86% overall yield from commercially available starting material.^{xx,58}

1.3 Conclusions

There have been several synthetic efforts over the years that have answered a limited number of questions about this series of related structures. The previous efforts primarily focused on proof of structure and determination of absolute configuration. However, even these aspects have not been fully addressed because two of the four structures (caloundrin B (**10**) and baconipyone A (**6**))^{xxi} have never been synthesized: caloundrin B (**10**) has not been the subject of any synthetic study.

There remain many unanswered questions in this series of potentially related compounds. For example, no study has addressed the formation and potential relationships between these molecules. Specifically, is there an acyclic precursor (cf. **14** or **15**) that gives rise to caloundrin B (**10**) and siphonarin B (**4**) via alternative folding patterns and is this folding under thermodynamic control? Why is it that siphonarin B (**4**) has been observed multiple times, but caloundrin B (**10**) only a single time? Are the baconipyrones A (**6**) and C

^{xx} The synthesis was described as starting from *ent*-**31**, but *ent*-**31** is a synthetic product and is available 3 steps, 88% overall yield from (*S*)-(+)-3-hydroxy-2-methylpropionate.

^{xxi} Conceivably routes to fragments of this compound exist, but the fragments have never been coupled.

(**8**) formed from any of the former via retro-Claisen rearrangement (cf. **8**) and retro-Claisen rearrangement/aldol cascades (cf. **6**)? Further, is baconipyrone C (**8**) the precursor of baconipyrone A (**6**)? If this were the case, then how is it possible that the resulting aldol reaction is face and group selective since no other diastereomers have been observed?

As shown in these synthetic studies, accessing siphonariid polypropionates in reasonable yield is extremely challenging due to the sensitivity of these molecules towards even mild conditions,^{15, 28, 51} storage,³⁰ and in the case of caloundrin B (**10**), decomposition during NMR studies to determine structure.⁹ Further, the strategy to reveal and create functionality has to be carefully planned and executed otherwise a synthetic approach can rapidly reach a dead end due to unexpected ring-chain tautomerization events¹⁵ or undesirable epimerization events.²⁸

These unresolved questions coupled with the inherent synthetic challenge present the possibility of an intriguing research project.

RESULTS AND DISCUSSION

2.1 Research objectives

The objectives of this research project were to establish relationships between siphonarin B (**4**), baconipyrone A (**6**), baconipyrone C (**8**), and caloundrin B (**10**), ideally through the putative acyclic precursor (cf. **14** and **15**) (**Figure 2.1**). With the acyclic precursor in hand, conditions could be investigated to attempt to control these alternative cyclization pathways and/or facilitate the proposed chemical transformations that would lead to the observed structures. Additionally, with one, or more, of these isolated structures in hand, conditions could be investigated to test for conversion of one isolated structure to another. If successful, some comment could be made about the natural product status of this series of compounds; a subject which has not been broached by any of the synthetic studies performed on this series of compounds.

Model studies would be used where literature precedent is weak or non-existent. These studies are, however, not research objectives *per se*, but are tools to determine how to progress towards answering the above research questions.

A secondary research objective was to showcase the power that the Thiopyran Route to Polypropionates (see **Section 2.3**) provides in rapidly assembling polypropionate structural motifs. The available adducts from this synthetic strategy are useful building blocks for the total synthesis of complex polypropionate natural products.




Figure 2.1 Research objectives

2.2. Target selection and synthetic considerations

Of the four isolated, related structures (**4**, **6**, **8** and **10**), the target that was selected to become the primary focus for synthetic study was caloundrin B (**10**) (**Figure 2.2**). This selection was made primarily because of the structures containing contiguous carbon

skeletons (siphonarin B (**4**) and caloundrin B (**10**)), only caloundrin B (**10**) has never before been synthesized. This molecule also contains several unique structural features and eight stereogenic centers, providing significant synthetic challenge in its construction. Further, caloundrin B (**10**) is reportedly unstable,⁹ presenting an even higher degree of challenge.




Figure 2.2 Caloundrin B (**10**) structural features

Any synthesis of caloundrin B (**10**) would require control over the relative configuration of the eight stereogenic centers present in the molecule, as well as control over the absolute configuration since these natural products exist as single enantiomers (**Figure 2.2**). The Thiopyran Route to Polypropionates (**Section 2.3**) was envisioned to provide the control required for both of these aspects.

Caloundrin B (**10**) contains an intriguing and unusual bis-acetal/hemiacetal ring system (hereafter referred to as “trioxaadamantane ring system” or “trioxaadamantane”) (**Figure 2.2**), a rare structural feature present in just one other marine polypropionate natural product, muamvatin (**3**) (**Figure 1.1**).⁶ There are very few synthetic studies on trioxaadamantanes and these are limited to muamvatin (**3**)⁵⁹⁻⁶² and related systems.¹⁶ Thus, the caloundrin B (**10**) trioxaadamantane ring system would require study through a model

system in order to determine how to form it and gain an understanding of the conditions that it may be stable towards in order to develop a synthetic strategy (**Section 2.4**).

In addition to studying the trioxaadamantane ring system, the synthesis also requires installation of a γ -pyrone moiety (**Figure 2.2**). The timing and conditions required for the formation of the γ -pyrone moiety also require study (**Section 2.5**).


2.3 The Thiopyran Route to Polypropionates

The Thiopyran Route to Polypropionates is a long-standing research theme in Prof. Ward's research group (**Figure 2.3**).⁶³⁻⁷⁶ The route has been designed and optimized to rapidly and efficiently construct tetrapropionate synthons **118** (4 diastereomers) and hexapropionate synthons **119** (20 diastereomers). These synthons are useful building blocks for the synthesis of polypropionate natural products. Thus far, the Thiopyran Route to Polypropionates has been utilized in the synthesis of serricornin (**123**)⁷² and membrenone B (**121**).⁷⁷

A key aspect of any synthetic strategy, and indeed the Thiopyran Route to Polypropionates, is the preparation of starting materials through, ideally, simple, efficient, scalable, and cost-effective procedures with minimal chromatography (**Figure 2.3**). My contribution in this area included: 1) optimizing a multi-gram procedure (ca. 0.5 kilogram) to prepare Dieckmann product **126**;⁷⁴ 2) development of a multi-gram procedure (ca. 100 gram) to prepare ketone **117** in free-flowing, white, crystalline form;⁷⁴ 3) and the investigation of an alternative oxidation protocol⁷⁸ to prepare multi-gram (ca. 40 gram) quantities of aldehyde (\pm)-**116**,^{xxii} a previously challenging endeavor under available standard laboratory

^{xxii} Athanasios Karagiannis, unpublished results. Experimental conception and design under my supervision.

conditions.^{xxiii,66, 79} Following optimization, all of the aforementioned reactions no longer required chromatography to produce their respective products in excellent yield and purity.



a) Na, MeOH b) (HOCH₂)₂, *p*-TSOH (cat.), benzene, reflux c) 10% H₂SO₄, reflux d) LiAlH₄, THF
e) IBX, MeCN, Δ f) refs. 63, 66 g) refs. 64, 73, 76, 86

Figure 2.3 The Thiopyran Route to Polypropionates


^{xxiii} The volumes of solvent (CH₂Cl₂) involved to conduct a Swern reaction at this scale (>2 L) exceed available equipment and cooling (-78 °C) mechanisms.

The syntheses of polypropionate natural products, generally speaking, require single enantiomers to be accessed. Control over absolute configuration has been established in the Thiopyran Route to Polypropionates in the synthesis of the tetrapropionate synthons **118**^{67, 68, 70, 72} and in a specialized example of a *meso* hexapropionate synthon **119** via an enantiotopic group selective reaction (desymmetrization reaction).⁷¹ With respect to the tetrapropionate synthons **118**, access to all four enantioenriched diastereomers has been established via diastereoselective aldol reactions through the use of enantioenriched aldehyde **116**.⁶⁷ Alternatively, a direct aldol reaction between (\pm)-**116** and **117** that occurs with enantiotopic group selectivity⁸⁰ and dynamic kinetic resolution⁸¹ accesses **122** in >98% ee has been established (**Scheme 2.1**).⁷⁰

The latter chemistry presented an opportunity for improvement as the yield of the proline-mediated version of the reaction was a modest 56% (>98% ee) and required a substantial amount (6 equivalents) of ketone **117** (**Scheme 2.1**). Considering that the direct aldol reaction between **117** and (\pm)-**116**, mediated by proline, had been extensively optimized to achieve this remarkable result, one of the few avenues left to explore was the catalyst employed in the reaction (**Scheme 2.1**). Tetrazole catalyst **127** is known to be more soluble than proline.⁸²⁻⁸⁵ By employing this catalyst, the yield of the direct aldol reaction between **117** and (\pm)-**116** was improved (86%, >98% ee).⁷² It was also found that by increasing the concentration of the reaction substantially (9 M in (\pm)-**116** vs. 1 M), that the amount of ketone **117** could be reduced (from 12 equivalents to 2) while maintaining a similar yield (75%, >98% ee) at gram^{xxiv} scale. Conditions to isomerize aldol **122** to **128** were identified and optimized.⁷² Thus two of the four tetrapropionate synthons **118** (cf. **122** and **128**) could

^{xxiv} This reaction has been performed at ca. 40 gram scale in >70% isolated yield (>98% ee) with no chromatography; Athanasios Karagiannis, unpublished results.

be obtained in enantiopure form from a racemic reactant ((±)-**116**) in high yield and enantioselectivity.



Scheme 2.1

An aldol reaction between tetrapropionate synthon **118** and aldehyde **116** produces the next layer of complexity in the Thiopyran Route to Polypropionates: hexapropionate synthons **119** (also referred to as “bisaldols”) (**Figure 2.3**). Now, however, there are twenty^{xxv} possible diastereomers (all known).^{64, 73, 76, 86} My contribution to this area was related to deepening the understanding of the stereochemical control elements operating in the aldol reactions between tetrapropionate synthons **129** and **130** and aldehyde **116** (**Figure 2.4**).⁷³ The systematic study of these reactions allowed a model to be developed that rationalized the stereochemical outcome of these reactions. From this model, reactions were designed to exploit these stereochemical control elements to access single diastereomers of **134** or **135**^{xxvi} in high yield and diastereoselectivity through the kinetic resolution of (±)-**116**.⁷⁶

^{xxv} Chiral diastereoisomers (even # of stereogenic centers, n) = 2^{n-2} ; meso forms = $2^{(n-2)/2}$.

^{xxvi} Eight (8) stereoisomers are possible from an aldol reaction of tetrapropionate synthon **129** (or **130**) with aldehyde (±)-**116**. Protecting groups other than MOM were used in the subsequent study.




Figure 2.4 Model for stereoselectivity in aldol reaction of **129** and **130** with (\pm) -**116**

2.4 Trioxaadamantane ring system synthesis and isomerization: model study

This model study has been previously published in *Organic Letters*.⁷⁵ Much of the original text and tables have been included herein, with some modification for clarity and consistency with this thesis. The schemes and figures in the following are somewhat different

than in the *Organic Letters* publication, which was done to be consistent with the graphical presentation of this thesis.





Figure 2.5 Natural products containing a trioxaadamantane ring system

The highly unusual trioxaadamantane ring system has been identified in only two siphonariid natural products: muamvatin (**3**)⁶ caloundrin B (**10**) (**Figure 2.5**).⁹ The difference between the trioxaadamantane ring systems in muamvatin (**3**) and caloundrin B (**10**) is the configuration of C-4. This difference is used to distinguish between the two ring systems in the following discussion.

The trioxaadamantane ring system is formally derived from ring-chain tautomerism of a 3-hydroxy-1,5,7-trione (**Scheme 2.2**). Although this ring system is thermodynamically stable, its formation is impeded because it proceeds via the less stable of the intermediate hemiacetal anomers (i.e., **140/141** and **148/149** vs. **138/139** and **146/147**), and these hemiacetals readily undergo dehydration (to **152/153**) or retro-Claisen (to **154/155**) under acidic and basic conditions.^{16, 59-62} Consequently, the precursor hydroxytrione rearrangement (i.e., **136/137** or **144/145**) must be unveiled under very mild conditions.




Scheme 2.2


Synthetic studies are limited to the muamvatin (**3**) ring system (cf. **151**),^{16, 59-62} but despite the limited study two different approaches have been described (**Scheme 2.3**). The first approach, utilized by Hoffmann⁶⁰⁻⁶² and Perkins,¹⁶ approached formation of the muamvatin-related trioxaadamantane ring system via the deprotection of a silyl-protected triketone. Treatment of these silyl-protected triketones (**157** and **158**) under mild conditions provided the desired trioxaadamantane ring system in good yield. Paterson approached the formation of the trioxaadamantane moiety based on trihydroxy ketone **160**.⁵⁹ Internal protection of one of the alcohols as a hemiacetal served as a means to differentiate one of the three alcohols present in **160**. Oxidation of the exposed alcohols of **160** via a double Swern followed by exposure to silica gel provided the desired trioxaadamantane ring system **162** in

excellent yield. All of these studies underscored the mildness of the conditions required to generate the trioxaadamantane moiety.

1) Deprotection of a silyl-protected hydroxytriketone




2) Oxidation of a trihydroxy ketone followed by cyclization



a) HF•pyridine, pyridine, H₂O (cat.), b) TASF c) DBU d) (COCl)₂, DMSO, Et₃N e) silica gel, ca. 18 h

Scheme 2.3

It was reasoned that by exploiting a thiopyran template like **163/164**, formation of sulfur-bridged trioxaadamantane **167** or **168** would not require such mild conditions. Acidic conditions could be used because dehydration of the required intermediate hemiacetal anomer **165/166** is disfavored by Bredt's rule (**Scheme 2.4**).^{87, 88}




Scheme 2.4

2.4.1 Muamvatin's trioxaadamantane ring system and isomerization

To test the hypothesis outlined in **Section 2.4**, the preparation of known⁶¹ trioxaadamantane (\pm)-**151** related to muamvatin (**3**) was attempted (**Scheme 2.5**). Aldol **169** was first protected as its corresponding MOM ether **170**,^{69, 73} which was followed by an aldol reaction of the enol borinate of (\pm)-**170** with propanal gave aldol adduct (\pm)-**171**^{xxvii, 73, 76} as a 9:1 mixture of diastereomers. Oxidation of (\pm)-**171** with IBX in DMSO followed by treatment of the crude reaction mixture with $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ in refluxing acetone/MeOH^{xxviii, 89} served to hydrolyze the acetal protecting groups and catalyze the formation of unusual trioxadithiapentacycle (\pm)-**168** in good yield. Desulfurization of (\pm)-**168** with Raney nickel surprisingly provided trioxaadamantane (\pm)-**143**, whose structure was confirmed by X-ray crystallography (**Figure 2.6**).

^{xxvii} The relative configuration shown was assumed based on precedent established in refs 73 and 76.

^{xxviii} MeOH was added to facilitate removal of the MOM protecting group.



Scheme 2.5

The isolation of (\pm)-**143** was surprising because it is thermodynamically unstable relative to its epimer (\pm)-**151** due to the syn-pentane relationship between the C-8 and C-9 methyl groups. It was expected that under the conditions for desulfurization (refluxing ethanol) that epimerization would have occurred spontaneously. Investigation of suitable isomerization conditions was required to overcome the unexpected kinetic stability of (\pm)-**143**.





Figure 2.6 ORTEP plot of (±)-**143**.^{xxix}

Considering previous studies on this ring system (**Scheme 2.3**), there were several conditions that could be attempted: HF•pyridine,⁶⁰⁻⁶² silica,⁵⁹ and DBU.¹⁶ In addition to attempting these conditions, imidazole in chloroform was also attempted based on previous experience with this catalyst in the isomerizations (via keto-enol tautomerization) of sensitive aldol adducts (**Table 2.1**).^{65, 69}

^{xxix} Thermal ellipsoids shown at 30% probability. Hydrogen atoms omitted for clarity. X-ray data is available at the Cambridge Crystallographic Data Center: CCDC 721137 and ref 75.

Table 2.1 Isomerization studies on (±)-**143**

Entry	Conditions	Temp.	Time	Product Distribution (%) ^a			
				(±)- 143	(±)- 151	(±)- 153	(±)- 156
1	silica gel ^b	rt	1 d	85	15		
2		rt	5 d	35	65		
3	HF•pyridine/ pyridine/H ₂ O ^c	rt	1 d	95	5		
4		rt	7 d	70	30		
5		40 °C	1 d	30	70		
6		40 °C	5 d		95	5	
7	DBU/C ₆ D ₆ ^e	rt	2 d	6	83		11 ^d
8		rt	5 d	1	81		18 ^d
9		rt	10 d		30		70 ^d
10	Im/CDCl ₃ ^f	rt	1 d	>95	<5		
11		40 °C	1 d	30	70		
12		40 °C	4 d		100 ^g		

^a By ¹H NMR spectroscopy. ^b Absorption of a CH₂Cl₂ solution of (±)-**143** onto silica gel 60 (a 0.25 mm PTLT plate) followed by elution after the indicated time. ^c Pyridine (1.2 mL), HF•pyridine (0.4 mL), and H₂O (50 μL) were added to a solution of (±)-**143** (10-20 mg) in THF (2 mL). ^d Tentatively identified. ^e DBU (0.02 M; ca. 1 equiv.). ^f Imidazole 0.6 M. ^g 85% isolated yield on 20 mg scale.

Absorption of (±)-**143** onto silica gel produced (±)-**151** very slowly (entries 1 and 2). Reaction of (±)-**143** with HF•pyridine at room temperature also slowly produced (±)-**151**; isomerization was accelerated at elevated temperature (40 °C), but small amounts of dehydrated product (±)-**153** were detected at longer reaction times (entry 6). Treatment of (±)-**143** with DBU in C₆D₆ at room temperature gave (±)-**151** in addition to (±)-**156** (entries 7-9). The formation of (±)-**156** presumably results from elimination of propanoic acid from

an initially formed retro-Claisen ester **155**.^{xxx} Alternatively, a warm (40 °C) solution of (±)-**143** in CDCl₃ containing imidazole (0.6 M) cleanly produced (±)-**151** in 85% isolated yield (entry 12).

2.4.1.1 Structure determination of (±)-**143**, (±)-**153**, (±)-**156**, and (±)-**168**

The structure of (±)-**151** is known^{xxxi, 61} and the structure of (±)-**143** was confirmed by X-ray crystallography (**Figure 2.6**). The structure of (±)-**168** was inferred on the basis of the X-ray crystal structure of (±)-**143** and by analogy to **167** – the structure of which was confirmed by an X-ray crystal structure (*vide infra*).




Figure 2.7 Structure determination of (±)-**168**, (±)-**143**, and (±)-**151**

The significant spectroscopic differences (in C₆D₆) between (±)-**151** and (±)-**143** include: *i*) the small 4J coupling (W-coupling) between HC-8 and HC-9 (as revealed by COSY) in the latter that is absent in the former; *ii*) the large upfield shift for C-9 in (±)-**151** (δ_C 36.0) compared to (±)-**143** (δ_C 44.7) due to the axial-axial interaction between H₃CC-8 and HC-9 in (±)-**151** (**Figure 2.7**).

^{xxx} The retro-Claisen ester was never observed in the crude reaction mixture or by following the reaction by ¹H NMR spectroscopy.

^{xxxi} Hoffman reported obtaining an X-ray crystal structure of this compound.

2.4.2 Caloundrin B's trioxaadamanthane ring system and isomerization

Armed with the knowledge obtained from the production of known trioxaadamanthane (\pm)-**151**, the synthesis of its 4*S* diastereomer **150** – the trioxaadamanthane corresponding to caloundrin B (**10**) – was attempted (Scheme 2.6). Enantiopure **122**, readily available from the organocatalyzed direct aldol reaction of **117** and (\pm)-**116** (Section 2.3),^{70, 72} protected as its triethylsilyl ether **172**, was subjected to a boron-mediated aldol reaction with propanal to give aldol adduct **173**^{xxxii, 73, 76} in excellent yield. Oxidation of **173** with IBX followed by treatment with FeCl₃-impregnated silica gel⁹⁰ provided trioxadithiapentacycle **167**, which readily crystallized to provide a crystal suitable for X-ray crystallography (Figure 2.8).





Figure 2.8 ORTEP plot of **167**.^{xxxiii}

^{xxxii} The relative configuration shown was assumed based on precedent established in refs 73 and 76.

^{xxxiii} Thermal ellipsoids shown at 30% probability. Hydrogen atoms omitted for clarity. X-ray data is available at the Cambridge Crystallographic Data Center: CCDC 721136 and ref 75.



a) Et_3SiOTf , 2,6-lutidine b) $(\text{Chx})_2\text{BCl}$, Et_3N , propanal c) IBX, DMSO d) $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$, acetone, MeOH e) R = Me, Me_3SiOTf or R = Et, Et_3SiOTf , 2,6-lutidine e) Raney nickel, EtOH f) $\text{HF} \cdot \text{pyridine}$, pyridine, H_2O (cat.)

Scheme 2.6


Desulfurization of **167** with Raney nickel gave the anticipated trioxaadamantane ring system, **142** (Scheme 2.6). The yield of this step was variable (ca. 30 – 60%) and could not be optimized, which could reflect a lower stability of **142** relative to (\pm) -**143** (*vide infra*). Alternatively, reaction of **167** with $(\text{CH}_3)_3\text{SiOTf}$ (or Et_3SiOTf) gave silyl acetal **174** in excellent yield, which could be readily desulfurized with Raney-nickel to afford **175**. Attempts to hydrolyze the silyl-protecting group of **175a** with TBAF in THF led to rapid

decomposition and employing aqueous HF in MeCN led to quantitative formation of **152** (from **175b**). Brief treatment of **175a** with HF•pyridine, however, cleanly gave **142** in good yield (80%). Interestingly, the design of this strategy to access these trioxaadamanthane ring systems was validated by reversing the steps (i.e., desulfurization of **173**, oxidation by IBX in DMSO, and then FeCl₃•6H₂O in acetone quantitatively gave **152**).

Applying the isomerization conditions developed for (±)-**143** to **142**, clearly showed a difference in reactivity and several additional products were isolated (**Table 2.2**). For example, (±)-**143** was relatively stable to silica gel, but **142** (entry 1) gave a mixture of trioxaadamanthanes **142** and **150**, hemiacetal **146**, dihydropyrone **152**, and retro-Claisen ester **154** products. Whereas (±)-**143** was isomerized to (±)-**151** by HF•pyridine at 40 °C, only the dihydropyrone **152** was obtained from the trimethylsilyl ether of **142** (cf. **175a**) under these conditions (entry 5). At room temperature, hemiacetal **138** accumulated and could be isolated in reasonable yield (entry 3).

Exposure of **138** to HF•pyridine produced a 5:1 mixture of **142** and **150** at low conversion demonstrating the reversible formation of **142** (entries 6 and 7). In contrast to (±)-**143**, treatment of **142** with DBU in C₆D₆ rapidly gave a 1:2 mixture of **150** and **154**, respectively (entries 8 and 9), presumably via **138** (entry 13). Similar treatment of **150** also produced **154** although much more slowly (entries 10-12). In all cases, treatment with DBU led to **156** via elimination of propanoic acid from **154** (entries 9-15). Attempts to isolate **156** met with failure presumably because of its volatility and thus **156** was tentatively identified by NMR spectroscopy as a mixture of **156** and the propanoic salt of DBU (see **Figure 2.12**). Imidazole catalyzed the isomerization of **142** at room temperature predominantly gave **150** along with smaller amounts of **138** and **154** (entries 16 and 17).

Table 2.2 Isomerization studies on **142**



Entry	SM ^b	Conditions	Temp.	Time	Product Distribution (%) ^a					
					142	150	138	152	154	156
1	142	silica gel ^c	rt	1 d	13	31	9	24	33	
2	175^d		rt	2 h	86		9	5		
3			rt	2 d	22	15	56 ^f	7		
4		HF•pyridine/	rt	5 d	4	57	30	9		
5		pyridine/H ₂ O ^e	40 °C	4 d				>90		
6	146		rt	1 d	7	36	44	13		
7			rt	3 d	10	44	31	15		
8	142		rt	2 h	26	22	12		40	
9			rt	1 d		31			63 ^h	6 ⁱ
10	150		rt	1 d		67		4	26	3 ⁱ
11		DBU/C ₆ D ₆ ^g	rt	7 d		40		7	37	15 ⁱ
12			rt	18 d		30		2	36	32 ⁱ
13	138		rt	8 h		33			67	
14	154		rt	1 d					55	45 ⁱ
15			rt	7 d						>90 ⁱ
16	142		rt	2 d	19	65	10	2	4	
17		Im/CDCl ₃ ^j	rt	5 d		76 ^k	10		14	
18	150		rt	5 d		>90				
19	146		rt	1 d	5	67	16		12	

^a By ¹H NMR spectroscopy. ^b Starting material. ^c Absorption of a CH₂Cl₂ solution of **142** onto silica gel 60 (a 0.25 mm PTLC plate) followed by elution after the indicated time. ^d The trimethylsilyl ether **175a** was used. ^e Pyridine (1.2 mL), HF•pyridine (0.4 mL), and H₂O (50 μL) were added to a solution of **142** (10-20 mg) in THF (2 mL). ^f 49% isolated yield on 40 mg scale. ^g DBU (0.02 M; ca. 1 equiv.). ^h 47% yield on 45 mg scale. ⁱ Tentatively identified by NMR spectroscopy, but not isolated (*vide infra*). ^j Imidazole 0.6 M. ^k 77% isolated yield on 16 mg scale.

Similar results were obtained from **138**, confirming the reversible formation of **142** (entry 19). Thus, any of **138**, **150**, **152**, **154**, or **156** can be obtained as major products from **142** depending upon the conditions selected.

2.4.2.1 Structure determination of **138**, **142**, **150**, **152**, **154**, **156**, and **167**

The structure of **167** was verified by X-ray crystallography (**Figure 2.8**).




Figure 2.9 Structure determination of **142**, **150**, and **167**

The structures of **142** and **150** were assumed based on analogy to (\pm)-**143** and (\pm)-**151** (**Figure 2.9**). In analogy to (\pm)-**143** and (\pm)-**151**, there is a small 4J coupling (W-coupling) between HC-8 and HC-9 (as revealed by COSY) in **142** that is absent in **150**. Similarly, there is a large upfield shift for C-9 in **150** (δ_{C} 36.6) compared to **142** (δ_{C} 45.4). The significant NMR spectroscopic differences (in C_6D_6) between (\pm)-**151/143** and **150/142** include: i) the chemical shifts for C-8 in **150/142** (δ_{C} 36.5/36.9) are well upfield from those in (\pm)-**151/143**

(δ_C 43.3/43.3); ii) the 3J coupling constants between HC-7 and HC-10 are much larger in **150/142** (3.5/2.5 Hz) than in (\pm)-**151/143** (<2Hz); iii) the 1H chemical shifts (in C_6D_6) for H_3CC -10 in **150/142** (δ_H 0.65/0.63) are well upfield from those in (\pm)-**151/143** (δ_H 1.10/1.11). These differences in the NMR spectrum are consistent with the data reported for muamvatin (**3**)⁶ and caloundrin B (**10**).⁹ The absolute configuration of **142** is based on that of **167**. The absolute configuration of **150** is based on that of **142**.




Figure 2.10 Structure determination of **138**

The relative configuration of **138** was determined by 1H NMR spectroscopy (**Figure 2.10**). The trans diaxial relationship between the HC-5 and HC-6 was confirmed by the 10.7 Hz coupling constant between them. The axial OH group was suggested by a positive NOE on HC-6 on irradiation of the OH and vice versa. This assignment was also supported by a small 4J coupling constant (1.6 Hz) between the OH and HC-3 (this W-coupling is consistent with a trans diaxial OH and HC-3). The axial position of HC-3 was suggested by the small 4J coupling constant (1.1 Hz) between the HC-3 and HC-5; this observation is consistent with that reported in related compounds.¹⁷ The relative configuration at C-1'' is assumed based on no change from **150**. It is notable that **138** was the only hemiacetal isolated and is calculated to be the most stable of the possible hemiacetals (i.e., **138-141** and **146-149**) (see **Scheme 2.2**) (*vide infra*). The absolute configuration is assumed based on that of **150**.




Figure 2.11 Structure determination of **152**

The trans relative configuration for the substituents at C-2 and C-3 in **152** was assigned based on the large coupling constant observed between the protons at these positions consistent with the large J values reported for several related compounds (**Figure 2.11**).⁹¹ The C-1' diastereomer **153** is known⁶¹ and its reported NMR data are significantly different from **152**; thus the relative configuration at C-1' in **152** is assigned as indicated. The absolute configuration for **152** is assumed based on **150**.

The assigned relative configuration of **154** is confirmed by its C_1 symmetry (14 signals in the ^{13}C NMR spectrum; the 4*R*,6*S* diastereomers (e.g., **155**) are *meso*). The absolute configuration is assumed based on **150**.

Compound **156** was observed in various isomerization experiments (**Table 2.1** and **2.2**) in the presence of DBU in C_6D_6 . In a larger scale reaction, DBU (10 μL , 10 mg, 0.07 mmol) was added to a solution of **154** (8 mg, 0.03 mmol) in C_6D_6 (0.4 mL) at room temperature (**Figure 2.12**). The reaction was monitored by ^1H NMR spectroscopy and after 14 days, <5% of **154** remained. Attempted isolation of **156** from the reaction mixture by standard aqueous workup failed. However, the structure for **156** was assigned based on its NMR data that were easily extracted by comparison of the ^{13}C spectra of the reaction mixture with that obtained from a mixture of DBU and propanoic acid (i.e., the other components in the reaction mixture). The presence of two ketone carbonyls (δ_{C} 209.1, 200.9), two isolated

CH₃CH₂- groups, and a -(CH₃)C=CHCH(CH₃)- spin system were readily identified and confirmed by COSY, DEPT and HSQC. The (*E*) configuration is tentatively assigned based on the absence of NOE between the vinyl CH₃ and vinyl H and the presence of a weak NOE between the vinyl CH₃ and the allylic CH. The specific rotation of **156** (from **154**) was not determined.




Figure 2.12 Structure determination of **156**

2.4.3 Trioxaadamantane ring system comparison and conclusions

Compounds **150** and (\pm)-**151** differ by a single stereocenter (C-4), yet their isomerization behavior is remarkably different. In an attempt to identify the reasons for these differences, Prof. Jonathan M. Goodman^{xxxiv} was contacted about the possibility of studying these systems computationally.^{xxxv} **Figure 2.13** illustrates the results of the computational experiments graphically.

The computational studies found that the preferred conformation of **140** was the chair with equatorial methyl groups, and those of **141** and **149** were twist boats stabilized by H-bonding (**Figure 2.14**). The more facile isomerizations of **142** compared to (\pm)-**143** (cf. **Tables 2.1** and **2.2**) and to **150** (**Table 2.2**, entries 9 and 10) are consistent with the differences in energies between these trioxaadamantanes and their hemiacetal precursors (**140-142**, 16.8 kJ/mol; **141-143**, 23.8 kJ/mol; **150-148**, 32 kJ/mol).^{xxxvi} The lack of intermediates observed in the isomerization of (\pm)-**143** to (\pm)-**151** (**Table 2.1**) can be rationalized by considering the much smaller differences in energies between **139** and **149** (7.3 kJ/mol) vs. **141** (13.3 kJ/mol) (i.e., transformation of **139** to **151** should be faster than that of **143** to **139**) and the low equilibrium concentration expected for **139**.^{xxxvii} Although a similar analysis of **138**, **140**, and **148** supports a greater persistence and equilibrium concentration of **138** (i.e., facilitating more elimination and retro-Claisen rearrangement) compared to **139**, it does not account for the significant accumulation of **138** on treatment of **142** with HF•pyridine.

^{xxxiv} University Chemical Laboratory, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, U.K.; a computational chemist with significant experience computationally studying polypropionate natural products.

^{xxxv} All computations were made by Prof. Goodman.

^{xxxvi} The computed energies are for ground states.

^{xxxvii} Relative reaction facilities are based on Hammond's postulate (more stable intermediates are formed faster).




Figure 2.13 B3LYP/6-31G** energies (kJ/mol) relative to **151**





Figure 2.14 Illustrations of the preferred conformations of **140**, **141**, and **149**, as determined by computational studies.

In conclusion, the isomerization of **142** under different conditions leads selectively to **138**, **150**, or **154**. These compounds represent structural motifs present in siphonarin B (**4**), caloundrin B (**10**), and baconipyron C (**8**), respectively. In principle, each compound in this series of natural products could be accessed via a structure analogous to **142**.

2.5 γ -Pyrone formation model study

The synthesis of γ -pyrones can be accomplished through a variety of means and methods, but none of these methods are general.⁹² A common approach used in the synthesis of marine polypropionate natural products is through the dehydrative cyclization of 1,3,5-triketones (e.g. **179**, **Scheme 2.7**).^{24, 30, 39, 93}




a) H^+ or $(\text{COCl})_2$, DMSO or PPh_3 , CCl_4 b) DBU or Δ

Scheme 2.7

Early methods to dehydratively cyclize 1,3,5-triketones typically relied upon strong acid,⁹² which are not well suited to the synthesis of complex, potentially acid and base sensitive, polypropionate natural products, such as caloundrin B (**10**). This issue was recognized by several research groups and several alternative approaches have been disclosed, i.e.: $\text{PPh}_3/\text{CCl}_4$,^{23, 24} amberlyst-15 with celite-supported P_2O_5 ,³⁹ $\text{DMSO}/(\text{COCl})_2$,^{23, 24} bulky Brønsted acids,^{94, 95} base³⁰ and thermal⁹³ cyclization of silyl-protected triketones. The most popular of these methods is Yamamura's methodology,^{23, 24} which has been used in the synthesis of several natural products.^{15, 24, 28, 29} However, even this method has not been proven general.³⁹

Even rarer are examples of γ -pyrones accessed directly from protected 1,3,5-triketones.^{30, 93, 96} An example is provided by Hoveyda³⁰ (**178** \rightarrow **71**) in his synthesis of baconipyrone C (**8**). Hoveyda's sequence for installation of the γ -pyrone was later adapted by Jung in his synthesis of auripyrone A.⁹³

The γ -pyrone required for the synthesis at hand was envisioned coming from a 1,3,5-triketone via Yamamura's or a related methodology (**Scheme 2.8**).^{23, 24} We opted to form 1,3,5-triketone **182**, in protected form (cf. **181**), through an aldol reaction with dithioacetal aldehyde **179** followed by oxidation to the protected diketone. Hydrolysis of the dithioacetal protecting group of **181** would provide 1,3,5-triketone **182**. Known⁹⁷ γ -pyrone **177** would then be accessed through established methodology.



a) LDA b) IBX, DMSO c) hydrolysis d) γ -pyrone formation e) LiAlH_4 f) $(\text{CH}_2\text{SH})_2$, $\text{BF}_3 \cdot \text{OEt}_2$ g) KH

Scheme 2.8

Dithioacetal aldehyde **179** was accessed in three steps from readily-available⁹⁸ β -keto-ester **184** (Scheme 2.8). β -Keto-ester **184** was protected as its corresponding dithioacetal **185** by treatment with ethanedithiol and $\text{BF}_3 \cdot \text{OEt}_2$ as catalyst. Reduction of **185** with LiAlH_4 gave **186**, which was oxidized in excellent yield by oxidation with IBX in DMSO to afford aldehyde **179**. The synthesis of aldehyde **179** from **183** was accomplished on multi-gram scale in high yield without chromatography.

Aldehyde **179** was then subjected to an LDA-mediated aldol reaction with 3-pentanone (**43**) to form a complicated mixture of aldol adducts (**Scheme 2.8**).^{xxxviii} An attempted oxidation with IBX in hot (80 °C) acetonitrile⁷⁸ of this mixture of aldol adducts failed to provide the anticipated diketone **181**. Instead, known⁹⁷ γ -pyrone **177** was directly obtained in ca. 30% yield.

If the yield of this process could be improved, then a rapid synthetic sequence to γ -pyrones could be realized. Further, this initial result indicated that it might be possible to annulate a pyrone onto a ketone through an aldol reaction followed by oxidation: conceivably, only two steps would be required for this process, a possible advantage over other methodologies. Further, variation of the dithioacetal aldehyde or the ketone employed in the reaction could provide the means to easily substitute the γ -pyrone ring at any position: there are no known general methodologies or strategies capable of this.⁹²

Investigation of yield improvements through aldol **180** did not reveal any promising possibilities through the usual reaction optimization parameters (time, temperature, solvent, reagent amounts, concentration, etc.) (entry 1, **Table 2.3**). Considering, however, what must occur during the process, namely, oxidation of the aldol **180** to the corresponding diketone **181**, provided an alternative front for investigation.


Oxidation of aldol **180** under alternative oxidation conditions (i.e., IBX in DMSO)^{xxxix,99, 100} provided diketone **181** in excellent yield. Subjecting diketone **181** to IBX in hot (80 °C) acetonitrile gave γ -pyrone **177** in much improved yield (entry 2). The reaction proved responsive to the amount of IBX employed in the reaction (entries 2-4). Alternative

^{xxxviii} An aldol reaction between 3-pentanone (**43**) and aldehyde **180** can form up to 8 stereoisomers. In the present reaction, 4 products were obtained, but these could not be separated and were not characterized.

^{xxxix} IBX is soluble in DMSO. IBX-mediated oxidation in DMSO is a fairly recent discovery by Santagostino.

solvents (entries 5 and 6) were unproductive or led to decomposition products that were unidentifiable. Interestingly, heating diketone **181** with IBX in DMSO led to decomposition (entry 6), but under similar conditions, without the application of heat, diketone **181** is stable and can be isolated in excellent yield from the oxidation of **180**.^{xi} The addition of H₂O (entries 7 and 8), to aid hydrolysis of the ethanedithiol protecting group,¹⁰¹⁻¹⁰⁴ significantly attenuated the rate of the reaction or was unproductive.

Table 2.3 γ -Pyrone **177** optimization studies



Entry	SM ^a	Solvent	Equiv. IBX	Additive	Temp.	Time	Yield (%) ^b
1	180	MeCN	Various ^c	-	80 °C	various	<30
2	181	MeCN	1	-	80 °C	24 h	63
3		MeCN	1.5	-	80 °C	24 h	77
4		MeCN	2	-	80 °C	24 h	77
5		EtOAc	2	-	80 °C	24 h	NR ^d
6		DMSO	2	-	80 °C	24 h	decomp. ^e
7		MeCN	2	H ₂ O ^f	80 °C	24 h	<40
8		DMSO	2	H ₂ O ^f	80 °C	4 h	NR ^d
9	185	MeCN	2	-	80 °C	24 h	<15 ^g
10	181	MeCN	2	<i>p</i> -TsOH	80 °C	24 h	100 ^h
11		MeCN	0	<i>p</i> -TsOH	80 °C	24 h	NR ^d
12		MeCN	2	CF ₃ SO ₃ H	rt	18 h	92

^a Starting material. ^b Yield of **177**, unless stated otherwise. ^c Various conditions attempted including: solvent, reaction time, equiv. IBX, concentration. ^d No reaction. ^e No identifiable products obtained. ^f 5% (v/v). ^g Deprotection to **184**; as judged by ¹H NMR spectroscopy of the crude reaction mixture. ^h Yield by ¹H NMR spectroscopy using an internal standard (ClCH=CCl₂).

^{xi} This reaction takes 24 h to go to completion.

The fate of the ethanedithiol protecting group in this reaction was unknown because no products attributable to ethanedithiol could be detected in the crude reaction mixture or by monitoring the reaction by ^1H NMR spectroscopy.^{xli} It is known that the sulphur atoms of an *S,S*-acetal protecting group can be oxidized by IBX;¹⁰⁴ it is conceivable that a sulfinic or a sulfonic acid could be formed *in situ* and thus promote the reaction through acid catalysis. Interestingly, exposure of ester **185** to IBX resulted in very slow deprotection to **184** (entry 9) suggesting the involvement of the diketone functionality (perhaps through its enol tautomer) in facilitating the observed reaction. Therefore, the effect of added acid on the reaction was investigated. Dramatic improvement of yield was observed with the addition of *p*-TsOH (entry 10).^{xlii} Attempts to promote the formation of γ -pyrone **177** with *p*-TsOH, in the absence of IBX, returned starting material (entry 11). The use of triflic acid (entry 12) with IBX, however, allowed the reaction to be performed at room temperature with excellent conversion to desired γ -pyrone **177**.^{xliii}

2.5.1 γ -Pyrone model study conclusions

A simple, three-step procedure to annulate a γ -pyrone onto a ketone was optimized to a high-yielding process. The scope and limitations of this method have not yet been fully explored. However, sufficient information was obtained through this model study to attempt installation of the required γ -pyrone of caloundrin B (**10**) through novel conditions.

The use of triflic acid as a catalyst in the reaction is concerning due to its high acidity ($\text{pK}_a = 2.6$ in MeCN; for comparison CH_3COOH in $\text{H}_2\text{O} = 4.76$ and in MeCN = 23.5).¹⁰⁵ The use of this method could, therefore, present a problem in a more complicated, and

^{xli} The reaction was conducted in an NMR tube using MeCN- d_3 , which allowed real-time monitoring.

^{xlii} Trichloroethylene as an internal standard for ^1H NMR spectroscopic determination of yield was validated through isolation of the product following determination of yield by internal standard.

^{xliii} Athanasios Karagiannis, unpublished results.

potentially sensitive, substrate. However, the original plan to access the γ -pyrone could still be explored (i.e., hydrolysis of **181** to triketone **182**, followed by γ -pyrone formation through a known method²⁴ to give **177**) should this novel method fail.

2.6 Retrosynthetic analysis

Based on the model studies performed (Sections 2.4 and 2.5) and the known instability of the trioxadamantane ring system, it was clear that the sensitive trioxadamantane would have to be installed late in the synthesis of caloundrin B (**10**) (Figure 2.15). Thus, working backwards, the synthesis would be geared towards production of trioxadithiapentacycle **187**.




Figure 2.15 Retrosynthetic analysis of caloundrin B (**10**)

Disconnection of the C-3'',7' bond in **187**, leads to **188** - a protected version of **122**, which is available from the Thiopyran Route to Polypropionates in enantiopure form (**Scheme 2.1**) - and aldehyde **189**. A significant advantage of this disconnection is that the reaction to couple these two fragments together does not require any stereoselectivity.^{xliv}

The γ -pyrone aldehyde **189** was seen as being accessed via the chemistry developed in the model study described in **Section 2.5**, leading to dithioacetal aldehyde **179** and ketone **190** available⁷⁰ in enantioenriched form from the Thiopyran Route to Polypropionates.

The protecting group strategy is critical to the success of this synthesis. Not only must the P₁ protecting group (cf. **189**) be orthogonal to protecting groups P₂ (cf. **188**) and P₃ (cf. **189**), P₁ must also survive the conditions required to form the trioxadithiapentacycle (cf. **187**) and be removable under mild conditions that will not interfere with the sensitive trioxaadamantane ring system. P₂ (cf. **188**) must be removable under the aforementioned conditions in order to form the trioxadithiapentacycle.^{xlv} The final protecting group, P₃ (cf. **189**), must be robust enough to survive through the synthesis of aldehyde **189** and the steps that lead up to the formation of **187**. An ideal situation would be P₃'s concomitant removal during the reaction to form trioxadithiapentacycle **187** (see **Section 2.4**).

2.7 Synthesis of key aldehyde


2.7.1 γ -Pyrone formation

As discussed previously (**Section 2.6**), the synthesis of γ -pyrone containing aldehyde **189** requires the enantioselective synthesis of known⁷⁰ ketone **190** (**Scheme 2.10**). Few changes were made to the reactions to obtain ketone **190** with the exception of the preparation of dial **196** (**Scheme 2.9**). Oxidation of diols **194** and **195** under the previously

^{xliv} The aldol reaction between **188** and **189** would form an alcohol at C-7' (cf. **187**) which, upon oxidation, both the C-7' and C-3'' stereocenters will be destroyed (C-7') and/or exist as an epimeric/enol mixture (C-3'').

^{xlv} C-1'' of **187** initiates trioxaadamantane formation by forming a hemiacetal with the C-7' carbonyl.

established Swern conditions⁷⁰ presented a significant problem in regards to scale-up due to low solubility of trans-diol **194**. Due to these issues, reaction scale is limited using available laboratory equipment. Investigation into an alternative oxidation protocol for **194** to **196** was warranted to support this synthesis.



a) LDA, CH_3COCl b) $(\text{CH}_2\text{OTMS})_2$, TMSOTf c) LiAlH_4 d) $(\text{COCl})_2$, DMSO, DIPEA, e) IBX, MeCN


Scheme 2.9

Oxidation of a ca. 1.5:1 mixture of diols **194** and **195** with IBX in hot (80 °C) acetonitrile⁷⁸ produced desired dialdehyde **196** as an inseparable mixture of *meso/dl* forms and lactone **197** (Scheme 2.9). Lactone **197** could be separated from dialdehyde **196**, but its production reduces the yield of dialdehyde **196**. Upon considering this dilemma, it was realized that lactone **197** would only be produced from oxidation of cis-diol **195**.^{xlvi} In this particular sequence, only diesters **192** and **193** are separable; therefore, **192** and **193** were

^{xlvi} The production of lactone **197** requires production of a hemiacetal precursor, which can undergo further oxidation to form the lactone.

separated and carried through separately. Oxidation of **194** and **195** under different conditions maximized the overall yield of dialdehyde **196**.

The enantioselective aldol reaction between dialdehyde **196** (mixture of *meso* and *d/l* forms) and **117** to enantioselectively produce hemiacetal **190** had undergone rigorous screening of reaction parameters when the reaction was first developed (**Scheme 2.10**). In analogy to the improvements made to the enantioselective direct aldol between **117** and (\pm)-**116** (**Scheme 2.1**), tetrazole catalyst **127** was attempted. Unfortunately, none of the attempts or conditions investigated appeared promising; therefore, the reaction was scaled (ca. 8 grams of dialdehyde **196**) to a level appropriate to support this synthesis.



a) **117**, wet DMSO, L-proline b) $(\text{CH}_3)_3\text{COCl}$, DMAP, Et_3N c) i) Raney nickel, THF ii) IBX, DMSO

Scheme 2.10

At this stage, hemiacetal **190** had to be set up to receive dithioacetal aldehyde **179**. Protection of hemiacetal **190** by reaction with pivoyl chloride produced **198** as a 1:1 mixture

of anomers that could not be separated and was carried forward as a mixture. The sulfur atoms in **198** were no longer required and were removed by reaction with Raney nickel in refluxing THF.^{xlvi} These conditions resulted in the production (ca. 10%) of reduction products (via hydrogenation of the ketone), which were dealt with by treatment of the crude reaction mixture with IBX in DMSO. The resulting anomers of **199** (1:1) could be separated, but were typically carried forward as a mixture in subsequent reactions.

The structure of each anomer of **199** was inferred based upon the assumption that no isomerization occurred during pivaloylation or the reaction with Raney nickel (the structure of **190** is secure).⁷⁰ The two different anomers were distinguished on the basis of NOE. The conformation of β -**199** shown in **Figure 2.16** was established based on the small (<1 Hz) $^4J_{HH}$ (W-coupling) between HC-6 and HC-10 (as revealed by COSY): this coupling was absent in α -**199**. The axial position of the pivaloate in β -**199** was established based on a positive NOE on HC-6 and HC-9 on irradiation of the ^tBu group of the pivaloate and vice versa. Further, C-6-methyl exhibited a positive NOE upon irradiation of HC-7 and vice versa, which is consistent with the conformation shown in **Figure 2.16**. The absolute configuration of **199** is based on **190**. By default, the configuration of the pivaloate in α -**199** was established.





Figure 2.16 Structure elucidation of β -**199**

^{xlvi} Desulfurization in alcoholic solvent led to significant reduction products and side products which were not isolated or characterized.

An unselective LDA-mediated aldol reaction between **199** and dithioacetal aldehyde **179** produced a complicated mixture of aldol adducts **200** that were not separable, but, as previously discussed (**Section 2.6**), selectivity was unimportant relative to a high yielding process (**Scheme 2.11**).



Scheme 2.11

As a first step toward formation of the γ -pyrone (see **Section 2.5**), β -diketone **201** was subjected to IBX in hot (80 °C) MeCN to test if this adduct would form the desired γ -pyrone as a mixture of anomers **203** (**Scheme 2.11**). Instead of generating the expected products **203**, pyrone-dihydropyrone **202** was produced in low yield (ca. 30%). In addition to the formation of the expected γ -pyrone moiety, the C-4'' carbonyl was revealed and the pivaloate was eliminated across C-5'',6''. A mechanism is proposed in **Figure 2.17**, based on the known¹⁰⁴ sulfur oxidation of *S,S*-acetals by IBX.




Figure 2.17 Proposed mechanism for the formation of pyrone-dihydropyrone **202**


Generation of pyrone-dihydropyrone **202** provided a mixed blessing in that a step could be saved due to the hydrolysis of the ethylene ketal that occurred during the reaction. Additionally, the C-4'' carbonyl was isolated and conditions could be investigated to reduce it with the correct configuration followed by protection. However, the stereocenter at C-5'' had

been lost; the C-5'',6'' double bond would have to be regio- and stereoselectively hydrated to reestablish the aldehyde functionality at C-6'' and concomitantly reset the C-5'' stereocenter.

The source of the additional transformations (acetal deprotection and pivaloate elimination) was of interest and was thus investigated. Exposure of **199** (1:1 mixture of anomers), as a model substrate, to IBX in hot (80 °C) MeCN for 24 hours returned starting material (entry 1, **Table 2.4**). Exposure of the recovered starting material to IBA^{xlvi} in hot (80 °C) MeCN for 24 hrs also returned starting material (entry 2). Exposure of **199** to 2-iodobenzoic acid (IB) also returned starting material (entry 3). Thus IBX and its reduction products were not responsible for the additional reaction chemistry observed in the formation of pyrone-dihydropyrone **202** (**Scheme 2.11**). Exposure once again to IBX in hot (80 °C) MeCN along with the addition of a controlled amount of ethanedithiol (entry 4), produced dihydropyrone **208** as the sole product in the reaction crude (56% yield, unoptimized). Further, dihydropyrone **208** could be produced by brief exposure of **199** (1:1 mixture of anomers) to 1M HCl in THF. This confirmed the prior hypothesis (**Section 2.5**) that an acid (perhaps a sulfinic or a sulfonic acid) was produced during the course of the reaction to form the γ -pyrone. The acid produced in the reaction catalyzed acetal deprotection and elimination of the pivaloate. Unfortunately, despite several attempts, the acidic compound(s) responsible could not be observed^{xlvi} or isolated from the reaction mixture.

^{xlvi} Obtained from the IBX oxidation of isopropanol (of solvent) in hot (80°C) MeCN for several days.


^{xlvi} Monitoring the reaction by ¹H NMR spectroscopy over time in MeCN-d₃ and analysis of the crude reaction mixture.

Table 2.4 Dehydration and deprotection of **199**

Entry	Starting Material	Reagent 1	Reagent 2	Product
1	199	IBX	-	199
2		IBA	-	199
3		IB	-	199
4		IBX	(CH ₂ SH) ₂	208
5		1M HCl	-	208

At this stage, it was worthwhile to attempt optimization of the initial poor yield of pyrone-dihydropyrone **202** because this adduct afforded several positive attributes, as discussed previously. Despite repeated attempts (entries 1-3, **Table 2.5**), the yield could not be improved to the levels seen previously with IBX alone in the model substrate (cf. **Section 2.5, Table 2.3**). Addition of *p*-TSOH at elevated temperature improved yield somewhat (entry 4), but isomerization¹ was also detected. At lower temperature, isomerization was attenuated and the desired compound was isolated in slightly improved yield (entries 5 and 6). Addition of CF₃SO₃H under previously optimized conditions improved yield significantly (entry 7) in a small-scale reaction. Upon scale up (same stoichiometry, concentration, etc.), the reaction still performed well (entry 8), but not to the same level as the small-scale reaction. The reasons for this disparity are unclear.

¹ Isomerization presumably occurred at C-3' (of **202**) to lead to the more stable pseudo-equatorial diastereomer; however, this was not rigorously established since the minor diastereomer could not be separated from the desired product (**202**).

Table 2.5 Pyrone-dihydropyrone **202** optimization studies


Entry	Starting Material	Equiv. IBX	Additive	Temp.	Time	Yield (%)
1	201	2	-	80 °C	24 h	41
2		2	-	80 °C	48 h	41
3		2 ^a	-	80 °C	36 h	48
4		2	<i>p</i> -TsOH	80 °C	24 h	60 ^b
5		2	<i>p</i> -TsOH	rt	48 h	57
6		2	<i>p</i> -TsOH	rt	72 h	63
7 ^c		2	CF ₃ SO ₃ H	rt	16 h	81
8 ^d		2	CF ₃ SO ₃ H	rt	17 h	71

^a IBX added portion-wise. ^b Accompanied with ca. 20% isomerization. ^c 117 mg scale. ^d 2.41 g scale.

This improvement of the yield of pyrone-dihydropyrone **202** could make this approach viable synthetically, provided the C-5'',6'' double bond could be hydrated with reasonable selectivity when resetting the C-5'' stereocenter.

2.7.2 Hydration of pyrone-dihydropyrone **202**

Prior to attempting any experiments to hydrate pyrone-dihydropyrone **202**, reduction of the C-4'' carbonyl was attempted (**Scheme 2.12**). Inspired by Danishefsky,¹⁰⁶⁻¹⁰⁹ reduction under Luche conditions¹¹⁰⁻¹¹² provided an extremely selective reaction (>20:1). At this stage, the selectivity shown in alcohol **209** was assumed based upon the well-documented¹¹³ delivery of the hydride to a pseudo-axial position in the product. Protection of C-4''-OH of **209** as its corresponding acetate **211** and benzyl ether **210** provided substrates for attempted hydration of the C-5'',6'' double bond.



a) $\text{CeCl}_3 \cdot 6\text{H}_2\text{O}$, NaBH_4 b) KHMDS, BnBr, HMPA, $t\text{BuOH}$ c) Ac_2O , DMAP

Scheme 2.12

It is well known that such systems (cf. **209** - **211**) are prone to Ferrier rearrangement.¹¹⁴ Danishefsky exploited this facility towards Ferrier rearrangement as a multi-step solution to hydrate similar dihydropyrans obtained by his LACDAC (Lewis-acid catalyzed diene-aldehyde cyclocondensation) chemistry.^{106-109, 115-119} This series of transformations, however well preceded, would significantly increase the number of steps in the synthesis at hand. A direct method to hydrate the C-5'',6'' double bond and concomitantly reset the C-5'' stereocenter would be highly advantageous, but such a method appears to be unprecedented in C-5'' substituted dihydropyrans.

There are a number of methodologies that have been developed over the years to hydrate C-5'' unsubstituted dihydropyrans based on Lewis acids,¹²⁰⁻¹²² transition metal complexes,¹²³ electrophilic iodine,¹²⁴ acidic resin,¹²⁵ Brønsted acids,¹²⁶⁻¹²⁸ triphenylphosphine hydrobromide,^{126, 129, 130} and hydroxymercuration/demercuration.¹³¹⁻¹³³ Of these methods,

triphenylphosphine hydrobromide ($\text{PPh}_3\bullet\text{HBr}$) had been used beyond model studies^{134, 135} and hydroxymercuration/demercuration is a well-established approach to olefin and enol ether hydration.¹³⁶ Both methods looked promising from this perspective and were thus attempted concurrently.





Figure 2.18 Electrophile addition to dihydropyran **211**


It was expected that reagent addition would occur from the top face because the bottom face is more sterically hindered (due to the C-3'' pseudo-axial methyl), based on conformational analysis of the dihydropyran (**Figure 2.18**). Regioselectivity would be 'controlled' through the oxygen atom of the dihydropyran ring and its ability to stabilize the resulting carbocation.

Treatment of **211** (**Scheme 2.13**) with $\text{PPh}_3\bullet\text{HBr}$ and methanol in CH_2Cl_2 gave Ferrier product **212** and a small amount of starting material (ca. 10%) detected in the crude reaction mixture. The configuration of the methoxy group was suggested by a positive NOE on HC-2'' upon irradiation of the methoxy group and vice versa.



Scheme 2.13

In parallel, hydroxymercuration/demercuration of benzyl-dihydropyran **210** was attempted (**Scheme 2.14**). The initial reaction resulted in the production of two fully-reduced compounds in low yield with structures proposed to be **213** and **214**.



Scheme 2.14

At this stage, it was unknown which of the two compounds produced, **213** or **214**, corresponded to the required configuration at C-6'. Further, none of the structures in this synthetic sequence (**198** → **213** and **214**) had been rigorously established. Fortunately, an analogue of these two compounds (cf. *ent*-**39**, **Scheme 1.9**) had been used in the three previous syntheses of baconipyronone C (**8**): the difference between the two unknown compounds and the known baconipyronone C intermediate, PMB-diol *ent*-**39**, was the aromatic group of the C-5' ether (4-methoxyphenyl vs. phenyl).

Comparison of the ¹H NMR spectra of Bn-diols **213** and **214** with the data reported by Hovedya³⁰ for **39** showed a close match (**Table 2.6**) to Bn-diol **213**. The major difference in the spectra for **39** and Bn-diol **213** was the methyl singlet at 3.78 ppm for **39** and the signals in the aromatic region of the spectrum – essentially differences attributable to differences in the aromatic moiety of the respective protecting groups. Bn-diol **214** showed a significant number of differences in its ¹H NMR spectra compared with that of **39**, not inclusive of differences attributable to the protecting group. Thus, tentative assignments were made based on ¹H NMR spectroscopy. This tentative assignment was confirmed by comparison of the ¹³C NMR spectra (**Table 2.7**).

Table 2.6 ¹H NMR (CDCl₃) comparison of **213**, **214** and **39**

39^{a, b}		213		214	
δ_{H}^c	multiplicity (<i>J</i> 's in Hz)	δ_{H}^d	multiplicity (<i>J</i> 's in Hz)	δ_{H}^d	multiplicity (<i>J</i> 's in Hz)
7.23	d (8.8)	7.33-7.26	m	7.35-7.26	m
6.83	d (8.8)				
4.61	q (10.6)	4.72-4.66	m	4.67	d (11)
4.21	d (9.7)	4.22	br d (10)	4.63	d (11)
3.81-3.68	m	3.84-3.77	m	4.22	br d (10)
3.78	s	3.75-3.68	m	3.70-3.61	m
3.55	dd (3.7, 8.1)	3.59	dd (4, 7.5)	3.11	dq (10, 7)
3.14-3.06	m	3.14-3.05	m		
2.60	dddd (15.0, 7.7, 7.7, 7.7)	2.64-2.51	m	2.65-2.48	m
2.58	dddd (15.0, 7.7, 7.7, 7.7)				
2.19	br m	2.22	br s		
2.09-1.95	m	2.09-1.99	m	2.11-1.98	m
1.99	s	1.98	s	1.98	s
1.91	s	1.90	s	1.91	s
1.19	t (7.7)	1.17	t (7.5)	1.14	t (7.5)
1.14	d (7.1)	1.14	d (7)	1.11	d (7)
1.09	d (7.1) ^e	1.10	d (7)	1.03	d (7)
1.04	d (7.1)	1.07	d (7)	1.02	d (7)

^a Ref 30. ^b Ref 28., 300 MHz in ref 29. ^c 400 MHz, 7.26 ppm as reference. ^d 500 MHz, 7.26 ppm as reference. ^e Reported as a triplet (t), but is clearly a doublet (d) in the provided supporting information.

Table 2.7 ^{13}C NMR (CDCl_3) comparison of **213**, **214** and **39**


39^{a, b}	213		214	
$\delta_{\text{C}}^{c, d}$	$\delta_{\text{C}}^{e, f}$	$ \Delta\delta_{\text{C}} ^g$	$\delta_{\text{C}}^{e, f}$	$ \Delta\delta_{\text{C}} ^g$
179.9	180.0	0.1	180.0	0.1
164.7	164.8	0.1	164.9	0.2
164.1	164.1	0	164.3	0.2
159.7 ^h	128.8 ^h	-	128.7 ^h	-
129.8 ^h	128.3 ^h	-	128.0 ^h	-
129.7 ^h	128.0 ^h	-	127.9 ^h	-
119.5	119.6	0.1	119.7	0.2
118.0 ⁱ	118.0	0	118.1	0.1
114.1 ^h	-	-	-	-
88.3	88.2	0.1	83.8	0.5
76.3	76.6	0.3	75.6	0.7
72.0	72.1	0.1	72.4	0.4
65.5	65.3	0.2	66.2	0.7
55.4 ^h	-	-	-	-
38.9	39.1	0.2	39.5	0.6
38.0	38.0	0	38.5	0.5
35.4	35.6	0.2	36.6	1.2
24.9	25.0	0.1	25.0	0.1
15.2	15.2	0	14.8	0.4
14.6	14.7	0.1	12.0	2.6
11.4	11.4	0	11.4	0
11.1	11.0	0.1	10.2	0.9
9.8	9.9	0.1	9.9	0.01
9.7	9.7	0	9.7	0

^a Ref 30. ^b Ref 28, 75 MHz in ref 29. ^c 100 MHz, δ_{C} in ppm. ^d 77.16 ppm selected as reference. ^e 125 MHz, δ_{C} in ppm. ^f 77.23 ppm selected as reference. ^g $|\Delta\delta_{\text{C}}|$ Difference between **39** and the applicable adduct. ^h ^{13}C resonances belonging to the protecting group \therefore not applicable. ⁱ Reported as a 118.9 ppm, but the attached peak-picked spectra provided in the supporting information clearly shows this signal is at 118.0 ppm.

As shown in **Table 2.7**, comparable ^{13}C signals for **213** are only 0.1-0.3 ppm different from known compound **39**. The ^{13}C signals for C-6' epimer **214** are as high as 2.6 ppm different from known compound **39**. Based on this analysis, the tentative assignment based on the ^1H NMR spectroscopy is far more secure, but not absolute. Additional work to secure the structures of these compounds is required (*vide infra*).

With the desired transformation of **210** to **213** (and minor compound **214**) now known to occur using hydroxymercuration/demercuration, the initial low yield and selectivity observed would have to be investigated to establish this approach as a synthetic possibility.

Table 2.8 Hydration of **210**



Entry	SM ^a	THF: H ₂ O	Equiv. Hg(OAc) ₂	Additive	Reaction Time	Conversion (%)	Selectivity (213 : 214)
1	210	10:1	2	-	40 h	48 ^b	1.7:1
2		8:1	1.5	-	48 h ^c	80	2:1
3		2:1	2	-	1 h	60	1:1
4		1:1	2	-	1 h	95	1:1
5		1:1	1	Na ₂ CO ₃	1.5 h	>95	3:1
6		1:1	1	Na ₂ CO ₃	10 min	9	3:1
7		1:1	1	Na ₂ CO ₃	30 min	95	2.9:1
8		1:1	1	Na ₂ CO ₃	1 h	>95	3:1
9		2:1	1.1	Na ₂ CO ₃	2 h	>95 ^d	3.5:1

^a Starting Material. ^b Isolated yield of **213** (33%), **214** (15%), and **210** (52%). ^c 16 h at 2-8 °C then 24 h at rt. ^d Isolated yield of **213** (62%) and **214** (16%).

Initially, the hydroxymercuration/demercuration reaction produced low levels of conversion and marginal selectivity in favour of the desired Bn-diol **213** (**Table 2.8**). It was found that reactivity could be improved through adjustment of solvent composition (entries

1-4), seemingly at the expense of selectivity. This could be the result of reaction reversibility and other equilibrium processes, which according to Brown, are well known in hydromercuration/demercuration reactions.¹³⁷ These competitive reactions can be suppressed through the addition of base to the reaction, just prior to the radical¹³⁸ demercuration step, but the time between addition of base and NaBH₄ must be carefully controlled to obtain reproducible results.¹³⁷ Attempting this modification (entry 5) by addition of aq. Na₂CO₃ improved conversion substantially with reasonable selectivity in favour of the desired compound. Based on this result, the amount of time required before base was added to the reaction was investigated to determine if conversion and selectivity changed as a function of time. As shown in entries 6-8, the reaction progresses over the course of an hour with no change in selectivity; selectivity may be a result of the radical mechanism¹³⁸ operating in the demercuration step when using NaBH₄. Other research groups have found that sodium amalgam (Na/Hg) reduces organomercurials with complete retention of configuration.¹³⁹ This modification was attempted without success.


Attempting the established conditions in subsequent reactions, showed no change in selectivity, but, conversion was not always consistently high.^{li} Solvent composition and reaction time before addition of base were adjusted (entry 9, **Table 2.8**) to attain reproducibility.

Attempts were made to make the hydroxymercuration/demercuration reaction and the subsequent reduction of the hemiacetals^{lii} into a one-pot reaction. Unfortunately, some of the constituents of the reaction mixture were not stable to the conditions and decomposition occurred: presumably, extended exposure to base was responsible for the decomposition

^{li} Conversion in subsequent experiments under these conditions ranged from 90->95%.

^{lii} Reduction of the hemiacetals is slow. After 3 h, only 50-60% reduction had occurred (by ¹H NMR spectroscopy): complete reduction was consistently observed after 16 h.

but the reaction selectivity in the hydroxymercuration/demercuration step was the same.^{liii} Comparison of the ^1H and ^{13}C NMR of the two PMB diols (*ent*-**39** and **216**) obtained from the hydroxymercuration/demercuration of **215** showed an excellent match to the previously reported data.^{29, 30} Comparison of the optical rotation for *ent*-**39**,^{liv} $[\alpha]_{\text{D}} -15$ (*c* 0.45, CHCl_3) to literature values $[\alpha]_{\text{D}} -9.9$ (*c* 0.91, CHCl_3) for *ent*-**39**²⁹ and $[\alpha]_{\text{D}} +8.4$ (*c* 0.15, CHCl_3) for **39**,³⁰ confirmed that the required absolute configuration was accessed.



Scheme 2.16


The synthesis of hydroxydione **41** was seen coming directly from the Thiopyran Route to Polypropionates (Section 2.3), specifically through aldol diastereomer **122** that can be obtained in excellent yield (86%) and enantioselectivity (>98% ee) from **116** and **117**

^{liii} Reactions performed with **215** were attempted a limited number of times; i.e., not optimized to the same degree as the reaction with **210**.

^{liv} The adduct produced in this synthesis.

(**Scheme 2.1**). From **122**, all that is required to obtain **41** is desulfurization and deprotection of the ethylene acetal (**Scheme 2.17**).

Towards this end, aldol **122** was subjected to Raney nickel in refluxing THF,^{lv, 140} which smoothly desulfurized (**Scheme 2.17**). At the end of the reaction, the reaction mixture was cooled and aq. HCl was added to destroy the Raney nickel. The aqueous acid also served to deprotect the ethylene acetal. Thus **41** was obtained from **122** in a one-pot process in excellent yield (79%). The NMR data matched previously reported data.²⁸⁻³⁰



a) i) Raney nickel ii) aq. HCl

Scheme 2.17

Comparison of the three previous routes to the two key intermediates previously used in the synthesis of baconipyronone C (**8**) to this work are shown in **Table 2.9**.

As shown in **Table 2.9**, the synthetic route to both **41** and *ent*-**39** compare favorably to Paterson's synthesis. While fewer steps are required in this synthesis to construct *ent*-**39**, Paterson's synthesis is over three times as efficient, a truly amazing feat. The same is not true for **41**, despite one extra step, the yield of **41** in this synthesis is nearly twice that of Paterson's and was produced with much higher ee than what Paterson achieved. Both the Hoveyda^{lvi} and Yadav syntheses are longer and less efficient than the current work

^{lv} It is known that the use of alcoholic solvent increases the ability of Raney nickel to reduce other functionality by increasing available H₂ through hydrogenolysis of the solvent to its corresponding carbonyl compound.

^{lvi} For clarity, Hoveyda never synthesized baconipyronone C (**8**).

Table 2.9 Key baconipyronone C (**8**) intermediates synthesis comparison

		This Work	Paterson 2000 ^a	Hoveyda 2007 ^{b, c}	Yadav 2009 ^d
<i>ent</i> - 39	Longest linear sequence	14	16	20	21
	Total number of steps	18	19	22	22
	Yield	7.3%	26%	2.3%	3.8%
	$[\alpha]_D^{25}$ ^e	-15 (<i>c</i> 0.45)	NR ^f	+8.4 (<i>c</i> 0.15)	-9.9 (<i>c</i> 0.91)
41	Longest linear sequence	6	5	10	14
	Total number of steps	7	5	10	14
	Yield	45%	32%	7%	3.3%
	ee	>98%	85% ^g	>98%	NR ^f
	$[\alpha]_D^{25}$ ^e	-20 (<i>c</i> 1.1)	-16.4 (<i>c</i> 1.1)	+12 (<i>c</i> 1.0)	-15.6 (<i>c</i> 2.0)


^a Ref 28. ^b Ref 30. ^c Antipodes of *ent*-**39** and **41** prepared. ^d Ref 29. ^e CHCl₃. ^f Not reported. ^g Also synthesized diastereoselectively from (*R*)-ethyl lactate (9 steps; 38% overall yield).

2.7.4 Aldehyde **218** synthesis

In Paterson's 1st attempted synthesis of siphonarin B (**4**) (**Scheme 1.13**), PMB-diol *ent*-**39** could be bis-silylated by treatment with Et₃SiOTf and 2,6-lutidine and then the 1° triethylsilyl ether was selectively deprotected; both reactions occurred in excellent yield.¹⁵ The same sequence was attempted with Bn-diol **213** (**Scheme 2.18**). Despite the similarity between *ent*-**39** and **213**, the C-3'-OH of **213** could not be silylated.^{lvii} This observation was capitalized upon through a one-pot reaction scheme by transient protection of the C-7'-OH (of **213**): C-7'-OH was silylated with Et₃SiOTf, followed by methoxymethylation of the C-

^{lvii} Repeated attempts employing extended reaction times (>24 h) and excess reagents (>5 equivalents in both Et₃SiOTf and 2,6-lutidine) were met without success. In all cases, only the C-7'-OH of **213** would silylate.

3'-OH. After TLC indicated complete reaction, MeOH^{lviii} and TBAF were added, cleanly removing the triethylsilyl group and delivering **217** in excellent yield.




a) *i.* Et₃SiOTf, 2,6-lutidine *ii.* MOMCl, DIPEA, ⁿBu₄Nl *iii.* MeOH, ⁿBu₄NF

Scheme 2.18

Oxidation of the C-7'-OH to the corresponding aldehyde (**218**) was accomplished with IBX in DMSO in quantitative yield without need for chromatography (**Scheme 2.19**). IBX in hot (80 °C) MeCN (cf. **Scheme 2.9**, oxidation of diol **194** to dialdehyde **196**) was attempted with a C-3'-acetate derivative (**Scheme 2.20**). This resulted in elimination and isomerization products.^{lix} Acetate derivative **221** was prepared as an alternative to aldehyde **218** and to investigate conditions to produce aldehyde **221** without competing isomerization and elimination pathways. Aldehyde **221** was not explored further other than to establish appropriate oxidation conditions for **217**.


^{lviii} Added as a sacrificial alcohol to prevent possible MOMylation of the C-7'-OH after removal of the silyl protecting group.

^{lix} Elimination was speculated to occur across the C-2,3 bond and isomerization at C-2 through tautomerism, but this could not be proven because all three compounds were inseparable from each other.



a) IBX, DMSO

Scheme 2.19



a) Ac_2O , DMAP b) K_2CO_3 , MeOH, H_2O c) IBX, DMSO

Scheme 2.20

2.8 Total synthesis of siphonarin B (4) and baconipyrones A (6) and C (8)

2.8.1 Carbon skeleton completion: total synthesis of the putative common precursor

With **222**^{lx} and aldehyde **218** in hand, an aldol reaction to couple these reactants could be attempted. Aldol reactions between **222** (and its diastereomers) (see **Figure 2.4**) and chiral aldehydes have been extensively studied in the Ward group in order to determine and exploit the stereocontrol elements present in these reactions.^{64, 73, 76} Based on these studies, the configurations at C-3 (of **222**) and C-2 and C-3 (of **218**) provide guidance as to the selection of an aldol mediator to efficiently couple these two reactants (**Figure 2.19**).




Figure 2.19 Considerations for the required aldol coupling of **222** and **218**

The aldol reactions of **222** (and its diastereomers) are unerringly *trans* selective (C-3 and C-5 of **222**) with aldehyde **116**. This is a result of pseudo-axial delivery of the electrophile for stereoelectronic reasons: conformational analysis places the existing C-3 ligand (of **222**) in a pseudo-equatorial position thus necessitating a *trans* relationship of the existing ligand at C-3 and the newly installed ligand. Further, the *anti* relative configuration of the α -methyl and β -OBn substituents of aldehyde **218** are expected to reinforce Felkin


^{lx} Methoxymethylation of **122** produced **222**. Compound **188** (P_2 = MOM, **Figure 2.15**) is the generic version of **222**.

selective addition to the carbonyl.¹⁴¹ These strong diastereoface selectivities require an aldol mediator with either no selectivity preference or one that favours *syn* relative aldol topicity.

The aldol mediators investigated with **222** (and its diastereomers) that show either no selectivity or are *syn* selective are based on titanium(IV). Ward et al. have shown that the transmetalation of Li enolates of **222** (and its diastereomers) with Ti(O^{*i*}Pr)₄ produces Ti(O^{*i*}Pr)₄Li “ate” enolates that react with *syn* relative aldol topicity selectively with one enantiomer of (±)-**116** (**Figure 2.4**) to produce single compounds (i.e., **134**).^{lxi,76} Titanium(IV) enolates of **222** based on TiCl₄ or TiCl₃O^{*i*}Pr have also been shown to efficiently couple **222** and **116**.⁷³ These reactions occur without significant preference of relative aldol topicity. In general, the latter reaction format is faster and is a simpler procedure to execute than the former.

Based on the above analysis, TiCl₄ was selected as the mediator for the aldol reaction between **222** and **218** (**Scheme 2.21**). Gratifyingly, this reaction gave a 79% yield of essentially one diastereomer (>20:1, as judged by ¹H NMR spectroscopy), clearly showing the effectiveness of the selected conditions.

^{lxi} Such reactions are kinetic resolutions of (±)-**116**.




Scheme 2.21

The structure of aldol adduct **223** was assumed to have the configuration shown (**Scheme 2.21**), based on the model in **Figure 2.4**. The relative configurations of C-3'' and C-7' were not rigorously proven: all stereocenters present in **222** and **218** were assumed to be unchanged from starting material.

The relative configurations of C-3'' and C-7' of **223** are not critical to the success or failure of this synthetic effort because C-7'-OH will be oxidized and the C-3'' stereocenter in resulting C-4'',7' β -diketone will be susceptible to keto-enol tautomerism.

2.8.2 Attempted trioxadithiapentacycle formation

With aldol adduct **223** in hand, the oxidation of C-7'-OH to the corresponding C-4'',7' β -diketone was attempted (**Scheme 2.22**). The resulting oxidized compounds proved to be a complicated mixture of keto (2 diastereomers) and enol forms and was taken forward as a crude product, as previously described in the model study (**Section 2.4**)



a) IBX, DMSO b) $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ under various conditions

Scheme 2.22

Despite numerous attempts using various conditions, nothing corresponding to trioxadithiapentacycle **224** could be isolated from the attempted reactions (**Scheme 2.22**). Indeed, no pure compounds could be identified and, although deprotection of acetal groups was occurring, the precise course of the reaction could not be determined. Unfortunately, the synthetic strategy outlined in **Section 2.6** had failed.


2.8.3 Alternative avenues of investigation

Despite the failures encountered in the attempted formation of desired trioxadithiapentacycle **224**, aldol adduct **223** still offered some potential towards addressing the objectives of this research project. Additionally, it was hoped that exploration with this adduct may offer some insight into reasons for the failure to form trioxadithiapentacycle **224**, which had so readily formed in the earlier model study (**Section 2.4**).

As a first attempt, aldol adduct **223** was subjected to $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$, which gave a mixture of desired deprotected compound **225** and retro-aldol adduct **226** (**Scheme 2.23**).^{lxii} Unfortunately, desired deprotected compound **225** was only isolated in ca. 80% purity (too

^{lxii} In this particular case, the resulting hemiacetal, obtained as a result of a retro-aldol reaction, was trapped as a methoxy acetal.

impure to characterize) and was produced in similar yield to retro-aldol adduct **226** (39% isolated yield).




a) $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$, acetone, MeOH

Scheme 2.23

Retro-aldol adduct **226** was obtained as a pure compound (Scheme 2.23). The structure was assumed to have undergone no isomerization events. The configuration of the methoxy group was suggested by a positive NOE on HC-4'' and HC-2'' on irradiation of the methoxy group and vice versa. A positive NOE on HC-2'' on irradiation of HC-4'' and vice versa was also observed.

Noting the propensity of aldol adduct **223** towards retro-aldol and anticipating the need for a desulfurization reaction soon in the reaction sequence, an adjustment was made in the order of steps. Desulfurization of **223** followed by deprotection of the three acetal groups with $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ in acetone/MeOH (5% v/v), cleanly furnishing **227** in 87% yield (Scheme 2.24) over two steps without detectable retro-aldol **226** (Scheme 2.23).



a) Raney nickel, THF, Δ b) $\text{FeCl}_3 \cdot 6 \text{H}_2\text{O}$, acetone, MeOH c) Et_3SiOTf , 2,6-lutidine, CH_2Cl_2
d) $\text{HF} \cdot \text{pyridine}$, pyridine, THF, H_2O (cat.)

Scheme 2.24

In order to effectively utilize **227**, the C-5, C-9, and C-13 alcohols require differentiation before oxidation of C-9 and C-13 alcohols could be attempted. Fortunately, C-13-OH was previously shown to be unreactive towards Et_3SiOTf in a related compound (cf. C-3'-OH in diol **213**, **Scheme 2.19**). It was hoped that this lack of reactivity would translate to **227**, leaving two alcohols to differentiate, C-5 and C-9. Considering the C-5 and C-9 alcohols have considerable differences in their surrounding environments, it was speculated that these two alcohols should have different reactivities. Depending on their relative reactivities, two potential strategies could be investigated: 1) the C-5-OH (of **227**) could be selectively protected; or, 2) the bis-protected compound (cf. **229**, **Scheme 2.24**) could be selectively hydrolyzed (i.e., if C-9-OH of **229** would be more reactive towards silylation, it should also be more reactive towards selective hydrolysis).

Treatment of **227** with Et₃SiOTf produced a 5:1 mixture of **228** and the C-9 triethylsilyl ether, as well as **229** and some recovered starting material (**Scheme 2.24**). The mono-silylated compounds were not separable from each other; therefore, the reaction was typically run to nearly equal ratios of **228** and **229** to avoid complication of carrying the minor C-9 triethylsilyl ether forward. Bis-silylated derivative **229** could be efficient recycled to starting material **227**.

The position of the silyl-protecting group of **228** was determined by NOE (**Figure 2.20**). A positive NOE was detected on HC-5 upon irradiation of the methylene (-H₂C-) group of the silyl-protecting group and vice versa. No NOE was detected on HC-9 upon irradiation of the methylene (-H₂C-) group^{lxiii} of the silyl-protecting group and vice-versa.




Figure 2.20 NOE results for **228**


Obtaining compound **228** provided an avenue for further investigation because C-5-OH was differentially protected from C-9 and C-13-OH. Where the previous strategy had failed (**Section 2.8.2**), a new possibility emerged that could address the objectives of this research project (**Section 2.1**).

^{lxiii} The methylene H's of the silyl group are interchangeable. **Figure 2.19** is drawn arbitrarily.

2.8.4 Synthesis and isomerization of the putative common precursor

Oxidation of **228** with IBX in DMSO gave the corresponding tetraone **230** in good yield (**Scheme 2.25**). Hydrogenolysis of the benzyl group with Raney nickel gave a complicated mixture of compounds that was not characterized, but was immediately subjected to HF•pyridine to hydrolyze the triethylsilyl group. Interestingly, a mixture of hemiacetals (ca. 80% of the reaction mixture; identified by the signals at ca. δ_{H} 6.19, 6.35, 6.39, and 6.46 ppm and acetal carbons δ_{C} 104.4, 104.6, and 104.7) was produced with a very small amount of enol, β -diketone tautomers (2 diastereomers; C-8 signals at δ_{C} 61.9 and 61.1) content and a trace amount of siphonarin B (**4**) (ca. 2% of the reaction mixture).^{lxiv} This mixture of hemiacetals was speculated to be the elusive putative common precursor **14/15** of the siphonariid polypropionates (**4**, **6**, **8**, and **10**). If this were the case, this would be the first enantioselective synthesis of putative acyclic precursor **14/15**, but to claim this, the mixture of hemiacetals would have to be isomerized to one, or more, of the known compounds (**4**, **6**, **8**, and **10**) (*vide infra*).

^{lxiv} Diagnostic signal at 5.12 ppm (^1H NMR spectrum; CDCl_3).



a) IBX, DMSO b) Raney nickel, EtOH, Δ c) $\text{HF} \cdot \text{pyridine}$, pyridine, THF, H_2O (cat.)

Scheme 2.25^{lxv}

Putative common precursor **14/15** exists primarily as a mixture of hemiacetals **231** – **234** (Figure 2.21). This mixture of hemiacetals bears a strong resemblance to the impurities present in the ^1H NMR spectroscopy of natural siphonarin B (**4**), provided by Garson and reported in Paterson's total synthesis of siphonarin B (**4**).¹⁵ It is proposed that of the four observed hemiacetals, two (i.e., **231** and **233**) arise from addition of the C-5-OH group onto C-9 carbonyl and two (i.e., **232** and **234**) arise from addition of the C-11-OH group on the C-7 carbonyl. The relationships between **231** and **232** and between **233** and **234** are very close; i.e., they have identical configuration around the ring with only subtle differences in the substituents at C-9 and C-5 (in **231/233**) versus those at C-7 and C-11 (in **232/234**). It is important to note that an additional four hemiacetals are possible (8 total) from the two

^{lxv} Atom numbering in the intermediates leading up to the natural products was performed according to IUPAC. Atom numbering of the natural products was performed according to the numbering scheme applied by the scientists responsible for isolation and structure determination.

different cyclization pathways (C-5-OH \rightarrow C-9 carbonyl and C-11-OH \rightarrow C-7 carbonyl) that have the opposite configuration at the acetal carbon (i.e., C-9 in **213/233** and C-7 in **232/234**). However, the additional four hemiacetals (two from each cyclization pathway) do not benefit from anomeric stabilization (i.e., the hemiacetal OH group is in an equatorial orientation) and were discounted as possible contributors to the observed equilibrium. This hypothesis is consistent with the experimental and computation results from the model study (**Section 2.4**).

The hemiacetals **231** - **234** were remarkably stable to silica gel chromatography. Further support of their stability was provided by allowing the mixture to stand at room temperature (in the dark) in CDCl₃; the mixture of hemiacetals slowly produced siphonarin B (**4**) (ca. 9% of the reaction mixture after 28 days) with very little change in the hemiacetal ratio. None of the other known siphonariid polypropionates (**6**, **8**, and **10**) were detected.





Figure 2.21 ^1H NMR spectrum of the putative common precursor

Turning towards the earlier model study (**Section 2.4**) for guidance on how to proceed in isomerizing **14/15** into one or more of the isolated polypropionate structures (**4**, **6**, **8**, and **10**), the first condition attempted was imidazole in CDCl_3 (**Scheme 2.26**).⁷⁵ Based on the previous work, this condition was viewed as having the best chance to form caloundrin B (**10**) (**Section 2.4**).

Exposure of **14/15** (primarily as a mixture of hemiacetals **231** – **234**) to imidazole in CDCl_3 produced siphonarin B (**4**) as the only identifiable natural product in 70% isolated yield after 1 day along with some remaining **14/15**. This experiment conclusively showed that the putative common precursor **14/15** had been synthesized, as had been previously speculated, and concluded the first enantioselective total synthesis of siphonarin B (**4**).

Subjecting purified siphonarin B (**4**) to imidazole in CDCl_3 for 2 days, returned siphonarin B (**4**) and **14/15**. The **14/15** obtained from this experiment existed as a different ratio of hemiacetals than that obtained from triethylsilyl hydrolysis of **230** (see **Figure 2.21**). This experiment showed that, under these conditions, the formation of siphonarin B (**4**) is reversible. Caloundrin B (**10**) was not observed as a product of any of the isomerization experiments with imidazole in CDCl_3 .



Scheme 2.26

The NMR data of natural and synthetic siphonarin B (**4**) are compared in **Tables 2.10** and **2.11**.

Table 2.10. ^1H NMR (CDCl_3) comparison of natural and synthetic siphonarin B (**4**)

natural ^a			synthetic	
δ_{H}	multiplicity (J 's in Hz)	assignment ^a	δ_{H}	multiplicity (J 's in Hz)
5.14	s	HO	5.12	s
3.88	br d (10.5)	HC-5	3.91	d (10.5)
3.81	br s	HC-11	3.81	br s
3.28	q (7)	HC-14	3.27	q (7)
3.11	br s	HO	3.08	br s
2.79	q (7)	H ₂ C-20	2.77	q (7.5)
2.66	q (6.5)	HC-8	2.66	q (7)
2.61	br q (7)	HC-4	2.61	q (6.5)
2.48	dq (18.5, 7)	HC-2	2.48	dq (18.5, 7)
2.28	dq (10.5, 6.5)	HC-6	2.32-2.18	2H m
2.25	dq (18.5, 7)	HC-2		
2.04	dq (2.5, 7)	HC-12	2.05	dq (2.5, 7)
2.00	s	H ₃ CC-18	1.97	s
1.98	s	H ₃ CC-16	1.96	s
1.83	dq (2, 7)	HC-10	1.86	dq (2, 7)
1.25	d (7)	H ₃ CC-12	1.25	d (7)
1.21	d (7)	H ₃ CC-10	1.21	d (7)
1.20	t (7)	H ₃ CC-20	1.21	t (7)
1.18	d(7)	H ₃ CC-14	1.19	d (7)
1.07	d (7)	H ₃ CC-4	1.07	d (7)
1.07	d (6.5)	H ₃ CC-8	1.07	d (6.5)
0.94	t (7)	H ₃ CC-2	0.94	t (7)
0.76	d (6.5)	H ₃ CC-6	0.77	d (6.5)

^a Data and assignments according to ref 8.

Table 2.11. ^{13}C NMR (CDCl_3) comparison of natural and synthetic siphonarin B (**4**)

natural ^a			synthetic		
δ_{C}	assignment ^b (carbon #)	δ_{C}^c	δ_{C}	assignment ^b (carbon #)	δ_{C}^c
213.3	C-3	213.5	38.7	C-12	38.9
206.4	C-7	206.7	38.4	C-10	38.6
179.8	C-17	180.1	35.6	C-2	35.9
165.5	C-19	165.7	24.7	C-20	24.9
161.6	C-15	161.8	13.0	CH ₃ C-10	13.2
121.6	C-16	121.8	12.6	CH ₃ C-12	12.8
117.2	C-18	117.5	11.9	CH ₃ C-14	12.1
105.1	C-9	105.4	11.4	CH ₃ C-20	11.6
103.1	C-13	103.4	10.9	CH ₃ C-16	11.1
74.6	C-5	74.82	9.4	CH ₃ C-18	9.6
74.6	C-11	74.80	9.3	CH ₃ C-6	9.5
50.0	C-8	50.2	8.6	CH ₃ C-8	8.8
46.0	C-4	46.2	8.2	CH ₃ C-4	8.4
45.3	C-6	45.5	7.4	CH ₃ C-2	7.6
42.4	C-14	42.7			

^a Ref 8. ^b Assignments from ref 9. ^c Chemical shifts for synthetic material are consistently 0.2-0.3 ppm higher than those reported for the natural product presumably due to a different reference standard; δ_{C} CDCl_3 = 77.23 was used for this study.

The specific rotations of natural ($[\alpha]_{\text{D}} +13$ (c 0.14, CHCl_3)) and synthetic^{lxvi, 15} ($[\alpha]_{\text{D}} +12$ (c 0.1, CHCl_3)) compare favorably.

Of the four hemiacetals **231** – **234** originally present in **14/15**, only two hemiacetals were present in any appreciable amount (δ_{H} 6.39 and 6.19) following isomerization with


^{lxvi} Paterson obtained ($[\alpha]_{\text{D}} +10.5$ (c 0.12, CHCl_3)) for his synthetic sample.

imidazole. These hemiacetals are hypothesized to be **231** and **232**, considering **Figure 2.21**. This conclusion is further rationalized based on the results of the trioxaadamantane model study (**Section 2.4**): **231** is assumed to be the most stable hemiacetal from **14** (8*S*, C-5-OH → C-9 carbonyl) and **232** is the most stable from **15** (8*R*, C-11-OH → C-7 carbonyl). No definitive structure proof was attempted.

Continuing with investigation of the conditions identified in the earlier model study (**Section 2.4**), exposure of **14/15** to DBU in benzene-*d*₆ rapidly induced a retro-Claisen rearrangement (**Scheme 2.27**). However, significant C-14 epimerization occurred during the course of the reaction to give a 1.4:1 ratio of baconipyronone C (**8**): 14-*epi*-baconipyronone C (**235**). Baconipyronone C (**8**) was isolated from this reaction mixture in 50% yield providing the first total synthesis of **8** via the proposed retro-Claisen rearrangement from the contiguous carbon skeleton. 14-*epi*-baconipyronone C (**235**) was isolated from the crude reaction mixture in 30% yield for a combined yield of 80%.

The isomerization of baconipyronone C (**8**) to 14-*epi*-baconipyronone C (**235**) was verified by exposing baconipyronone C (**8**) to DBU in benzene-*d*₆ (**Scheme 2.27**). Rapid epimerization occurred to give a 1.3:1 ratio of **8** and **235**, respectively, within 45 minutes. Interestingly, the C-14 epimer **235** isolated from these experiments did not match the NMR data, specific rotation, and *R_f* (same mobile and stationary phases as reported previously) of a compound that was tentatively assigned as 14-*epi*-baconipyronone C (**235**) in a previous study.^{lxvii, 28, 142}

^{lxvii} Data for the putative 14-*epi*-baconipyronone C (actually C-10 epimer **236**) was provided by Prof. Paterson in a private communication. See also Chen, D. Y-K. Ph.D. Thesis, University of Cambridge, Cambridge, U.K., 2002.



Scheme 2.27

Comparison of the ¹³C NMR data (CDCl₃) for all three compounds (baconipyronone C (**8**), the 14-*epi*-baconipyronone C (**235**) isolated from this study, and the putative 14-*epi*-baconipyronone C (**236**)^{lxviii} isolated by Paterson²⁸) led to the hypothesis that 10-*epi*-baconipyronone C (**236**) had been formed in all three syntheses based on the esterification approach.^{lxix, 28-30}

^{lxviii} Likely the C-10 epimer (*vide infra*).

^{lxix} It is possible that C-10 epimerization occurred via enolization of the activated ester and/or ketene formation.

Table 2.12. ^{13}C NMR (CDCl_3) comparison of baconipyronone C (**8**), 14-*epi*-baconipyronone C (**235**), and 10-*epi*-baconipyronone C (**236**)

assignment ^a	8	14-<i>epi</i>-baconipyronone C (235)		10-<i>epi</i>-baconipyronone C (236)	
	δ_{C}^b	δ_{C}^b	$ \Delta\delta_{\text{C}} $	δ_{C}^c	$ \Delta\delta_{\text{C}} $
C-7 or C-3	212.1	212.3	0.2	213.5	1.4
C-3 or C-7	211.1	211.7	0.6	211.7	0.6
C-13	210.7	210.4	0.3	210.4	0.3
C-17	179.9	179.9	0	179.9	0
C-9	174.3	173.8	0.5	173.4	1.1
C-19	164.8	165.0	0.2	164.7	0.1
C-15	160.8	160.0	0.8	161.0	0.2
C-16	120.6	120.4	0.2	120.4	0.2
C-18	118.5	118.4	0.1	118.3	0.2
C-11	77.8	76.6	0.2	74.9	2.9
C-5	74.0	74.1	0.1	73.5	0.5
C-14	51.2	48.7	2.5	51.3	0.1
C-12	48.8	47.8	1.0	47.0	1.8
C-4 or C-6	47.5	47.6	0.1	45.7	1.8
C-6 or C-4	46.0	46.1	0.1	45.6	0.4
C-10	41.1	42.4	1.3	41.7	0.6
C-2 or C-8	35.1	35.5	0.4	35.6	0.5
		35.4	0.3		
C-20	24.7	25.0	0.3	24.7	0
CH ₃ C-10	15.0	15.1	0.1	13.5	1.5
CH ₃ C-12	14.1	14.9	0.8	13.3	0.8
CH ₃ C-4 or CH ₃ C-6	13.8	13.7	0.1	12.7	0.9
CH ₃ C-14	13.1	13.5	0.4	11.4	1.7
CH ₃ C-20	11.3	11.5	0.2	9.9	1.4
CH ₃ C-16	9.9	10.0	0.1	9.5	0.4
CH ₃ C-6 or CH ₃ C-4	9.6	10.0	0.4	9.2	0.4
CH ₃ C-18	9.5	9.7	0.2	8.0	1.5
CH ₃ C-8 or CH ₃ C-2	7.7	7.9	0.2	7.6	0.1
CH ₃ C-2 or CH ₃ C-8	7.2	7.7	0.5	7.3	0.1

^a Assignments made via COSY, HSQC and HMBC. Although two different sets of signals can be assigned for two different $\text{CH}_3\text{CH}_2\text{C}(\text{O})\text{CH}(\text{Me})$ - fragments, the fragments cannot be assigned (e.g. C-4 vs. C-6). Assignments only apply to **8** and **235**. ^b Reference standard: $\delta_{\text{C}} \text{CDCl}_3 = 77.23$. ^c Reference standard: $\delta_{\text{C}} \text{CDCl}_3 = 77.0$.

The assignment of **235** is supported in two ways. The most acidic proton in baconipyrone C (**8**) is expected to be HC-14 (vinylogous β -ketoester): brief treatment of **8** with base (DBU) produced **235** as the only product. The ^{13}C NMR of **8** and **235** are very similar with $\Delta\delta_{\text{C}}$ only 0.8-1.2 ppm for C-10, C-11, C-12, and the largest difference (2.5 ppm) for C-14. However, **236** is quite different from that of **8** with 7 carbons having $\Delta\delta_{\text{C}} > 1.5$ and there are significant differences in the chemical shifts for the methyl signals. Unfortunately, the hypothesis that the latter is actually the C-10 epimer **236** cannot be confirmed because assignments for the ^{13}C data are not available.

Considering the conditions explored in the earlier model study (**Section 2.4**), lengthy exposure of **14/15** to HF•pyridine remained as a possible route to caloundrin B (**10**). Exposure of **14/15** for 16 hrs HF•pyridine gave a small amount (20% isolated) of siphonarins B (**4**) and recovered starting hemiacetals (60% isolated). Resubjecting the hemiacetals for a longer period of time under identical conditions was unproductive and led to unidentifiable compounds.

2.4.8.1 Conclusions on the synthesis and isomerization of the putative common precursor 14/15

The enantioselective total synthesis of putative common precursor **14/15** was achieved in 18 steps in 3.1% overall yield (20 total steps). The putative common precursor **14/15** exists mainly as a mixture of four hemiacetals, speculated to be hemiacetals **231** - **234** (**Figure 2.21**). The hemiacetals **231** - **234** proved to be remarkably stable to silica gel chromatography and did not spontaneously form any of the polypropionate structures isolated from siphonariid extracts (i.e., **4**, **6**, **8**, and **10**) upon standing (28 days in CDCl_3).

The isomerization conditions identified in the model study (**Section 2.4**) were attempted with the putative common precursor **14/15**.

Imidazole in chloroform readily isomerized **14/15** to provide siphonarin B (**4**) (**Scheme 2.26**). This work was the first enantioselective synthesis of siphonarin B (**4**). Interestingly, these conditions were effective in the model study to provide trioxaadamantane ring system **150** (see **Section 2.4**), but the presence of caloundrin B (**10**) was not detected in the reaction mixture.

HF•pyridine, a reagent proven favourable in the model system (**Section 2.4**) to produce the truncated structure of siphonarin B (**4**) (cf. **138**, **Scheme 2.2**), was not as productive or clean when applied to **14/15**.

Exposure of **14/15** to DBU in benzene- d_6 readily induced retro-Claisen rearrangement. Baconipyrone C (**8**) was obtained was obtain in 50% yield (final step). This is first total synthesis of baconipyrone C (**8**) via the proposed “biomimetic” route and the first synthesis to explore a route other than that based on esterification. Unfortunately, these conditions also readily epimerized baconipyrone C (**8**) to provide 14-*epi*-baconipyrone C (**235**). Baconipyrone A (**6**) was not detected; i.e., no retro-Claisen rearrangement/aldol cascade occurred under these conditions.

Caloundrin B (**10**) was never observed in any of these isomerization experiments. Other conditions, or an alternative strategy, would have to be investigated to access the elusive caloundrin B (**10**).

2.8.5 Investigation of alternative conditions

An early experiment to determine the correct order of deprotection of tetraone **230** to access putative common precursor **14/15** (**Scheme 2.25**), found that triethylsilyl hydrolysis

followed by attempted hydrogenolysis of the Bn group with a very small amount of Raney nickel in refluxing EtOH gave what appeared to be a mixture of Bn-protected retro-Claisen rearrangement products by ^1H NMR spectroscopy.^{lxx} It was hypothesized that exposure of **14/15** to a solid phase might induce retro-Claisen rearrangement under more controlled conditions^{lxxi}. Silica gel and aluminum oxide are known to induce retro-Claisen rearrangement in related systems during chromatography.^{14, 15}


Subjecting **14/15** to neutral aluminum oxide in refluxing ethanol^{lxxii} gave a 3: 5: 7: 10 mixture of baconipyrone A (**6**), siphonarin B (**4**), baconipyrone C (**8**), and retro-Claisen ester **237** (Scheme 2.28). Ester **237** arises from the alternative hemiacetal formed from C-11-OH addition onto the C-7 carbonyl. Interestingly, ester **237** from the alternative hemiacetal was the dominant compound (40%) in the reaction mixture. Also, for the first time, baconipyrone A (**6**) was detected.

The observation of **237** confirmed the hypothesis (Section 2.8.4) that the alternative addition of C-11-OH onto C-7 carbonyl to form hemiacetals **232** and **234** (Figure 2.21) was occurring. Under these conditions, isomerization to the alternative hemiacetals arising from C-5-OH onto C-9 carbonyl is slow relative to retro-Claisen rearrangement.

^{lxx} Essentially, hydrogenolysis of the benzyl group had failed; diagnostic ester peaks were observed in the ^1H NMR (ca. 5.0 – 5.5 ppm) spectrum of the crude reaction mixture. The products of this reaction were not characterized.

^{lxxi} Reactions employing Raney nickel with this substrate were capricious.


^{lxxii} A control experiment of **14/15** in refluxing ethanol returned unaltered starting material.



a) aluminum oxide, EtOH, Δ

Scheme 2.28


The structure of **237** was determined by two dimensional NMR spectroscopy: COSY, HSQC, and HMBC (**Figure 2.22**). Eight isolated spin systems were determined by COSY. One bond connectivity (H to C) was established by HSQC. Three of the spin systems corresponded to the γ -pyrone methyl (x2) and ethyl group signals. There were two additional isolated ethyl groups, two spin systems each containing a proton correlated to a carbinol signal (δ_C 76.1 and 73.1 ppm) (as determined by HSQC), and an isolated proton at 4.03 ppm. The isolated proton, HC-1', was identified by its diagnostic ^1H NMR chemical shift and multiplicity (HC-1': quartet, 4.03 ppm). $\text{H}_3\text{CC-1'}$ (as determined by COSY) showed an HMBC correlation to C-3' and C-2''. The HC-4' to HC-6' spin system (as determined by COSY) showed an HMBC correlation from $\text{H}_3\text{CC-4'}$ to C-3'. The isolated ethyl signals were distinguished on the basis of HMBC correlation from $\text{H}_3\text{CC-9'}$ to C-7'; an HMBC correlation from $\text{H}_3\text{CC-6'}$ to C-7' was also detected. HC-2 was differentiated from HC-4 on the basis of HMBC correlations from their respective methyl groups: $\text{H}_3\text{CC-2}$ to C-1 (δ_C 174.3) and $\text{H}_3\text{CC-4}$ to C-5 (δ_C 215.4). The remaining ethyl group showed an HMBC correlation from $\text{H}_3\text{C-7}$ to C-5. It is assumed that no isomerization events occurred.



key HMBC correlations (H → C)

Figure 2.22 Structure determination of **237**

Exposure of siphonarin B (**4**) to aluminum oxide in refluxing ethanol gave recovered starting material (siphonarin B (**4**)), baconipyronone C (**8**), and baconipyronone A (**6**) in a ratio of 2.3: 3: 1 (**Scheme 2.29**). Retro-Claisen ester **237** was not detected in the ^1H NMR spectrum (CDCl_3) of the crude reaction mixture. Under these conditions, isomerization to the alternative C-11-OH addition onto C-7 carbonyl is slow relative to the retro-Claisen reaction.



Scheme 2.29


With this latter experiment in mind and armed with the following knowledge:

- 1) No C-14 epimerization occurred in the reactions of siphonarin B (**4**) and **14/15** with aluminum oxide.

2) Paterson found no cyclization of the C-9 hemiacetal onto the C-13 carbonyl in any of the PMB derivatives leading up to the culmination of his total synthesis of siphonarin B (**4**) (cf. **Scheme 1.14**) (i.e., no C-11 PMB-protected siphonarin B was formed).

3) The alternative C-11-OH addition onto C-7 carbonyl cannot occur with C-11-OH blocked as its corresponding benzyl ether.

Therefore, leaving the benzyl group intact prior during the retro-Claisen rearrangement reaction could provide a means to access baconipyron C (**8**) without epimerization that had been so extensive when **14/15** was subjected to DBU (**Scheme 2.27**).



a) HF•pyridine, pyridine, THF, H₂O (cat.) b) basic aluminum oxide, EtOH, Δ c) H₂, Pd/C, EtOH

Scheme 2.30

The triethylsilyl ether protecting group was hydrolyzed by brief treatment with HF•pyridine (**Scheme 2.30**). Gratifyingly, subjecting **238** to basic aluminum oxide^{lxxiii} in refluxing EtOH gave a 1:4 mixture of products that were speculated to be the Bn-protected derivatives of baconipyrones A (**6**) and C (**8**), **242** and **243**, respectively (**Figure 2.23**).^{lxxiv} Treating this mixture with palladium on carbon (10%) under an atmosphere of H₂ slowly (ca. 16 hours)^{lxxv,15} hydrogenolyzed the benzyl ether protecting groups to give baconipyrones A (**6**) and C (**8**) in excellent isolated yield (88% combined yield over two steps). There was no evidence of 14-*epi*-baconipyronone C (**235**), **237**, or siphonarins B (**4**) in the ¹H NMR spectrum of the crude reaction mixture.

The selectivity of this transformation can be rationalized by the transition state model proposed by Vogel to explain a related aldol reaction (see **241**, **Figure 2.23**).⁵¹ In the reaction of **238** with aluminum oxide, group selectivity between C-3 and C-7 carbonyls is achieved as a result of the retro-Claisen rearrangement (cf. **239** → **240**). Ketonization of enol(ate) **240** provides **242**, whereas intramolecular attack of enol(ate) **240** onto C-3 carbonyl, via **241**, results in **243**. This type of retro-Claisen rearrangement/aldol cascade reaction appears to be unprecedented.

^{lxxiii} Neutral aluminum oxide proved ineffective in this case.

^{lxxiv} Characteristic signals (dd's) above 5 ppm (¹H NMR spectrum (CDCl₃)). No attempt was made to separate or characterize the individual compounds, presumed to be benzyl-protected precursors of **6** and **8**.

^{lxxv} Paterson also observed slow hydrogenolysis of a similar PMB ether under these conditions.




Figure 2.23 Proposed retro-Claisen rearrangement and retro-Claisen rearrangement/aldol cascade pathways

A comparison of NMR data for natural and synthetic baconipyrones A (**6**) and C (**8**) are shown in **Tables 2.13, 2.14, 2.15, and 2.16**. The specific rotations of natural ($[\alpha]_D -82.0$ (c 0.47, $CHCl_3$)) and synthetic ($[\alpha]_D -96$ (c 0.13, $CHCl_3$)) baconipyrene A (**6**) compare

favorably as do those for natural^{lxxvi, 4, 28}: $[\alpha]_D$ -82 (*c* 0.16, MeOH) and synthetic^{lxxvii, 28-30}:
 $[\alpha]_D$ -81 (*c* 0.1, MeOH) baconipyrone C (**8**).

^{lxxvi} Initially reported by Faulkner as $[\alpha]_D$ -19 (*c* 0.90, MeOH), but revised by Paterson in a subsequent report.
^{lxxvi} Paterson: $[\alpha]_D$ -73.3 (*c* 0.77, MeOH); Yadav : $[\alpha]_D$ -70.20 (*c* 0.4, MeOH); Hoveyda: $[\alpha]_D$ +11.8 (*c* 0.09, MeOH).

Table 2.13. ^1H NMR (CDCl_3) comparison of natural and synthetic baconipyrone C (**8**)

natural ^a			synthetic	
δ_{H}	multiplicity (J 's in Hz)	assignment ^{a,b}	δ_{H}	multiplicity (J 's in Hz)
5.46	dd (9.0, 3.5)	HC-5	5.47	dd (3.5, 9)
4.16	q (6.9)	HC-14	4.15	q (7)
3.54	ddd (7.2, 9.0, 10.5)	HC-11	3.55	ddd (3, 9, 10)
3.64 ^c	d (10.5)	HO	3.38	d (10)
2.86	dq (9.0, 7.2)	HC-12	2.89-2.79	3H m
2.83	m	HC-4		
2.83	m	HC-6		
2.76	dq (18.1, 7.2)	HC-8	2.75	dq (18, 7)
2.56	dq (18.3, 7.2)	HC-2	2.60-2.45	4H m
2.56	q (7.6)	H ₂ C-20		
2.55	dq (2.7, 7.2)	HC-10		
2.39	dq (18.1, 7.2)	HC-8	2.44-2.29	2H m
2.34	dq (18.3, 7.2)	HC-2		
2.03 ^d	s	H ₃ CC-16	2.09	s
1.93	s	H ₃ CC-18	1.93	s
1.38	d (6.9)	H ₃ CC-14	1.38	d (7)
1.22	d (7.2)	H ₃ CC-10	1.22	d (7)
1.16	t (7.6)	H ₃ CC-20	1.16	t (7.5)
1.09	d (7.2)	H ₃ CC-12 ^e	1.09	d (7)
1.02	d (6.9)	H ₃ CC-6	1.02	d (7)
1.01	t (7.2)	H ₃ CC-8	1.01	t (7.5)
0.91	t (7.2)	H ₃ CC-2	0.91	t (7)
0.85	d (6.8)	H ₃ CC-4 ^e	0.86	d (7)

^a Data and assignments according to ref 4. ^b Although two different sets of signals can be assigned for two different $\text{CH}_3\text{CH}_2\text{C}(\text{O})\text{CH}(\text{Me})$ - fragments, the assignment of the individual fragments (e.g., C-4 vs. C-6) should be considered as arbitrary. ^c Other workers have reported this signal at 3.38 and 3.39 ppm.^{28, 29} ^d Other workers have reported this signal at 2.09 ppm.^{28, 29} ^e Assignments are reversed compared to ref 4. The methyls at C-4 (or C-6)^b and C-12 were assigned by HMBC through their correlations to C-5 and C-11, respectively.

Table 2.14. Comparison of ^{13}C NMR spectra of natural and synthetic baconipyrone C (**8**)

natural ^a			synthetic		
δ_{C}	assignment ^b	δ_{C} ^c	δ_{C}	assignment ^b	δ_{C} ^c
211.9	C-7 or C-3	212.1	41.1	C-10	41.3
210.9	C-3 or C-7	211.1	35.1 ^d	C-2 or C-8	35.32
210.4	C-13	210.7		C-2 or C-8	35.28
179.7	C-17	179.9	24.7	C-20	24.9
174.0	C-9	174.3	15.0	CH ₃ C-10	15.3
164.7	C-19	164.8	14.1	CH ₃ C-12	14.4
160.6	C-15	160.8	13.8	CH ₃ C-4 or CH ₃ C-6	13.7
120.4	C-16	120.6	13.1	CH ₃ C-14	13.4
118.2	C-18	118.5	11.3	CH ₃ C-20	11.5
77.5	C-11	77.8	9.9	CH ₃ C-16	10.1
73.7	C-5	74.0	9.6	CH ₃ C-6 or CH ₃ C-4	9.9
50.9	C-14	51.2	9.5	CH ₃ C-18	9.7
48.6	C-12	48.8	7.7	CH ₃ C-8 or CH ₃ C-2	7.9
47.2	C-4 or C-6	47.5	7.2	CH ₃ C-2 or CH ₃ C-8	7.5
45.7	C-6 or C-4	46.0			

^a Data from ref 4. ^b Assignments made via COSY, HSQC and HMBC. Although two different sets of signals can be assigned for two different CH₃CH₂C(O)CH(Me) - fragments, the fragments cannot be assigned (e.g. C-4 vs. C-6). ^c Chemical shifts for synthetic material are consistently 0.2-0.3 ppm higher than those reported for the natural product presumably due to a different reference standard; we used δ_{C} CDCl₃ = 77.23. ^d Two (2) overlapping signals.

Table 2.15. ^1H NMR (CDCl_3) comparison of natural and synthetic baconipyrone A (**6**)


natural ^a			synthetic	
δ_{H}	multiplicity (J 's in Hz)	assignment ^a	δ_{H}	multiplicity (J 's in Hz)
5.05	dd (4.7, 6.3)	HC-5	5.00	dd (4.5, 6.5)
4.09	q (6.9)	HC-14	4.04	q (7)
3.68	ddd (3.4, 8.6, 9.6)	HC-11	3.62	ddd (3.5, 8.5, 9.5)
3.43	d (9.6)	HOC-11	3.35	d (9.5)
3.00	dq (4.7, 7.2)	HC-6	2.96	(dq (4.5, 7)
2.84	dq (8.6, 6.9)	HC-12	2.79	(dq (8.5, 7)
2.65	dq (3.4, 7.2)	HC-10	2.64	dq (3.5, 7)
2.60	q (6.8)	HC-8	2.62-2.51	m
2.60	m	H ₂ C-20		
2.13	dq (6.3, 6.9)	HC-4	2.13	dq (6.5, 7)
2.05	s	H ₃ CC-16	2.05	s
1.95	s	H ₃ CC-18	1.95	s
1.66	dq (14, 7.5)	HC-2	1.66	dq (14.5, 7)
1.54	dq (14, 7.5)	HC-2	1.52	dq (14.5, 7)
1.38	d (6.9)	H ₃ CC-14	1.38	d (7)
1.29	d (7.2)	H ₃ CC-10	1.29	d (7)
1.16	t (7.5)	H ₃ CC-20	1.16	t (7.5)
1.07	d (6.8)	H ₃ CC-8	1.07	d (7)
1.06	d (6.9)	H ₃ CC-4	1.06	d (7)
1.00	d (7.2)	H ₃ CC-6	1.00	d (7)
0.91	d (6.9)	H ₃ CC-12	0.90	d (7)
0.86	t (7.5)	H ₃ C-1	0.86	t (7.5)

^a Data and assignments according to ref 4.

Table 2.16. ^{13}C NMR (CDCl_3) comparison of natural and synthetic baconipyrone A (**6**)

natural ^a			synthetic		
δ_{C}	assignment ^b	δ_{C} ^c	δ_{C}	assignment ^b	δ_{C} ^c
221.4 ^{d,e}	C-7	211.5	41.4	C-10	41.6
210.2	C-13	210.5	37.8	C-4	38.0
179.6	C-17	179.8	30.1	C-2	30.5
174.7	C-9	175.0	24.7	C-20	24.9
164.8	C-19	165.0	15.1	CH ₃ C-10	15.4
160.3	C-15	160.5	14.2	CH ₃ C-12	14.5
120.3	C-16	120.5	12.9	CH ₃ C-14	13.2
118.4	C-18	118.7	11.9	CH ₃ C-4 or CH ₃ C-6	12.1
77.3	C-5 or C-11	77.5	11.5	CH ₃ C-6 or CH ₃ C-4	11.8
77.1	C-11 or C-5	77.4	11.3	CH ₃ C-20	11.5
77.0 ^{d,f}	C-3	76.6	9.9	CH ₃ C-16	10.2
51.1	C-14	51.4	9.5	CH ₃ C-18	9.8
48.1	C-12	48.3	8.8	C-1	9.0
46.2	C-8	46.4	7.3	CH ₃ C-8	7.6
44.7	C-6	44.8			

^a Ref 4. ^b Assignments made via HSQC and HMBC. ^c Chemical shifts for synthetic material are consistently 0.2-0.3 ppm higher than those reported for the natural product presumably due to a different reference standard; we used $\delta_{\text{C}} \text{CDCl}_3 = 77.23$. ^d With the exception of the signals due to the γ -pyrone moiety, the chemical shifts reported for baconipyrone A (**6**) are within 0.1 ppm for those for baconipyrone B (**7**). ^e This value is much too high and must be an error (211.2 in baconipyrone B (**7**)). ^f This signal (76.1 in baconipyrone B (**7**)) would be obscured by solvent; the value from this study was obtained from a DEPT experiment.



a) neutral aluminum oxide, EtOH, Δ , 1 h b) basic aluminum oxide, EtOH, Δ , 1 h

Scheme 2.31

Several control experiments were performed to determine the origin of baconipyrene A (**6**) and its relationship to baconipyrene C (**8**) (**Scheme 2.31**). Exposure of baconipyrene C (**8**) to neutral alumina oxide (conditions that had induced retro-Claisen rearrangement in siphonarin B (**4**), **Scheme 2.29**), returned baconipyrene C (**8**) with no sign of epimerization (cf. **235**, **Scheme 2.27**) and no baconipyrene A (**6**). Repeating with basic aluminum oxide gave a 3:1 ratio of baconipyrene C (**8**) to C-14 epimer **235**,^{lxxviii} again with no detectable baconipyrene A (**6**). These control experiments suggest that the sequence of events leading to baconipyrene A (**6**) from the acyclic precursor or either of the contiguous carbon skeleton structures (**4** and possibly **10**) does not proceed through baconipyrene C (**8**). Subjecting baconipyrene A (**6**) to neutral alumina oxide in refluxing ethanol returned starting material,

^{lxxviii} Epimerization under these conditions and not during the transformation of **234** to **6** and **8** suggests that the C-11-OH may be facilitating HC-14 epimerization, perhaps through hydrogen bonding.

indicating that the reaction leading to **6** is not reversible under these conditions. No attempt was made to use basic aluminum oxide due to the high likelihood of inducing HC-14 epimerization, as demonstrated by baconipyrone C (**8**) producing **235** under these conditions.

2.8.5.1 Conclusion of the investigations into alternative conditions

Exposure of putative common precursor **14/15** to aluminum oxide in refluxing ethanol for 1 hour produced ester **237**, a compound never isolated from siphonariid extracts (**Scheme 2.28**). Ester **237** was not observed when siphonarin B (**4**) was exposed to the same conditions, but these conditions produced baconipyrones A (**6**) and C (**8**) in addition to recovered starting material (siphonarin B (**4**)) (**Scheme 2.29**). This implies that **14/15** is not present in any appreciable amount when retro-Claisen rearrangement occurred in the isolation experiments on siphonariid mollusks. Either isomerization to siphonarin B (**4**) preceded retro-Claisen rearrangement or **14/15** is not a biosynthetic product.

The investigation of alternative conditions led to the total synthesis of baconipyrones A (**6**) and C (**8**) in excellent combined yield without competing C-14 epimerization (**Scheme 2.30**). This was the first total synthesis of baconipyrone A (**6**). Interestingly, under the conditions examined, the processes leading to baconipyrones A (**6**) and C (**8**) are irreversible implying that baconipyrone C (**8**) is not a precursor to baconipyrone A (**6**).

2.9 Conclusions

In summary, the siphonariid polypropionates: siphonarin B (**4**), baconipyrone A (**6**), and baconipyrone C (**8**) were synthesized from their putative common precursor **14/15** (existing mainly as hemiacetals **231** - **234**). This work constitutes the first enantioselective synthesis of siphonarin B (**4**), baconipyrone A (**6**), and the putative common precursor **14/15**. The synthesis of baconipyrones A (**6**) and C (**8**) were achieved "biomimetically" via the

proposed retro-Claisen rearrangement (**8**) and an unprecedented retro-Claisen rearrangement/aldol cascade (**6**). This work is the first total synthesis of baconipyronone C (**8**) via a route other than the "classical" route based on esterification.




Figure 2.24 Synthetic summary

The synthesis of **14/15** proceeded in a longest linear sequence of 18 steps in 3.1% overall yield (20 total steps) by convergent aldol coupling of simple achiral, *meso*, or racemic precursors. Enantioselective organocatalyzed direct aldol reactions proceeding with dynamic kinetic resolution generated five of the seven stereocenters in the putative acyclic precursor (C-4, 5, 6, 12, 14; dr >20:1). The remaining two stereocenters result from carbonyl reduction (C-11; dr >20:1) and an unusual enol ether oxymercuration/demercuration (C-10; dr 3.5:1).

Evidence was provided showing that both baconipyrones A (**6**) and C (**8**) can be derived from siphonarins B (**4**) and, as such, the baconipyrones are likely artifacts of isolation.

Under the conditions examined, baconipyronone A (**6**) could not be generated from baconipyronone C (**8**) and vice-versa indicating that the processes at work are irreversible and that baconipyronone C (**8**) is not a precursor of baconipyronone A (**6**). Despite all the experiments performed and paying keen attention to the products of each reaction, caloundrin B (**10**) was never detected.

Interestingly, experiments have shown that the common precursor **14/15** (existing as hemiacetals **231 - 234**) under the same conditions that produced the baconipyrones A (**6**) and C (**8**) from siphonarin B (**4**) also produced ester **237** from retro-Claisen rearrangement of an alternative hemiacetal (C-11-OH addition onto C-7 carbonyl). This sequence of events occurred with equal facility to the events that produced the known compounds, baconipyronone A (**6**) and C (**8**). Ester **237** has never been observed in any isolation experiment. Based on this, it seems unlikely that hemiacetals **231 - 234** are the precursors of baconipyronone A (**6**) and C (**8**) unless equilibration to siphonarin B (**4**) occurred before retro-Claisen rearrangement. Considering that siphonarin B (**4**) has always been co-isolated with every compound in this series, siphonarin B (**4**) is more likely a biosynthetic product as opposed to **14/15**. This is further supported by the remarkable stability that **14/15** exhibits.

Caloundrin B (**10**) is the 'missing link' in this work: it was never observed despite careful analysis. This fact challenges the hypothesis that caloundrin B (**10**) is an artifact of isolation because **10** should be present at a level that represents its relative stability. It is possible that caloundrin B (**10**) is a biosynthetic product, which isomerizes to more stable ring-chain tautomers (**4**) and/or rearranges to baconipyrones A (**6**) and C (**8**).

2.10 Suggestions for future research

The missing piece of this puzzle is caloundrin B (**10**). With this compound in hand, it would have been possible to more clearly determine which of these compounds are artifacts of isolation and what might be the real biosynthetic product.

Considering the failure to form the pentacyclic ring system in the elaborated structure (cf. **223** → **224**, **Section 2.82**), it would be worthwhile to test whether a more truncated system would form the required ring system, but still have functionality to use a handle to install more of the structure (**Figure 2.25**).

In a preliminary experiment, pentacyclic compound **245** was formed from **172** and isobutyraldehyde (**244**) (unoptimized and uncharacterized, but the NMR spectra of this compound were consistent to **167**, **Section 2.4**) through the previously established synthetic sequence described in **Section 2.4**. Based on this result, it seems likely that the increased steric hindrance (or the presence of a branched chain) present in **223** (or **224**), versus **245**, may not be the culprit in the observed failure.

It is suggested to continue this line of research and test whether **172** and *ent*-**31** will form the corresponding pentacyclic compound **246** (**Figure 2.25**). A positive result from this reaction would provide a substrate that could be synthetically viable. A negative result could implicate the benzyl protecting group as the source of the problem. If the benzyl group is the source of the problem, a change of this protecting group might solve the observed failure (i.e., appropriate selection of P in **247**).

Either way, there are still several avenues of investigation left to explore that could lead to a first total synthesis of caloundrin B (**10**), an unusual and intriguing compound.




Figure 2.25 Proposed continuation of this research

EXPERIMENTAL

3.1 General methods

Anhydrous solvents were distilled under argon atmosphere as follows: Tetrahydrofuran (THF) from benzophenone sodium ketyl; diethyl ether from benzophenone sodium ketyl; CH_2Cl_2 from CaH_2 ; MeOH from $\text{Mg}(\text{OMe})_2$. All experiments involving air- and/or moisture sensitive compounds were conducted in an oven dried round-bottom flask capped with a rubber septum, and attached via a needle and connecting tubing to an argon manifold equipped with mercury bubbler (ca. 5 mm positive pressure of argon). Low temperature baths were: ice/water (0 °C) and $\text{CO}_2(\text{s})/\text{acetone}$ (-78 °C). Unless otherwise noted, reaction temperatures refer to that of the bath.

Preparative TLC (PTLC) was carried out on glass plates (20×20 cm) pre-coated (0.25 mm) with silica gel 60 F₂₅₄. Materials were detected by visualization under an ultraviolet lamp (254 nm) and/or by treating a 1 cm vertical strip removed from the plate with a solution of phosphomolybdic acid (5%) containing a trace of ceric sulfate in aq sulfuric acid (5% v/v), or with basic KMnO_4 [KMnO_4 (1.5 g), K_2CO_3 (10 g), 10% aq. NaOH (1.25 mL), in H_2O (200 ml)], followed by charring on a hot plate. TLC was carried out on glass plates (1×3 cm) pre-coated (0.25 mm) with silica gel 60 F₂₅₄ and was visualized in the same manner as that described for PTLC.

Concentration refers to removal of volatiles with a rotary evaporator under vacuum supplied by a water aspirator. Evacuation at ca. 0.5 torr with a vacuum pump generally followed rotary evaporation.

Flash column chromatography (FCC) was performed according to Still et al.¹⁴³ with Merck Silica Gel 60 (40-63 μm). All mixed solvent eluents are reported as v/v solutions.

Unless otherwise noted, all reported compounds were homogeneous by thin layer chromatography (TLC) and by ^1H NMR spectroscopy.

3.2 Spectral data

High resolution mass spectra (HRMS) and low resolution mass spectra (LRMS) were obtained on a VG 70E double focusing high resolution spectrometer; only partial data are reported. EI ionization was accomplished at 70 eV and CI at 50 eV with ammonia as the reagent gas; only partial data are reported. Alternatively, HRMS was obtained on an LC-MS/MS time-of-flight high resolution spectrometer with electrospray ionization (ESI) from acetonitrile solution.

IR spectra were recorded on a Fourier transform interferometer using a diffuse reflectance cell (DRIFT) or by Thin Film; only diagnostic and/or intense peaks are reported. Unless otherwise noted all experiments used DRIFT.

Unless otherwise noted, NMR spectra were measured in CDCl_3 solution at 500 MHz for ^1H and 125 MHz for ^{13}C . Signals due to the solvent (^{13}C NMR spectroscopy) or residual protonated solvent (^1H NMR spectroscopy) served as the internal standard: CDCl_3 (7.26 δ_{H} , 77.23 δ_{C}); C_6D_6 (7.16 δ_{H} , 128.39 δ_{C}). The ^1H NMR chemical shifts and coupling constants were determined assuming first-order behavior. Multiplicity is indicated by one or more of the following: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad), ap (apparent); the list of couplings constants (J) corresponds to the order of the multiplicity assignment. Couplings constants (J) are reported to the nearest 0.5 Hz (digital resolution ca. 0.2 Hz/pt) or the nearest 0.1 Hz (digital resolution ca. 0.03 Hz/pt). The ^1H NMR assignments were made based on chemical shift and multiplicity and were confirmed, where necessary, by homonuclear decoupling and/or two-dimensional correlation experiments (gCOSY, gHSQC,

gHMBC).¹⁴⁴ The ¹³C NMR assignments were made on the basis of chemical shift and multiplicity (as determined by ¹³C-DEPT or gHSQC) and were confirmed, where necessary, by two-dimensional ¹H/¹³C correlation experiments (gHSQC and/or gHMBC).¹⁴⁴ The multiplicity of ¹³C NMR signals refers to the number of attached H's (i.e., s = C, d = CH, t = CH₂, q = CH₃).

Specific rotations ([α]_D) are the average of 5 determinations at ambient temperature using a 1 mL, 10 dm cell; the units are 10⁻¹ deg cm² g⁻¹, the concentrations (*c*) are reported in g/100 mL, and the values are rounded to reflect the accuracy of the measured concentrations (the major source of error).

3.3 Materials

The following compounds and reagents were prepared as described previously: **124**,^{lxxix, 66} **125**,^{lxxx, 66} **127**,⁸⁵ **169**,⁶⁶ **170**,⁶⁹ **184**,⁹⁸ **190**,^{lxxxi, 70} **191**,⁷⁰ **192** and **193**,^{lxxxii, 70} **194** and **195**,⁷⁰ **196**,^{lxxxiii, 70}, IBX,¹⁴⁵ W-2 Raney nickel,¹⁴⁶ and FeCl₃-impregnated silica gel.⁹⁰ Et₃N and ⁱPr₂NEt (DIPEA) were distilled from KOH under argon and were stored over KOH. TiCl₄ and ⁱPr₂NH were distilled under argon atmosphere from CaH₂. All other reagents were commercially available and unless otherwise noted, were used as received.

3.4 Computational procedures

Computation procedures were carried out by Prof. Goodman (see **Section 2.4**). Conformation searches were carried out using the MMFF force field¹⁴⁷ as implemented in Batchmin¹⁴⁸ until all low energy structures had been found at least four times. The lowest energy structures were then reminimized at the B3LYP/6-31G** level¹⁴⁹⁻¹⁵² using Jaguar.¹⁴⁸

^{lxxix} Routinely performed at ca. 100 g scale.

^{lxxx} Routinely performed at 100-200 g scale.

^{lxxxi} Reaction scaled to ca. 8 g of **196**.

^{lxxxii} Reaction scaled to ca. 20 g.


^{lxxxiii} Known procedure applied to **195**. See below for a revised procedure to oxidize **194** to **196**.

In cases where the lowest energy MMFF conformations had similar energies, all the low energy structures were reminimized with B3LYP/6-31G**. Except for **141** and **149**, in all cases the lowest energy MMFF structure corresponded to the lowest energy B3LYP/6-31G** structure; for **141** and **149**, the preferred conformations were chairs (with the C-8 methyl group equatorial) according to MMFF, but were twist boats according to B3LYP/6-31G**.

3.5 Experimental Procedures and Spectral Data for Compounds

Spectral data and experimental procedures are presented in order by compound number with the exception of the natural products: these are presented last by compound number (i.e., **4**, **6**, **8**).

2-((2*S*,3*S*,4*S*,5*R*,6*R*)-3,7-Dihydroxy-5-((4-methoxybenzyl)oxy)-4,6-dimethylheptan-2-yl)-6-ethyl-3,5-dimethyl-4*H*-pyran-4-one (*ent*-39**)**



This procedure was not optimized. A solution of Hg(OAc)₂ (12 mg, 0.038 mmol) in water (1.5 mL) was added to a stirred solution of **215** (15 mg, 0.035 mmol) in THF (1.5 mL) at rt. The resulting yellow suspension was stirred at this temperature for 2 h and then a solution of Na₂CO₃ (20 mg, 0.19 mmol) in water (2 mL) was added in one portion. After 10 min, a solution of NaBH₄ (32 mg, 0.84 mmol) in water (2 mL) was added. After 1 min, the reaction was diluted with a 1:1 mixture of brine and water and extracted with CH₂Cl₂. The combined

organic layers were dried over Na₂SO₄, concentrated, and the residue taken up in ethanol (2 mL), and then NaBH₄ (12 mg, 0.32 mmol) was added to the stirred solution at rt. After ca. 48 h, the mixture was diluted with water and extracted with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by FCC (100% ethyl acetate, two elutions) to give **216** (3 mg; ca. 90% pure, ca.17%) and the known²⁸⁻³⁰ titled compound (8 mg, 51%)([α]_D -15 (*c* 0.45, CHCl₃)).

IR ν_{max} : 3430, 1652, 1609, 1588 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 7.23 (2H, ap d, *J* = 8.5 Hz, ArH), 6.84 (2H, ap d, *J* = 8.5 Hz, ArH), 4.63 (1H, d, *J* = 10.5 Hz, H₂CAr), 4.59 (1H, d, *J* = 10.5 Hz, H₂CAr), 4.21 (1H, br d, *J* = 9.5 Hz, HC-3'), 3.83-3.74 (1H, m, HC-7'), 3.78 (3H, s, H₃CO), 3.71 (1H, dd, *J* = 5, 10.5 Hz, HC-7'), 3.55 (1H, dd, *J* = 3.5, 8 Hz, HC-5'), 3.14-3.06 (2H, m, HO, HC-1), 2.61 (1H, dq, *J* = 15, 7.5 Hz, H₂C-C-6), 2.58 (1H, dq, *J* = 15, 7.5 Hz, H₂C-C-6), 2.09-1.94 (2H, m, HC-4', HC-6'), 1.99 (3H, s, H₃CC-3), 1.92 (3H, s, H₃CC-5), 1.18 (3H, t, *J* = 7.5 Hz, H₃CCH₂), 1.15 (3H, d, *J* = 7 Hz, H₃CC-4'), 1.09 (3H, d, *J* = 7 Hz, H₃C-1'), 1.04 (3H, d, *J* = 7 Hz, H₃CC-6').

¹³C NMR (125 MHz, CDCl₃) δ : 180.0 (s, C-4), 164.8 (s, C-2), 164.2 (s, C-6), 159.8 (s, Ar), 129.9 (s, Ar), 129.8 (d \times 2, Ar), 119.6 (s, C-3), 118.1 (s, C-5), 114.2 (d \times 2, Ar), 88.4 (d, C-5'), 76.4 (t, CH₂Ar), 72.1 (d, C-3'), 65.6 (t, C-7'), 55.5 (q, CH₃O), 39.0 (d, C-2'), 38.0 (d, C-6'), 35.5 (d, C-4'), 25.0 (t, CH₂C-6), 15.3 (q, CH₃C-6'), 14.7 (q, C-1'), 11.5 (q, CH₃CH₂), 11.2 (q, CH₃C-4'), 9.9 (q, CH₃C-3 or CH₃C-5), 9.7 (q, CH₃C-3 or CH₃C-5).

LRMS: *m/z* (relative intensity) 446 ([M]⁺, 1), 310 (7), 209 (13), 180 (36), 121 (100) (EI).

HRMS: *m/z* calcd for C₂₆H₃₈O₆ 446.2668, found 446.2672 (EI).

(4*S*,6*S*)-5-Hydroxy-4,6-dimethylnonane-3,7-dione (41)



41

Raney nickel (W2; 1 mL settled volume) was washed with THF (x3) and transferred to a solution of **122** (50 mg, 0.16 mmol) in THF (8 mL) and the resulting suspension was heated under reflux with vigorous stirring. After 5 h, the reaction mixture was allowed to cool to rt and aqueous HCl (1 M; 4 mL) was added. Concentrated HCl (12 M) was added dropwise (ca. 1 drop/min; **CAUTION**: H₂ evolution) until effervescence ceased (ca. 1 hr; pH<1). After 40 h, the mixture was diluted with ethyl acetate and washed sequentially with sat. NaHCO₃ and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by PTLC (20% acetone in hexanes; 2 elutions) to give the known²⁸⁻³⁰ titled compound (26 mg, 79%) ([α]_D -20 (*c* 1.1, CHCl₃)).

IR ν_{max} : 3498, 1709 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 4.02 (1H, ddd, *J* = 3.5, 4.5, 8 Hz), 3.22 (1H, d, *J* = 4.5 Hz), 2.73-2.62 (2H, m), 2.61-2.42 (4H, m), 1.15 (3H, d, *J* = 7 Hz), 1.05 (3H, t, *J* = 7 Hz), 1.04 (3H, d, *J* = 7 Hz), 1.04 (3H, t, *J* = 7 Hz).

¹³C NMR (125 MHz, CDCl₃): δ 216.0 (s), 215.9 (s), 73.2 (d), 47.7 (d), 47.6 (d), 36.6 (t), 35.1 (t), 14.2 (q), 10.3 (q), 7.9 (q), 7.6 (q).

LRMS: *m/z* (relative intensity) 218 ([M+18]⁺, 100), 210 (77), 183 (27), 101 (6) (CI, NH₃).

HRMS: m/z calcd for $C_{11}H_{20}O_3$ 200.1412 (218.1756 for $M+NH_4$), found 218.1754 (CI, NH_3).

1,4-Dioxo-8-thiaspiro[4.5]decane-6-carboxaldehyde (116)^{lxxxiv}



116

IBX (71.9 g, 0.257 mol, 1.2 equiv), was added to a stirred solution of **124**⁶⁶ (40.6 g, 0.214 mol) in acetonitrile (800 mL). The heterogeneous mixture was heated to 80 °C (oil bath temperature) and stirred at this temperature for 2 h. The reaction mixture was cooled in an ice bath for 1 h and then passed through a sintered glass funnel. The solid was washed with ethyl acetate (2 x 150 mL) and the combined filtrate and washings were concentrated to give an orange oil that was passed through a column of basic alumina (120 g; column diameter, 5.5 cm) eluting with ethyl acetate in hexane (1:1, 1200 mL). Concentration gave the titled compound as a pale yellow oil (33.3 g, 83%) that was homogeneous by ¹H NMR. The solids (62.5 g; mainly 2-iodosobenzoic acid by ¹H NMR in DMSO-*d*₆) were reoxidized to IBX (58.3 g, 81% yield based on initial amount of IBX used) with oxone® (1 equiv) according to Santagostino's procedure.^{lxxxv, 145}

IR ν_{\max} : 2840, 2737, 1721 cm^{-1} .

^{lxxxiv} Athanasios Karagiannis, unpublished results: under my direction.


^{lxxxv} There is an error in Santagostino's procedure to prepare IBX. They state that they used 1.3 equivalents of oxone®; however, by calculation they used 1.45 equivalents. In my experience, using 1.3 equivalents of oxone® did not cleanly produce IBX.

¹H NMR (300 MHz, CDCl₃): δ 9.85 (1H, s), 4.07-3.94 (4H, m), 2.96 (1H, dd, *J* = 9.5, 13.5 Hz), 2.86 (1H, br d, *J* = 13.5 Hz), 2.81-2.72 (2H, m), 2.64 (1H, m), 2.08 (1H, ddd, *J* = 3, 6, 13.5 Hz), 1.89 (1H, ddd, *J* = 3.5, 10, 13.5 Hz).

¹³C NMR (75 MHz, CDCl₃): δ 201.3 (d), 107.8 (s), 64.9 (t), 64.7 (t), 56.6 (d), 36.2 (t), 26.7 (t), 26.4 (t).

HRMS: *m/z* calcd for C₈H₁₂O₃S 188.0507, found 188.0512 (EI). Anal. Calcd for C₈H₁₂O₃S: C, 51.04; H, 6.43. Found: C, 51.20; H, 6.58.

Tetrahydro-4*H*-thiopyran-4-one (117)



117

Keto ester **126** (100 g, 0.57 mol) was added via a dropping funnel over 3–5 min to a well-stirred solution of 10% aq H₂SO₄ (1 L) heated under reflux. After ca. 1 h, the reaction was complete by TLC analysis (30% EtOAc in hexane) and the mixture was cooled to 40 °C with the aid of an ice bath. The aqueous layer was decanted from a yellow oil that separated and settled. The yellow oil was washed with H₂O (500 mL) at 40 °C and the combined aqueous layers were extracted with CH₂Cl₂ (3 × 200 mL) with each extract passed through a column of basic Al₂O₃ (Brockmann I, ca. 150 mesh; 200 g). The column was finally eluted with CH₂Cl₂ (600 mL) and the combined eluates were concentrated and then reconcentrated from

hexane to give the titled compound as a white, freely flowing, crystalline solid (52 g, 78%); mp 59–60 °C.


IR ν_{max} : 1704 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ 2.99–2.94 (m, 4H), 2.72–2.68 (m, 4H).

^{13}C NMR (125 MHz, CDCl_3): δ 210.0, 44.7, 30.6.

HRMS: m/z , calcd for $\text{C}_5\text{H}_8\text{OS}$: 116.0296; found: 116.0293 (EI).

(3*S*)-3-[(*R*)-(6*S*)-1,4-Dioxo-8-thiaspiro[4.5]dec-6-yl(hydroxy)-methyl]tetrahydro-4*H*-thiopyran-4-one (122**)**



A solution of ketone **117** (1.25 g, 10.8 mmol), aldehyde **117** (1.01 g, 5.37 mmol), catalyst **127** (145 mg, 1.04 mmol), water (0.10 mL, 0.10 g, 5.6 mmol), and DMSO (0.6 mL) was stirred at room temperature. After 8 days, the brownish semisolid reaction mixture was taken up in ethyl acetate and washed with water. The organic layer was dried over Na_2SO_4 , concentrated, and fractionated by FCC (5-10% ethyl acetate in CH_2Cl_2) to give **122** as a white solid (1.22 g, 75%): $[\alpha]_{\text{D}} -48$, c 1.0, CHCl_3 (lit.⁷⁰ for **122** of >98% ee: $[\alpha]_{\text{D}} -47$, c 1.0,

CHCl₃). The catalyst could be recovered in >80% yield by concentrating the water layers and precipitating the residue from hot MeOH on addition of benzene.^{lxxxvi}


IR ν_{max} : 3488, 3409, 1711 cm⁻¹.

¹H NMR (300 MHz, CDCl₃): δ 4.50 (1H, dd, J = 4.5, 6.5 Hz, HC-1), 4.05-3.92 (4H, m), 3.08-2.58 (12H, m), 2.12 (1H, ddd, J = 4.5, 4.5, 9 Hz), 2.03 (1H, ddd, J = 3.5, 6.5, 13.5 Hz), 1.74 (1H, ddd, J = 4, 9.5, 13.5 Hz).

¹³C NMR (75 MHz, CDCl₃): δ 211.5 (s), 109.3 (s), 69.3 (d), 64.4 (t), 64.3 (t), 55.5 (d), 47.0 (d), 44.4 (t), 35.5 (t), 34.3 (t), 31.4 (t), 27.4 (t), 26.5 (t).

HRMS: m/z calcd for C₁₃H₂₀O₄S₂ 304.0803, found 304.0801. Anal. Calcd for C₁₃H₂₀O₄S₂: C, 51.29; H, 6.62. Found: C, 51.59; H, 6.55.

Methyl Tetrahydro-4-oxo-2H-thiopyran-3-carboxylate (126)



Anhydrous MeOH (41 mL, 32 g, 1.0 mol) was added via a dropping funnel over 30 min to a stirred suspension of Na metal (21.7 g, 0.95 mol; Na metal was cut into pieces weighing ca. 50–100 mg (3–5 mm per side). The rate of Na consumption depends on the size of pieces; with larger pieces, more time is required to reach 90% conversion.) in THF (300 mL) at 0 °C

^{lxxxvi} Prepared on ca. 40 gram scale by the same procedure in 70% yield (no chromatography). Athanasios Karagiannis, unpublished results: under my direction.

(ice bath) under argon (**Caution!** H₂ evolution). The ice bath was removed and stirring continued at rt for 15–20 h, at which point most of the Na was consumed (ca. 90%; more time may be required if the Na pieces are larger than specified) leaving a grayish-white mixture of NaOMe in THF. The mixture was cooled in an ice bath and the diester **115** (150 g, 0.728 mol) was added via a dropping funnel over 1 h (the dropping funnel was rinsed with 15 mL of THF). The ice bath was removed and the mixture, initially a thick slurry, became a homogeneous amber solution (a few specks of Na metal may be present). After stirring for 3 h at rt, the reaction was complete by TLC analysis (30% EtOAc in hexane). The mixture was transferred to a beaker equipped with a mechanical stirrer and cooled in an ice bath. Aq H₂SO₄ (0.475 mol; prepared by adding 47.5 g of 98% H₂SO₄ to ca. 45 g of ice) was added slowly with stirring maintaining the temperature below 20 °C; the final pH was 6–7. To the resulting creamy yellow mixture, CH₂Cl₂ (400 mL) was added after which the Na₂SO₄ hydrate precipitated as granules that readily settle, leaving a pale yellow solution; occasionally, a small amount of H₂O (2–10 mL) must be added to achieve the desired consistency. Na₂SO₄ (20 g) and solid NaHCO₃ (21 g) were added with stirring and after 30 min, the supernatant was filtered through cotton wool and the residue was washed with CH₂Cl₂ (200 mL). The combined filtrate and washings were concentrated to give the titled compound as a pale yellow oil (*stench!*); yield: 124.5 g (98%); >95% purity by NMR. The oil solidified (keto form) on standing for several days at 5 °C.

IR ν_{max} : 3100 (br), 1745, 1720, 1658, 1617 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ (for the enol tautomer) = 12.5 (s, 1H), 3.79 (s, 3 H), 3.36 (s, 2 H), 2.80 (app t, J = 5.5 Hz, 2 H), 2.60 (app t, J = 5.5 Hz, 2 H); δ (for the keto tautomer) =

3.80 (s, 3 H), 3.70 (dd, $J = 4, 8.5$ Hz, 1 H), 3.31 (dd, $J = 8.5, 14$ Hz, 1 H), 3.06 (dd, $J = 4, 14$ Hz, 1 H), 2.99–2.94 (m, 2 H), 2.91–2.85 (m, 1 H), 2.77–2.72 (m, 1 H).

^{13}C NMR (125 MHz, CDCl_3): δ (for the enol tautomer) = 172.0, 169.3, 97.4, 51.9, 30.9, 24.6, 23.4; δ (for the keto tautomer) = 203.7, 172.6, 58.7, 52.7, 43.7, 32.6, 30.5.

HRMS: m/z calcd for $\text{C}_7\text{H}_{10}\text{O}_3\text{S}$: 174.0351; found: 174.0348 (EI).

(2*R*,3*S*,5*S*,6*S*)-2-Ethyl-2,3,5,6-tetrahydro-2-hydroxy-3,5-dimethyl-6-[(1*S*)-1-methyl-2-oxobutyl]-4*H*-pyran-4-one (138)



138

Pyridine (1.2 mL, 1.2 g, 15 mmol), HF•pyridine (0.4 mL), and water (0.050 mL, 2.8 mmol) were added to a stirred solution of **175a** (50 mg, 0.15 mmol) in THF (2 mL). After 2 days, the mixture was diluted with ethyl acetate, washed with 2% aqueous citric acid ($\times 3$), NaHCO_3 and brine, dried over Na_2SO_4 , concentrated, and fractionated by FCC (40% diethyl ether in hexane) to give a 14:1 mixture of **150** and **142**, respectively (13 mg, 33%), and the titled compound (19 mg, 49%): $[\alpha]_{\text{D}} +24$ (c 1.1, C_6H_6).

IR ν_{max} : 3475, 1711 cm^{-1} .

^1H NMR (600 MHz, C_6D_6): δ 4.26 (1H, dd, $J = 2.6, 10.7$ Hz, HC-6), 2.32 (variable) (1H, d, $J = 1.6$ Hz, HO), 2.19 (1H, dq, $J = 18, 7.1$ Hz, HC-3"), 2.16 (1H, dq, $J = 2.6, 7.0$ Hz, HC-1"),


2.10 (1H, dqd, $J = 1.1, 1.6, 6.7$ Hz, HC-3), 2.06 (1H, dq, $J = 18, 7.1$ Hz, HC-3''), 1.98 (1H, ddq, $J = 1.1, 10.7, 6.6$ Hz, HC-5), 1.40 (1H, dq, $J = 13.9, 7.4$ Hz, HC-1'), 1.28 (3H, dq, $J = 13.9, 7.4$ Hz, HC-1'), 1.07 (3H, d, $J = 6.7$ Hz, H₃CC-3), 1.03 (3H, t, $J = 7.1$ Hz, H₃C-4''), 1.02 (3H, d, $J = 7.0$ Hz, H₃CC-1''), 0.70 (1H, t, $J = 7.4$ Hz, H₃C-2').

¹³C NMR (125 MHz, C₆D₆): δ 209.5 (s, C-2''), 206.9 (s, C-4), 102.8 (s, C-2), 75.3 (d, C-6), 50.9 (d, HC-3), 48.2 (d, HC-7), 46.6 (d, HC-5), 33.4 (t, C-3''), 33.1 (t, C-1'), 9.7 (q, CH₃C-5), 9.2 (q, CH₃C-3), 8.5 (q, C-4'' or CH₃C-1''), 8.4 (q, C-4'' or CH₃C-1''), 7.8 (q, C-2').

LRMS: m/z (relative intensity) 274 ([M+18]⁺, 49), 257 ([M+1]⁺, 7), 239 (34), 200 (51), 183 (100), 160 (26), 143 (25), 74 (22) (CI, NH₃).

HRMS: m/z calcd for C₁₄H₂₄O₄ 256.1675 (274.2018 for M+NH₄), found 274.2009 (CI, NH₃).

(1R,3R,5R,7R,8S,9S,10S)-3,5-Diethyl-8,9,10-trimethyl-2,4,6-trioxatricyclo [3.3.1.1^{3,7}] decan-1-ol (142)



From 167: A suspension of Raney nickel (W2; 2 mL settled volume) in EtOH (4 mL) was added to **167** (17 mg, 0.054 mmol) and the mixture was heated under reflux with vigorous stirring. After 45 min, the mixture was decanted and the solid suspended in ethanol and heated under reflux with rapid stirring for several min. This washing procedure was repeated

once with EtOH, once with CH₂Cl₂/acetone (1:1), and once with ethyl acetate. The combined organic layers were filter through Celite® and concentrated. The residue was fractionated by PTLC (33% diethyl ether in hexane) to give the titled compound (8 mg, 60%).

From 175a: Pyridine (1.2 mL), HF•pyridine (0.4 mL), and water (2.8 mmol, 50 mL) were sequentially added to a stirred solution of **175a** (50 mg, 0.15 mmol) in THF (2 mL) at ambient temperature. After 2 h, the mixture was diluted with ethyl acetate, washed sequentially with 2% aqueous citric acid (×3), NaHCO₃ and brine, dried over Na₂SO₄, concentrated, and fractionated by FCC (40% diethyl ether in hexane) to give **138** (3 mg, 8%) and the titled compound (ca. 95% pure by ¹H NMR; 31 mg, 80%): ([α]_D +11 (c 1.0, C₆H₆).

IR ν_{max}: 3407 cm⁻¹.

¹H NMR (500 MHz, C₆D₆): δ 3.68 (1H, br d, *J* = 2.5 Hz, HC-7), 2.23 (1H, br s, HO), 2.07 (1H, dq, *J* = 3.5, 7 Hz, HC-10), 1.91 (1H, br q, *J* = 7.5 Hz, HC-8), 1.85-1.77 (2H, m, HC-9, HCC-5), 1.70 (1H, dq, *J* = 15, 7.5 Hz, HCC-3), 1.57 (1H, dq, *J* = 7.5, 15 Hz, HCC-5), 1.54 (1H, dq, *J* = 7.5, 15 Hz, HCC-3), 1.12 (3H, d, *J* = 7.5 Hz, H₃CC-8), 1.05 (3H, t, *J* = 7.5 Hz, H₃CCC-5), 1.02 (3H, t, *J* = 7.5 Hz, H₃CCC-3), 0.97 (3H, d, *J* = 7.5 Hz, H₃CC-9), 0.63 (3H, d, *J* = 7 Hz, H₃CC-10).


¹³C NMR (125 MHz, C₆D₆): δ 103.2 (s, C-3), 102.3 (s, C-5), 98.9 (s, C-1), 79.3 (d, C-7), 45.4 (d, C-9), 37.9 (d, C-10), 35.9 (d, C-8), 30.4 (t, CH₂C-5), 30.2 (t, CH₂C-3), 14.8 (q, CH₃C-8), 13.0 (q, CH₃C-10), 11.2 (q, CH₃C-9), 7.1 (q, CH₃CC-5), 6.9 (q, CH₃CC-3).

LRMS: *m/z* (relative intensity) 256 ([M]⁺, 4), 182 (11), 153 (13), 125 (18), 113 (38), 96 (14), 86 (15), 69 (12), 57 (100) (EI).

HRMS: m/z calcd for $C_{14}H_{24}O_4$ 256.1675, found 256.1667 (EI).

(1*R*,3*R*,5*R*,7*R*,8*S*,9*S*,10*R*)-rel-3,5-Diethyl-8,9,10-trimethyl-2,4,6 trioxatricyclo[3.3.1.1^{3,7}]

decan-1-ol (143)



A suspension of W2 Raney nickel (5 mL settled volume) in ethanol (10 mL) was added to (±)-**168** (98 mg, 0.31 mmol) and the mixture was heated under reflux with vigorous stirring. After 45 min, the mixture was decanted and the solid suspended in ethanol and heated under reflux with rapid stirring for several min. This washing procedure was repeated twice with EtOH and once with ethyl acetate. The combined organic layers were filtered through Celite® and concentrated to give the titled compound (67 mg, 85%) that was homogeneous by ^1H NMR. A crystal suitable for X-ray crystallography was obtained from a petroleum ether solution.

IR ν_{max} : 3383 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ 3.83 (1H, br s, HC-7), 2.90 (1H, br s, HO), 1.95 (1H, br q, $J = 7$ Hz, HC-8), 1.92 (1H, br q, $J = 7.5$ Hz, HC-9), 1.74-1.47 (5H, m, HC-10, $\text{H}_2\text{C} \times 2$), 1.19 (3H, d, $J = 7.5$ Hz, H_3CC -8), 1.11 (3H, d, $J = 7$ Hz, H_3CC -10), 1.06 (3H, d, $J = 7.5$ Hz, H_3CC -9), 0.96 (3H, t, $J = 7.5$ Hz, H_3C), 0.89 (3H, t, $J = 7.5$ Hz, H_3C).


^{13}C NMR (125 MHz, CDCl_3): δ 102.8 (s, C-3), 102.0 (s, C-5), 98.8 (s, C-1), 79.6 (d, C-7), 44.7 (d, C-9), 43.3 (d, C-8), 38.1 (d, C-10), 29.85 (t, CH_2), 29.79 (t, CH_2), 14.5 (q, $\text{CH}_3\text{C-8}$), 13.9 (q, $\text{CH}_3\text{C-10}$), 10.8 (q, $\text{CH}_3\text{C-9}$), 6.4 (q, $\text{CH}_3\text{CH}_2\text{C-5}$), 6.1 (q, $\text{CH}_3\text{CH}_2\text{C-3}$).

LRMS: m/z (relative intensity) 256 ($[\text{M}]^+$, 1), 126 (10), 125 (11), 113 (28), 96 (10), 86 (13), 69 (10), 57 (100) (EI).

HRMS: m/z calcd for $\text{C}_{14}\text{H}_{24}\text{O}_4$ 256.1675, found 256.1672 (EI).

(1*R*,3*R*,5*R*,7*R*,8*S*,9*R*,10*S*)-3,5-Diethyl-8,9,10-trimethyl-2,4,6-trioxatricyclo[3.3.1.1^{3,7}]

decan-1-ol (150)



Pyridine (1.2 mL), $\text{HF}\cdot\text{pyridine}$ (0.4 mL), and water (50 mL) were sequentially added to a stirred solution of **175a** (20 mg, 0.061 mmol) in THF (2 mL) at ambient temperature. After 2 h, the mixture was diluted with ethyl acetate, washed with 2% aqueous citric acid ($\times 3$), NaHCO_3 and brine, dried over Na_2SO_4 , and concentrated. The residue (crude **142**) was taken up in chloroform (2 mL) and imidazole (75 mg, 1.1 mmol) was added. After 5 d, the mixture was diluted with ethyl acetate, washed sequentially with 1% aqueous citric acid ($\times 3$), NaHCO_3 and brine, dried over Na_2SO_4 , concentrated, and fractionated by PTLC (40% ethyl acetate in hexane) to give the titled compound (12 mg, 77%): $[\alpha]_{\text{D}} +34(c\ 1.0, \text{C}_6\text{H}_6)$.

IR ν_{\max} : 3428 cm^{-1} .


^1H NMR (500 MHz, C_6D_6): δ 3.62 (1H, br d, $J = 2.5$ Hz, HC-7), 2.06-1.98 (2H, m, HO, HC-10), 1.92 (1H, br q, $J = 6.5$ Hz, HC-9), 1.79 (1H, dq, $J = 14, 7.5$ Hz, HCC-5), 1.77 (1H, br q, $J = 6.5$ Hz, HC-8), 1.69 (1H, dq, $J = 14, 7.5$ Hz, HCC-3), 1.59-1.47 (2H, m, HCC-3, HCC-5), 1.06 (3H, d, $J = 7.5$ Hz, H_3CC -8), 1.04 (3H, t, $J = 8$ Hz, H_3CCC -3), 1.00 (3H, t, $J = 7.5$ Hz, H_3CCC -5), 0.96 (3H, d, $J = 6.5$ Hz, H_3CC -9), 0.65 (3H, d, $J = 7$ Hz, H_3CC -10).

^{13}C NMR (125 MHz, C_6D_6): δ 103.1 (s, C-3), 102.5 (s, C-5), 97.9 (s, C-1), 78.6 (d, C-7), 37.8 (d, C-10), 36.6 (d, C-9), 36.5 (d, C-8), 30.6 (t, CH_2C -5), 30.2 (t, CH_2C -3), 13.7 (q, CH_3C -8), 12.8 (q, CH_3C -10), 7.7 (q, CH_3C -9), 6.80 (q, CH_3CH_2), 6.75 (q, CH_3CH_2).

LRMS: m/z (relative intensity) 256 ($[\text{M}]^+$, 4), 182 (17), 126 (22), 125 (25), 113 (65), 96 (30), 86 (25), 69 (20), 57 (100) (EI).

HRMS: m/z calcd for $\text{C}_{14}\text{H}_{24}\text{O}_4$ 256.1675, found 256.1683 (EI).

(1R,3R,5R,7R,8S,9R,10R)-rel-3,5-Diethyl-8,9,10-trimethyl-2,4,6-trioxatricyclo[3.3.1.1^{3,7}]decan-1-ol (151)



A solution of **143** (20 mg, 0.31 mmol) and imidazole (15 mg, 0.22 mmol) in CDCl_3 (0.4 mL) was heated to 40 $^\circ\text{C}$ (oil bath temperature). After 4 days (isomerization was complete by ^1H NMR), the mixture was diluted with ethyl acetate, washed with 1% aqueous citric acid ($\times 3$),

NaHCO₃, and brine, dried over Na₂SO₄, concentrated, and fractionated by PTLC (40% ethyl acetate in hexane) to give the known^{lxxxvii,61} titled compound (17 mg, 85%).

IR ν_{max} : 3417 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 3.78 (1H, br s, HC-7), 2.56 (1H, br s, HO), 1.97 (1H, q, J = 6.5 Hz, HC-9), 1.91 (1H, br q, J = 7 Hz, HC-8), 1.73-1.49 (5H, m, HC-10, H₂C \times 2), 1.15 (3H, d, J = 7 Hz, H₃CC-8), 1.10 (3H, d, J = 7 Hz, H₃CC-10), 0.98 (3H, d, J = 6.5 Hz, H₃CC-9), 0.96 (3H, t, J = 7.5 Hz, H₃C), 0.94 (3H, t, J = 7.5 Hz, H₃C).


¹³C NMR (125 MHz, CDCl₃): δ 102.6 (s, C-3), 102.2 (s, C-5), 97.7 (s, C-1), 78.9 (d, C-7), 43.3 (d, C-8), 37.7 (d, C-10), 36.0 (d, C-9), 30.1 (t, CH₂), 30.0 (t, CH₂), 13.8 (q, CH₃C-10), 13.5 (q, CH₃C-8), 7.3 (q, CH₃C-9), 6.3 (q, CH₃CH₂C-5), 6.1 (q, CH₃CH₂C-3).

LRMS: m/z (relative intensity) 256 ([M]⁺, 2), 182 (8), 153 (6), 126 (13), 113 (35), 86 (14), 57 (100) (EI).

HRMS: m/z calcd for C₁₄H₂₄O₄ 256.1675, found 256.1675 (EI).

^{lxxxvii} Only a few specific ¹H NMR resonances are reported for **151** (data obtained at 300 MHz); our data (obtained at 500 MHz) is within 0.02-0.04 ppm. Our ¹³C NMR chemical shifts are consistently 0.2-0.4 ppm higher than those reported, presumably due to a different assignment of the reference frequency (we used $\delta_{\text{C}}=77.23$ for CDCl₃).

(2*S*,3*S*)-6-Ethyl-2,3-dihydro-3,5-dimethyl-2-[(1*S*)-1-methyl-2-oxobutyl]-4*H*-pyran-4-one
(152)



Aqueous HF (2 wt.%; 0.4 mL) was added to a stirred solution of **175b** (21 mg, 0.057 mmol) in MeCN (2 mL). After 2 h, the mixture was diluted with ethyl acetate, washed with NaHCO₃ and brine, dried over Na₂SO₄, concentrated, and fractionated by PTLC (10% diethyl ether in CH₂Cl₂) to give the titled compound (12 mg, 99%): [α]_D -90 (*c* 0.6, CHCl₃).

IR ν_{max} : 1715, 1663, 1616 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 4.42 (1H, dd, *J* = 4, 11.5 Hz, HC-2), 2.77 (1H, dq, *J* = 4, 7 Hz, HC-1'), 2.53 (2H, ap q, *J* = 7 Hz, H₂C-3'), 2.39 (1H, dq, *J* = 11.5, 7 Hz, HC-3), 2.36-2.22 (2H, m, H₂C-1''), 1.71 (3H, s, H₃CC-5), 1.21 (3H, d, *J* = 7 Hz, H₃CC-1'), 1.11 (3H, d, *J* = 7 Hz, H₃CC-3), 1.07 (3H, t, *J* = 7 Hz, H₃C-4'), 1.06 (3H, t, *J* = 7.5 Hz, H₃C-2'').

¹³C NMR (125 MHz, CDCl₃): δ 211.3 (s, C-2'), 194.9 (s, C-4), 172.4 (s, C-6), 108.5 (s, C-5), 82.8 (d, C-2), 47.6 (d, C-1'), 41.1 (d, C-3), 34.4 (t, C-3'), 25.6 (t, C-1''), 11.2 (q, CH₃C-3), 11.0 (q, C-4'), 9.8 (q, CH₃C-1'), 9.4 (q, CH₃C-5), 8.0 (q, C-2'').

LRMS: *m/z* (relative intensity) 238 ([M]⁺, 8), 181 (7), 153 (27), 125 (11), 113 (73), 83 (7), 57 (100) (EI).

HRMS: *m/z* calcd for C₁₄H₂₂O₃ 238.1569, found 238.1577 (EI).

(4*S*,6*S*)-4,6-Dimethyl-3,7-dioxonon-5-yl Propanoate (154)



Pyridine (1.2 mL), HF•pyridine (0.4 mL), and water (0.050 mL) were added to a stirred solution of **175a** (55 mg, 0.17 mmol) in THF (2 mL). After 2 h, the mixture was diluted with ethyl acetate, washed sequentially with 2% aqueous citric acid (×3), NaHCO₃ and brine, dried over Na₂SO₄, and concentrated. The resulting crude **142** was taken up in benzene (4 mL) and DBU (0.010 mL, 10 mg, 0.066 mmol) was added. After 24 h, the mixture was diluted with ethyl acetate, washed sequentially with 1% aqueous citric acid (x3), NaHCO₃ and brine, dried over Na₂SO₄, concentrated, and fractionated by PTLC (10% diethyl ether in CH₂Cl₂) to give **150** (13 mg, 32%) and the titled compound (20 mg, 47%): [α]_D +67 (*c* 1.0, CHCl₃).

IR ν_{max} : 1742, 1715, 1180 cm⁻¹.


¹H NMR (500 MHz, C₆D₆): δ 5.64 (1H, dd, *J* = 5, 8 Hz, HC-5'), 2.65 (1H, dq, *J* = 8, 7 Hz, HC-4'), 2.57 (1H, dq, *J* = 7, 18 Hz, HC-2'), 2.44 (1H, dq, *J* = 5, 7 Hz, HC6'), 2.19-2.04 (2H, m, H₂C-8'), 2.03-1.90 (3H, m, H₂C-2, HC-2'), 1.06 (3H, t, *J* = 7 Hz, H₃C-1'), 0.95 (3H, t, *J* = 7 Hz, H₃C-9'), 0.90 (3H, d, *J* = 7 Hz, H₃CC-6'), 0.89 (3H, t, *J* = 7.5 Hz, H₃C-3), 0.74 (3H, d, *J* = 7 Hz, H₃CC-4').

^{13}C NMR (125 MHz, C_6D_6): δ 210.7 (s, C-3' or C-7'), 210.4 (s, C-3' or C-7'), 173.0 (s, C-1), 74.6 (d, C-5'), 48.3 (d, C-4'), 46.8 (d, C-6'), 35.6 (t, C-8'), 35.2 (t, C-2'), 27.9 (t, C-2), 13.2 (q, $\text{CH}_3\text{C-4'}$), 11.1 (q, $\text{CH}_3\text{C-6'}$), 9.6 (q, C-3), 8.3 (q, C-1' or C-9'), 8.1 (q, C-1' or C-9').

LRMS: m/z (relative intensity) 274 ($[\text{M}+18]^+$, 92), 257 ($[\text{M}+1]^+$, 20), 200 (30), 183 (100), 165 (14), 126 (10), 57 (8) (CI, NH_3).

HRMS: m/z calcd for $\text{C}_{14}\text{H}_{24}\text{O}_4$ 256.1675 (274.2018 for $\text{M}+\text{NH}_4$), found 274.2012 (CI, NH_3).

(4E)-4,6-Dimethylnon-4-en-3,7-dione (156)




156

This compound was observed in various isomerization experiments of **138**, **142**, **143**, and **150**, and **154** in the presence of DBU in C_6D_6 . In a larger scale reaction, DBU (10 μL , 10 mg, 0.07 mmol) was added to a solution of **154** (8 mg, 0.03 mmol) in C_6D_6 (0.4 mL) at room temperature. The reaction was monitored by NMR and after 14 days, <5% of **154** remained. Attempted isolation of the titled compound from the reaction mixture by standard aqueous workup failed.

^1H NMR (500 MHz, C_6D_6): δ 6.26 (1H, qd, $J = 1, 10$ Hz, HC-5), 3.09 (1H, dq, $J = 10, 7$ Hz, HC-6), 2.19 (2H, ap q, $J = 7.5$ Hz, $\text{H}_2\text{C-2}$), 1.99-1.87 (2H, m, $\text{H}_2\text{C-8}$), 1.73 (3H, d, $J = 1$ Hz, $\text{H}_3\text{CC-3}$), 0.99 (3H, t, $J = 7.5$ Hz, $\text{H}_3\text{C-1}$), 0.96 (3H, d, $J = 7$ Hz, $\text{H}_3\text{CC-5}$), 0.91 (3H, t, $J = 7$ Hz, $\text{H}_3\text{C-9}$).

^{13}C NMR (125 MHz, C_6D_6): δ 209.1 (s, C-3), 200.9 (s, C-7), 139.6 (d, C-5), 138.5 (s, C-4), 46.9 (s, C-6), 34.9 (t, C-8), 30.7 (t, C-2), 16.6 (q, C-11), 12.2 (q, C-10), 9.0 (q, C-1), 8.2 (q, C-9).

(4*S*,4*aR*,5*aR*,9*aS*,10*R*,10*aS*,12*R*)-12-Ethyl octahydro-5*a*,4,10-(epoxymethenoxy)-1*H*,4*aH*,5*aH* bisthiopyrano [4,3-*b*:3',4'-*e*]pyran-4*a*-ol (167**)**



IBX (660 mg, 2.4 mmol) was added to a stirred solution of **173** (290 mg, 0.61 mmol) in DMSO (20 mL) at ambient temperature. After 5 h, the mixture was diluted with ethyl acetate and washed with water ($\times 3$) and brine. The organic phase was dried over Na_2SO_4 and concentrated. The residue was taken up in acetone (15 mL) and FeCl_3 -impregnated silica gel (60-200 mesh, ca. 7% FeCl_3 ; ⁹⁰ 760 mg) was added. The resulting yellowish suspension was heated under reflux with stirring for 30 min. The mixture was filtered through a small silica gel pad eluting with 50% ethyl acetate. The combined filtrate and washings were concentrated and fractionated by FCC (15% diethyl ether in CH_2Cl_2) to give the titled compound (128 mg, 66%): $[\alpha]_{\text{D}} +14$ (c 1, CHCl_3). A crystal suitable for X-ray crystallography was obtained from CH_2Cl_2 /hexane.

IR ν_{max} : 3385 cm^{-1} .


^1H NMR (500 MHz, CDCl_3): δ 4.29 (1H, br d, $J = 3.5$ Hz, HC-1'), 3.57 (1H, dd, $J = 3.5$, 14 Hz, HC-2), 3.55 (1H, dd, $J = 3$, 14 Hz, HC-6), 2.98 (1H, ddd, $J = 2.5$, 13.5, 13.5 Hz, HC-6'), 2.83 (1H, dd, $J = 13$, 13 Hz, HC-2'), 2.59-2.53 (2H, m, HC-2, HC-6), 2.47-2.40 (2H, m, HC-3', HC-6'), 2.25 (1H, ddd, $J = 2.5$, 3, 13 Hz, HC-2'), 2.14 (1H, br s, HC-3), 2.04 (1H, ddd, $J = 2.5$, 3, 14 Hz, HC-5'), 2.01 (1H, br s, HC-5), 1.89 (1H, ddd, $J = 4$, 13.5, 14 Hz, HC-5'), 1.83 (1H, dq, $J = 14.5$, 7.5 Hz, HC-2''), 1.65 (1H, dq, $J = 14.5$, 7.5 Hz, HC-2''), 0.98 (3H, t, $J = 7.5$ Hz, H_3C -3'').

^{13}C NMR (125 MHz, CDCl_3): δ 102.1 (s, C-4' or C-1''), 99.2 (s, C-4' or C-1''), 95.0 (s, C-4), 76.9 (d, C-1'), 45.1 (d, C-3'), 43.1 (d, C-5), 37.6 (t, C-5'), 35.8 (d, C-3), 29.7 (t, C-2''), 29.0 (t, C-2), 27.5 (t, C-2'), 25.2 (t, C-6'), 24.8 (t, C-6), 6.4 (q, C-3'').

LRMS: m/z (relative intensity) 316 ($[\text{M}]^+$, 100), 298 (10), 241 (18), 209 (21), 171 (7), 152 (30), 126 (35), 99 (45), 67 (61) (EI).

HRMS: m/z calcd for $\text{C}_{14}\text{H}_{20}\text{O}_4\text{S}_2$ 316.0803, found 316.0792 (EI).

**(4*S*,4*aR*,5*aR*,9*aR*,10*R*,10*aS*,12*R*)-12-Ethyloctahydro-5*a*,4,10-(epoxymethenoxy)-
1*H*,4*aH*,5*aH*-bisthiopyrano[4,3-*b*:3',4'-*e*]pyran-4*a*-ol (168)**



IBX (1.0 g, 3.6 mmol) was added to a stirred solution of (±)-**171** (270 mg, 0.67 mmol) in DMSO (20 mL) at ambient temperature. After 6 h, the mixture was diluted with ethyl acetate and washed with water (×3) and brine. The organic phase was dried over Na₂SO₄ and concentrated. The residue was taken up in acetone (20 mL) and MeOH (1 mL) and FeCl₃•6H₂O (200 mg, 0.74 mmol) was added. The resulting yellowish solution was heated under reflux for 1 h and then diluted with water and extracted with CH₂Cl₂. The combined organic layers were washed with water, dried over Na₂SO₄, concentrated, and filtered through a small silica gel pad eluting with 50% ethyl acetate in hexane to give the titled compound (157 mg, 75%) as a yellowish solid.

IR ν_{max} : 3390 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 4.25 (1H, br s, HC-1'), 3.55 (1H, dd, J = 2.5, 13 Hz, HC-2), 3.43 (1H, dd, J = 2, 13.5 Hz, HC-6), 3.28 (1H, dd, J = 12.5, 13 Hz, HC-2'), 2.97 (1H, ddd, J = 2, 13, 13.5 Hz, HC-6'), 2.81 (1H, br s, HO), 2.63-2.55 (2H, m, HC-2, HC-6), 2.45-2.33 (2H, m, HC-2', HC-6'), 2.09 (1H, br s, HC-3), 2.07 (1H, ddd, J = 3, 3, 13.5 Hz, HC-5'), 1.98 (1H, br s, HC-5), 1.90 (1H, dq, J = 14, 7.5 Hz, HC-2''), 1.84 (1H, dd, J = 2.5, 12.5 Hz, HC-


3'), 1.82 (1H, ddd, $J = 4, 13, 13.5$ Hz, HC-5'), 1.64 (1H, dq, $J = 14, 7.5$ Hz, HC-2''), 1.05 (3H, t, $J = 7.5$ Hz, H₃C-3'').

¹³C NMR (125 MHz, CDCl₃): δ 101.8 (s, C-4' or C-1''), 98.5 (s, C-4' or C-1''), 94.3 (s, C-4), 77.5 (d, C-1'), 44.6 (d, C-3'), 43.3 (d, C-5), 41.6 (d, C-3), 38.4 (t, C-5'), 30.0 (t, C-2''), 29.3 (t, C-2), 28.3 (t, C-2'), 24.9 (t, C-6'), 24.8 (t, C-6), 6.4 (t, C-3'').

LRMS: m/z (relative intensity) 316 ([M]⁺, 81), 242 (28), 209 (20), 153 (31), 126 (35), 99 (39), 67 (71), 57 (100) (EI).

HRMS: m/z calcd for C₁₄H₂₀O₄S₂ 316.0803, found 316.0801 (EI).

(3*S*,5*S*)-rel-3-[(*R*)-(6*R*)-1,4-Dioxo-8-thiaspiro[4.5]dec-6-yl(methoxymethoxy)methyl]- 5-[(*S*)-1-hydroxypropyl]tetrahydro-4*H*-thiopyran-4-one (171)



A solution of (±)-**170** (400 mg, 1.15 mmol) in CH₂Cl₂ (3 mL) was added dropwise via syringe to a stirred solution of triethylamine (0.48 mL, 0.35 g, 3.5 mmol) and chlorodicyclohexylborane (1 M in hexanes; 2.3 mL, 2.3 mmol) in CH₂Cl₂ (15 mL) at 0 °C under argon. After 20 min, the mixture was cooled to −78 °C and a solution of propanal (0.8 mL, 0.6 g, 0.01 mol) in CH₂Cl₂ (3 mL) was slowly added via syringe. After 1 h, MeOH (4 mL), pH 7 phosphate buffer (pH 7; 6 mL), and 30% aqueous H₂O₂ (6 mL) were sequentially added. The reaction mixture was transferred to a 0 °C bath and vigorously stirred for 10 min.

Saturated aqueous Na₂SO₃ was slowly added (**CAUTION**: effervescence) and then the mixture was then extracted with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by FCC (40% ethyl acetate in hexane and then 50% ether in CH₂Cl₂) to give a 9:1 mixture of the titled compound and an unidentified diastereomer (368 mg, 79%).

IR ν_{max} : 3513, 1701 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 4.71-4.68 (2H, m, HC-1', OCHO), 4.65 (1H, d, J = 6.5 Hz, OCHO), 4.12-4.01 (4H, m, H₂CO \times 2), 3.71-3.65 (1H, m, HC-1''), 3.38 (3H, s, H₃CO), 3.20 (1H, ddd, J = 2.5, 4.5, 14 Hz, HC-2), 3.06-3.00 (2H, m, HO, HC-3), 2.97 (1H, ddd, J = 4, 4.5, 8.5 Hz, HC-5), 2.93-2.72 (6H, m, HC-2, H₂C-6, H₂C-7', HC-9'), 2.53-2.47 (2H, m, HC-6', HC-9'), 2.13 (1H, ddd, J = 3, 4, 13.5 Hz, HC-10'), 1.74 (1H, ddd, J = 3.5, 13.5, 13.5 Hz, HC-10'), 1.58 (1H, ddq, J = 3.5, 14.5, 7.5 Hz, HC-2''), 1.50 (1H, ddq, J = 7, 14.5, 7.5 Hz, HC-2''), 0.99 (3H, t, J = 7.5 Hz, H₃C-3'').

¹³C NMR (125 MHz, CDCl₃): δ 213.2 (s, C-4), 108.4 (s, C-5'), 96.9 (t, OCH₂O), 76.2 (d, C-1'), 73.4 (d, C-1''), 64.7 (t, CH₂O), 64.2 (t, CH₂O), 56.7 (q, CH₃O), 54.9 (d, C-5), 54.7 (d, C-3), 50.8 (d, C-6'), 36.6 (t, C-10'), 33.4 (t \times 2, C-2, C-6), 28.3 (t, C-7'), 27.1 (t, C-2''), 26.9 (t, C-9'), 10.1 (q, C-3'').

LRMS: m/z (relative intensity) 406 ([M]⁺, 0.4), 343 (3), 282 (11), 159 (14), 157 (11), 132 (40), 99 (100), 86 (11) (EI).

HRMS: m/z calcd for C₁₈H₃₀O₆S₂ 406.1484, found 406.1480 (EI).

(3*S*)-3-[(*R*)-(6*S*)-1,4-Dioxo-8-thiaspiro[4.5]dec-6-yl(triethylsilyloxy)methyl]tetrahydro-4*H*-thiopyran-4-one (172)^{lxxxviii}



Pyridine (0.17 mL, 0.17 g, 2.1 mmol) and Et₃SiOTf (0.42 mL, 0.70 g, 1.8 mmol) were sequentially added to a stirred solution of **122** (>98% ee; 500 mg, 1.64 mmol) in CH₂Cl₂ (16 mL) at 0 °C under Ar. After 15 min, the mixture was diluted with ethyl acetate and washed sequentially with saturated aqueous NaHCO₃ and brine. The organic layer was dried over Na₂SO₄, concentrated, and fractionated by FCC (20-30% ethyl acetate in hexane) to afford the titled compound as a colorless oil (662 mg, 96%): [α]_D -60 (*c* 1.2, CHCl₃).

IR ν_{max} : 1700 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 4.88 (1H, br d, *J* = 5 Hz, HC-1'), 3.95-3.82 (4H, m, H₂CO \times 2), 3.11 (1H, dd, *J* = 11, 13 Hz, HC-2), 2.96-2.86 (3H, m, HC-2, HC-6, HC-7"), 2.84-2.70 (4H, m, HC-3, HC-5, HC-6, HC-7"), 2.69-2.54 (3H, m, HC-5, H₂C-9"), 2.13-2.03 (2H, m, HC-6", HC-10"), 1.60 (1H, ap ddd, *J* = 3.5, 8, 13 Hz, HC-10'), 0.95 (9H, t, *J* = 8 Hz, H₃C \times 3), 0.63 (6H, ap q, *J* = 8 Hz, H₂CSi \times 3).


^{lxxxviii} Characterization by Fabiola Becerril-Jimenez.

^{13}C NMR (500 MHz, CDCl_3): δ 206.5 (s, C-4), 109.3 (s, C-5"), 68.5 (d, C-1'), 64.5 (t, CH_2O), 63.7 (t, CH_2O), 60.2 (d, C-3), 47.7 (d, C-6"), 43.0 (t, C-5), 34.5 (t, C-10'), 29.6 (t, C-6), 29.2 (t, C-2), 27.8 (t, C-7"), 26.9 (t, C-9"), 7.2 (q $\times 3$, CH_3), 5.3 (t $\times 3$, CH_2Si).

LRMS: m/z (relative intensity) 419 ($[\text{M}+1]^+$, 46), 389 (31), 303 (27), 287 (59), 229 (100), 225 (19), 132 (28), 99 (64) (CI, NH_3).

HRMS: m/z calcd for $\text{C}_{19}\text{H}_{34}\text{O}_4\text{S}_2\text{Si}$ 418.1668 (389.1277 for $\text{M}-\text{C}_2\text{H}_5$), found 389.1276 (EI).

(3*S*,5*S*)-3-[(*R*)-(6*S*)-1,4-Dioxo-8-thiaspiro[4.5]dec-6-yl(triethylsilyloxy)methyl]-5-[(*S*)-1-hydroxypropyl]tetrahydro-4*H*-thiopyran-4-one (173)



A solution of **172** (763 mg, 1.8 mmol) in CH_2Cl_2 (2 mL) was added dropwise via syringe to a stirred solution of triethylamine (0.76 mL, 0.56 g, 5.5 mmol) and chlorodicyclohexylborane (1 M in hexanes; 3.7 mL, 3.7 mmol) in CH_2Cl_2 (15 mL) at 0 °C under Ar. After 20 min, the mixture was cooled to -78 °C and a solution of propanal (1.0 mL, 0.80 g, 14 mmol) in CH_2Cl_2 (1 mL) was slowly added via syringe. After 1 h, MeOH (4 mL), pH 7 phosphate buffer (pH 7; 10 mL), and 30% aqueous H_2O_2 (10 mL) were sequentially added. The reaction mixture was transferred to a 0 °C bath and vigorously stirred for 10 min. Saturated aqueous Na_2SO_3 was slowly added (**CAUTION**: effervescence) and then the mixture was then extracted with CH_2Cl_2 . The combined organic layers were dried over Na_2SO_4 , concentrated,

and fractionated by FCC (8% Et₂O in CH₂Cl₂) to afford the titled compound (813 mg, 94%):
[α]_D -90 (*c* 1.0, CHCl₃).

IR ν_{max} : 3513, 1699 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 4.74 (1H, br d, *J* = 4.5 Hz, HC-1'), 3.99-3.86 (4H, m, H₂CO \times 2), 3.83-3.77 (1H, m, HC-1''), 3.21 (1H, dd, *J* = 11, 13 Hz, HC-2), 3.18 (1H, d, *J* = 3.5 Hz, HO), 3.00 (1H, dd, *J* = 5, 12 Hz, HC-6), 2.89-2.76 (5H, m, HC-2, HC-3, HC-5, H₂C-7'), 2.73-2.61 (2H, m, HC-6, H₂C-9'), 2.11 (1H, ap ddd, *J* = 3.5, 7, 7.5 Hz, HC-6'), 2.08-2.01 (1H, m, HC-10'), 1.65-1.55 (2H, m, HC-2'', HC-10'), 1.50 (1H, ddq, *J* = 7, 7.5, 15 Hz, HC 2''), 0.99 (3H, t, *J* = 7.5 Hz, H₃C-3''), 0.97 (9H, t, *J* = 8 Hz, H₃CCSi \times 3), 0.66 (6H, ap q, *J* = 8 Hz, H₂CSi \times 3).

¹³C NMR (125 MHz, CDCl₃): δ 211.5 (s, C-4), 109.1 (s, C-5'), 73.3 (d, C-1''), 69.4 (d, C-1'), 64.6 (t, CH₂O), 63.9 (t, CH₂O), 60.7 (d, C-3), 53.0 (d, C-5), 47.9 (d, C-6'), 34.5 (t, C-10'), 29.5 (t, C-7'), 27.4 (t, C-6), 27.1 (t, C-2''), 26.9 (t, C-9'), 26.2 (t, C-2), 9.9 (t, C-3''), 7.2 (t \times 3, CH₂Si), 5.3 (q \times 3, CH₃CSi).

LRMS: *m/z* (relative intensity) 477 ([M+1]⁺, 24), 419 (99), 389 (36), 345 (62), 287 (100), 229 (86), 132 (38), 99 (46) (CI, NH₃).

HRMS: *m/z* calcd for C₂₂H₄₀O₅S₂Si 476.2086 (477.2165 for M+H), found 477.2183 (CI, NH₃).

(4*S*,4*aS*,5*aR*,9*aS*,10*R*,10*aS*,12*R*)-12-Ethyl-octahydro-5*a*,4,10-(epoxymethenoxy)-4*a*-trimethylsilyloxy-1*H*,4*aH*,5*aH*-bisthiopyrano[4,3-*b*:3',4'-*e*]pyran (174a**)**



2,6-Lutidine (0.50 mL, 0.46 g, 4.3 mmol) and Me₃SiOTf (0.20 mL, 0.25 g, 1.1 mmol) were added to a stirred solution of **167** (271 mg, 0.86 mmol) in CH₂Cl₂ (10 mL) at room temperature under Ar. After 1 h, the mixture was diluted with ethyl acetate, washed sequentially with 1% (w/v) aqueous citric acid monohydrate (×3), sat. NaHCO₃ and brine, dried over Na₂SO₄, concentrated, and fractionated by FCC (20% ethyl acetate in hexane) to give the titled compound as a clear oil (309 mg, 93%): [α]_D +18 (*c* 1, C₆H₆).

IR ν_{max} : 2924, 1248, 1149, 1083, 883, 851 cm⁻¹.


¹H NMR (500 MHz, C₆D₆): δ 3.79 (1H, br d, *J* = 3.5 Hz, HC-1'), 3.41 (1H, dd, *J* = 3.5, 13.5 Hz, HC-2), 3.37 (1H, dd, *J* = 3, 14 Hz, HC-6), 2.87 (1H, ddd, *J* = 3, 13.5, 13.5 Hz, HC-6'), 2.51 (1H, dd, *J* = 12.5, 13 Hz, HC-2'), 2.32 (1H, ddd, *J* = 3.5, 3.5, 12.5 Hz, HC-3'), 2.25 (1H, ddd, *J* = 2, 3, 14 Hz, HC-6), 2.08 (1H, ddd, *J* = 2, 2, 13.5 Hz, HC-2), 2.02 (1H, dddd, *J* = 2.5, 3.5, 3.5, 13.5 Hz, HC-6'), 1.94 (1H, ddd, *J* = 3, 3.5, 13.5 Hz, HC-5'), 1.92-1.82 (3H, m, HC-2'', HC-5, HC-5'), 1.63 (1H, ddd, *J* = 2.5, 3, 13 Hz, HC-2'), 1.62-1.59 (1H, m, HC-3), 1.54 (1H, dq, *J* = 15, 7.5 Hz, HC-2''), 1.00 (3H, t, *J* = 7.5 Hz, H₃C-3''), 0.20 (9H, s, H₃CSi ×3).

^{13}C NMR (125 MHz, C_6D_6): δ 102.7 (s, C-4' or C-1''), 99.6 (s, C-4' or C-1''), 97.5 (s, C-4), 76.9 (d, C-1'), 45.9 (d, C-3'), 44.4 (d, C-5), 38.4 (t, C-5'), 37.3 (d, C-3), 30.3 (t, C-2''), 29.4 (t, C-2), 27.8 (t, C-2'), 25.6 (t, C-6'), 25.3 (t, C-6), 6.9 (t, C-3''), 2.6 (q $\times 3$, CH_3Si).

LRMS: m/z (relative intensity): 388 ($[\text{M}]^+$, 71), 314 (10), 286 (15), 225 (23), 198 (42), 155 (31), 73 (100) (EI).

HRMS: m/z calcd for $\text{C}_{17}\text{H}_{28}\text{O}_4\text{S}_2\text{Si}$ 388.1198, found 388.1198 (EI).

(4*S*,4*aS*,5*aR*,9*aS*,10*R*,10*aS*,12*R*)-12-Ethyloctahydro-5*a*,4,10-(epoxymethenoxy)-4*a*-triethylsilyoxy-1*H*,4*aH*,5*aH*-bisthiopyrano[4,3-*b*:3',4'-*e*]pyran (174b)



2,6-Lutidine (0.11 mL, 0.10 g, 0.93 mmol) and $(\text{CH}_3\text{CH}_2)_3\text{OTf}$ (0.10 mL, 0.12 g, 0.45 mmol) were sequentially added to a stirred solution of **167** (59 mg, 0.19 mmol) in CH_2Cl_2 (5 mL) at room temperature under Ar. After 2 h, the mixture was diluted with ethyl acetate, washed sequentially with 1% (w/v) aqueous citric acid ($\times 3$), sat. NaHCO_3 and brine, dried over Na_2SO_4 , concentrated, and fractionated by FCC (15% ethyl acetate in hexane) to give the titled compound as a clear oil (78 mg, 97%): $[\alpha]_{\text{D}} +1.0$ (c 1.1, CHCl_3).

IR ν_{max} : 2952, 2925, 1267, 1150, 1082, 896, 768 cm^{-1} .


¹H NMR (500 MHz, CDCl₃): δ 4.25 (1H, br d, *J* = 3 Hz, HC-1'), 3.54 (1H, dd, *J* = 3.5, 13.5 Hz, HC-2), 3.41 (1H, dd, *J* = 3, 14 Hz, HC-6), 2.96 (1H, ddd, *J* = 2.5, 13.5, 13.5 Hz, HC-6'), 2.99 (1H, dd, *J* = 12.5, 13 Hz, HC-2'), 2.53-2.44 (3H, m, HC-2, HC-6, HC-6'), 2.40 (1H, ddd, *J* = 3.5, 3.5, 12.5 Hz, HC-3'), 2.24 (1H, ddd, *J* = 3, 3, 13 Hz, HC-2'), 2.06-2.00 (2H, m, HC-3, HC-5'), 1.94 (1H, br s, HC-5), 1.88 (1H, ddd, *J* = 4, 13.5, 13.5 Hz, HC-5'), 1.80 (1H, dq, *J* = 15, 7.5 Hz, HC-2''), 1.61 (1H, dq, *J* = 15, 7.5 Hz, HC-2''), 0.99 (9H, t, *J* = 8 Hz, H₃C × 3), 0.96 (3H, t, *J* = 7.5 Hz, H₃C-3''), 0.71-0.65 (6H, m, H₂CSi × 3).

¹³C NMR (125 MHz, CDCl₃): δ 102.2 (s, C-4' or C-1''), 99.1 (s, C-4' or C-1''), 96.3 (s, C-4), 77.0 (d, C-1'), 45.3 (d, C-3'), 43.8 (d, C-5), 37.7 (t, C-5'), 37.0 (d, C-3), 29.8 (t, C-2''), 29.1 (t, C-2), 27.7 (t, C-2'), 25.4 (t, C-6'), 24.9 (t, C-6), 7.3 (q × 3, CH₃), 6.8 (t × 3, CH₂Si), 6.4 (q, C-3'').

LRMS: *m/z* (relative intensity) 430 ([M]⁺, 77), 327 (47), 240 (31), 225 (63), 155 (38), 115 (46), 87 (59), 67 (100) (EI).

HRMS: *m/z* calcd for C₂₀H₃₄O₄S₂Si 430.1668, found 430.1665 (EI).

**(1*R*,3*R*,5*R*,7*R*,8*S*,9*S*,10*S*)-3,5-Diethyl-8,9,10-trimethyl-2,4,6-trioxatricyclo [3.3.1.1^{3,7}]
dec-1-yloxy(trimethyl)silane (**175a**)**



From **142**: Triethylamine (0.10 mL, 73 mg, 0.73 mmol), 2,6-lutidine (0.50 mL, 0.46 g, 4.3 mmol) and Me₃SiCl (0.050 mL, 43 mg, 0.40 mmol) were sequentially added to a stirred solution of **142** (8 mg, 0.03 mmol) in CH₂Cl₂ (1 mL) at ambient temperature. After 3 d, the mixture was concentrated and the resulting residue was suspended in hexane and filtered through Celite®. The combined filtrate and hexane washings were concentrated and fractionated by PTLC (20% ethyl acetate in hexane) to give the titled compound (6 mg, 59%).

From **174a**: A suspension of Raney nickel (W2; 12 mL settled volume) in ethanol (20 mL) was added to **174a** (309 mg, 0.8 mmol) and the mixture was heated under reflux with vigorous stirring. After 45 min, the mixture was decanted and the solid suspended in ethanol and heated under reflux with rapid stirring for several min. This washing procedure was repeated twice with EtOH and once with ethyl acetate. The combined organic layers were filter through Celite® and concentrated to give the titled compound (231 mg, 88%) that was homogeneous by ¹H NMR: [α]_D -9 (*c* 0.5, C₆H₆).

IR ν_{max} : 2792, 2940, 2883, 1465, 1455, 1380, 1352, 1328 cm^{-1} .


^1H NMR (500 MHz, C_6D_6): δ 3.70 (1H, br d, $J = 3.5$ Hz, HC-7), 2.09-2.03 (2H, m, HC-9, HC-10), 2.00 (1H, br q, $J = 7.5$ Hz, HC-8), 1.82 (1H, dq, $J = 15, 7.5$ Hz, HCC-5), 1.60 (1H, dq, $J = 15, 7.5$ Hz, HCC-3), 1.57 (1H, dq, $J = 15, 7.5$ Hz, HCC-5), 1.45 (1H, dq, $J = 15, 7.5$ Hz, HCC-3), 1.18 (3H, d, $J = 7.5$ Hz, H_3CC -8), 1.08 (3H, d, $J = 7.5$ Hz, H_3CC -9), 1.07 (3H, t, $J = 7.5$ Hz, H_3CCC -5), 1.01 (3H, t, $J = 7.5$ Hz, H_3CCC -3), 0.63 (3H, d, $J = 7$ Hz, H_3CC -10), 0.30 (9H, s, $\text{H}_3\text{CSi} \times 3$).

^{13}C NMR (125 MHz, C_6D_6): δ 103.3 (s, C-3), 102.6 (s, C-5), 101.0 (s, C-1), 79.2 (d, C-7), 46.3 (d, C-9), 38.2 (d, C-10), 37.3 (d, C-8), 30.5 (t, CH_2C -5), 30.2 (t, CH_2C -3), 14.8 (q, CH_3C -8), 13.1 (q, CH_3C -10), 11.2 (q, CH_3C -9), 7.0 (q, CH_3CC -5), 6.9 (q, CH_3CC -3), 2.7 (q $\times 3$, CH_3Si).

LRMS: m/z (relative intensity) 328 ($[\text{M}]^+$, 4), 239 (13), 203 (72), 197 (22), 187 (18), 113 (25), 73 (38), 57 (100) (EI).

HRMS: m/z calcd for $\text{C}_{17}\text{H}_{32}\text{O}_4\text{Si}$ 328.2070, found 328.2062 (EI).

**(1*R*,3*R*,5*R*,7*R*,8*S*,9*S*,10*S*)-3,5-Diethyl-8,9,10-trimethyl-2,4,6-trioxatricyclo [3.3.1.1^{3,7}]
dec-1-yloxy(triethyl)silane (175b)**



A suspension of Raney nickel (W2; 2 mL settled volume) in EtOH (10 mL) was added to **174b** (72 mg, 0.17 mmol) and the mixture was heated under reflux with vigorous stirring. After 30 min, the mixture was decanted and the solid suspended in ethanol and heated under reflux with rapid stirring for several min. This washing procedure was repeated three times with EtOH and once with ethyl acetate. The combined organic layers were filter through Celite®, concentrated, and fractionated by FCC (10% ethyl acetate in hexane) to give the titled compound (51 mg, 83%).

¹H NMR (500 MHz, CDCl₃): δ 3.81 (1H, br d, *J* = 3.5 Hz, HC-7) 2.11 (1H, dq, *J* = 3.5, 7 Hz, HC-10) 1.99 (1H, br q, *J* = 7.5 Hz, HC-8) 1.87 (1H, br q, *J* = 7.5 Hz, HC-9) 1.67-1.46 (4H, m, H₂C ×2) 1.13 (3H, d, *J* = 7.5 Hz, H₃CC-8) 1.01 (3H, d, *J* = 7.5 Hz, H₃CC-9) 0.97 (9H, t, *J* = 8 Hz, H₃CCSi ×3) 0.92 (3H, t, *J* = 7.5 Hz, H₃CCC-3 or H₃CCC-5) 0.91 (3H, t, *J* = 7.5 Hz, H₃CCC-3 or H₃CCC-5) 0.87 (3H, d, *J* = 7 Hz, H₃CC-10) 0.64 (6H, ap q, *J* = 8 Hz, H₂CSi ×3).


¹³C NMR (125 MHz, CDCl₃): δ 102.8 (s, C-3), 102.2 (s, C-5) 99.8 (s, C-1), 79.3 (d, C-7) 45.6 (d, C-9), 37.8 (d, C-10) 36.8 (d, C-8), 29.9 (t, CH₂C-5 or CH₂C-3) 29.7 (t, CH₂C-3 or

CH₂C-5), 14.5 (q, CH₃C-8) 13.1 (q, CH₃C-10), 10.7 (q, CH₃C-9) 7.2 (q ×3, CH₃CSi), 6.7 (t ×3, CH₂Si) 6.6 (q, CH₃CC-5 or CH₃CC-3), 6.4 (q, CH₃CC-3 or CH₃CC-5).

LRMS: *m/z* (relative intensity) 370 ([M]⁺, 7) 267 (47) 245 (92) 229 (23) 171 (23) 75 (22) 71 (60) 57 (100) (EI).

HRMS: *m/z* calcd for C₂₀H₃₈O₄Si 370.2539, found 370.2538 (EI).

2-(2-Ethyl-1,3-dithiolan-2-yl)propanal (**179**)



179

IBX (2.5 g, 8.9 mmol) was added to a stirred solution of **186** (1.13 g, 5.88 mmol) in anhydrous DMSO (30 mL) at rt. Reaction progress was monitored by TLC and after 2 h, the mixture was diluted with ethyl acetate (200 mL) and washed sequentially with sat. NaHCO₃, water, and brine. The organic layer was dried over Na₂SO₄ and concentrated to give the titled compound as a clear oil (1.10 g, 98%) that was homogeneous by NMR.

IR *v*_{max}: 1718 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 9.87 (1H, d, *J* = 2 Hz, HC-1), 3.35-3.23 (4H, m, H₂CS ×2), 2.80 (1H, dq, *J* = 2,7 Hz, HC-2), 2.01 (1H, dq, *J* = 14.5, 7 Hz, HC-1''), 1.93 (1H, dq, *J* = 14.5, 7 Hz, HC-1''), 1.25 (3H, d, *J* = 7 Hz, H₃C-3), 1.08 (3H, t, *J* = 7 Hz, H₃C-2'').

^{13}C NMR (125 MHz, CDCl_3): δ 204.1 (s, C-1), 72.4 (s, C-2'), 54.3 (d, C-2), 40.3 (t, CH_2S), 40.2 (t, CH_2S), 36.5 (t, C-1''), 13.2 (q, C-3), 10.7 (q, C-2'').

LRMS: m/z (relative intensity): 190 ($[\text{M}]^+$, 7), 161 (10), 133 (100), 102 (12), 73 (25), 61 (18) (EI).

HRMS: m/z calcd for $\text{C}_8\text{H}_{14}\text{OS}_2$ 190.0486, found 190.0484 (EI).

Ethyl 2-(2-Ethyl-1,3-dithiolan-2-yl)propanoate (185)



$\text{BF}_3 \cdot \text{OEt}_2$ (7.8 mL, 8.8 g, 6.2 mmol) was added to a stirred solution of **184** (8.91 g, 56.4 mmol) and 1,2-dithioethane (5.0 mL, 5.6 g, 5.9 mmol) in CH_2Cl_2 (80 mL) at rt under Ar. Reaction progress was monitored by TLC and after 10 min, the mixture was diluted with ether (300 mL) and sat. NaHCO_3 (200 mL) (**CAUTION! effervescence**) and the two-phase mixture was stirred for 30 min at rt. The organic layer was washed with brine, dried over Na_2SO_4 , and concentrated to give the titled compound as a pale yellow oil (13.07 g, 99%) that was homogeneous by NMR.

IR ν_{max} : 1731 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ 4.18 (2H, q, $J = 7\text{ Hz}$, H_2CO), 3.25-3.20 (4H, m, $\text{H}_2\text{CS} \times 2$), 3.02 (1H, q, $J = 7\text{ Hz}$, HC-2), 2.09 (1H, dq, $J = 14.5, 7\text{ Hz}$, HC-1''), 1.94 (1H, dq, $J = 14.5, 7$


Hz, HC-1"), 1.42 (3H, d, $J = 7$ Hz, H₃C-3), 1.27 (3H, t, $J = 7$ Hz, H₃CCH₂O), 1.12 (3H, t, $J = 7$ Hz, H₃C-2").

¹³C NMR (125 MHz, CDCl₃): δ 174.4 (s, C-1), 74.3 (s, C-2'), 60.7 (t, CH₂O), 50.7 (d, C-2), 40.5 (t, CH₂S), 40.2 (t, CH₂S), 34.8 (t, C-1"), 15.7 (q, C-3), 14.4 (q, CH₃CH₂O), 10.7 (q, C-2").

LRMS: m/z (relative intensity) 234 ([M]⁺, 17), 205 (44), 133 (100), 105 (10), 89 (12), 73 (19) (EI).

HRMS: m/z calcd for C₁₀H₁₈O₂S₂ 234.0748, found 234.0745 (EI).

2-(2-Ethyl-1,3-dithiolan-2-yl)propan-1-ol (**186**)



A solution of **185** (13.2 g, 56.4 mmol) in THF (20 mL + 2×5 mL rinses) was added dropwise via syringe to a stirred suspension of LiAlH₄ (2.6 g, 68 mmol) in THF (100 mL) at 0 °C under Ar. The mixture was allowed to warm to ambient temperature and the reaction progress was monitored by TLC. After 3 h, the mixture was cooled to 0 °C and then water (2.6 mL) (**CAUTION! H₂ evolution**), 15% aqueous NaOH (w/v; 2.6 mL), and water (7.8 mL) were sequentially added with vigorous stirring. The cooling bath was removed and the grayish suspension turned white over 1 h. The mixture was filtered through a short pad of Na₂SO₄ and Celite® and washed with ethyl acetate. The combined filtrate and washings

were concentrated to give the titled compound as a pale yellow oil (9.97 g, 92%) that was homogeneous by NMR.

IR ν_{max} : 3377 cm^{-1} .


^1H NMR (500 MHz, CDCl_3): δ 3.95 (1H, dd, $J = 5.5, 11$ Hz, HC-1), 3.70 (1H, br dd, $J = 5, 11$ Hz, HC-1), 3.28-3.23 (4H, m, $\text{H}_2\text{CS} \times 2$), 2.52 (1H, br s, HO), 2.17 (1H, ddq, $J = 5, 5.5, 7$ Hz, HC-2), 2.03 (1H, dq, $J = 14.5, 7$ Hz, HC-1''), 1.93 (1H, dq, $J = 14.5, 7$ Hz, HC-1''), 1.12 (3H, d, $J = 7$ Hz, $\text{H}_3\text{C-3}$), 1.07 (3H, t, $J = 7$ Hz, $\text{H}_3\text{C-2''}$).

^{13}C NMR (125 MHz, CDCl_3): δ 76.5 (s, C-2'), 66.7 (t, C-1), 44.5 (d, C-2), 40.1 (t, CH_2S), 39.8 (t, CH_2S), 36.4 (t, C-1''), 15.7 (q, C-3), 10.8 (q, C-2'').

LRMS: m/z (relative intensity) 192 ($[\text{M}]^+$, 3), 163 (13), 133 (100), 105 (9), 73 (8) (EI).

HRMS: m/z calcd for $\text{C}_8\text{H}_{16}\text{OS}_2$ 192.0643, found 192.0638 (EI).

(6*R*,10*S*)-1,4-Dioxa-8-thiaspiro[4.5]decane-6,10-dicarboxaldehyde (*meso*-196); (6*R*,10*R*)-*rel*-1,4-Dioxa-8-thiaspiro[4.5]decane-6,10-dicarboxaldehyde ((\pm)-196)



196

(*meso/dl*)

IBX (23.2 g, 82.9 mmol) was added to a stirred solution of (\pm)-**194**⁷⁰ (7.6 g, 35 mmol) in MeCN (250 mL) at 80 °C (oil bath temperature). After 2.5 h, the suspension was cooled and then filtered through a medium-porosity sintered glass funnel. The combined filtrate and

ethyl acetate washings were concentrated and fractionated by FCC (50% ethyl acetate in hexanes) to give the titled compound (7.18 g, 96%) as a variable mixture of *meso*/dl isomers (dl:*meso*, 4-25:1) by ^1H NMR (C_6D_6). The recovered solid (20.1 g, mainly IBA, >90%) could be reoxidized to IBX with Oxone® in >80% yield.⁷⁸

Data included here for completeness.

***meso*-196:**

^1H NMR (500 MHz, C_6D_6): δ 9.46 (2H, s, HC=O \times 2), 3.11 (4H, br s, H_2CO \times 2), 2.82 (2H, ap dd, J = 13, 13 Hz, HC-7, HC-9), 2.42-2.39 (4H, m, HC-6, HC-7, HC-9, HC-10).

^{13}C NMR (125 MHz, C_6D_6): δ 199.0 (\times 2, C=O), 110.2 (C-5), 66.5 (CH_2O), 66.3 (CH_2O), 60.3 (\times 2, C-6, C-10), 26.6 (\times 2, C-7, C-9).

LRMS: (EI), m/z (relative intensity): 216 ($[\text{M}]^+$, 12), 188 (9), 160 (6), 113 (11), 99 (100), 86 (5), 54 (18).


HRMS: m/z calcd for $\text{C}_9\text{H}_{12}\text{O}_4\text{S}$ 216.0456, found 216.0458. Anal. Calcd for $\text{C}_9\text{H}_{12}\text{O}_4\text{S}$: C, 49.99; H, 5.59. Found: C, 49.79; H, 5.59.

(\pm)-196:

^1H NMR (500 MHz, C_6D_6): δ 9.62 (2H, br s, HC=O \times 2), 3.12-3.02 (4H, m, H_2CO \times 2), 2.73 (2H, dd, J = 7.5, 14 Hz, HC-2, HC-6), 2.56 (2H, ddd, J = 1.5, 3.5, 14 Hz, HC-2, HC-6), 2.23 (2H, dd, J = 3.5, 7.5 Hz, HC-3, HC-5).

^{13}C NMR (125 MHz, C_6D_6): δ 199.4 (\times 2, C=O), 108.3, 65.1 (\times 2, CH_2O), 55.1 (\times 2, C-3, C-5), 27.1 (\times 2, C-2, C-6).

3-oxa-7-thiaspiro[bicyclo[3.3.1]nonane-9,2'-[1,3]dioxolan]-2-one (197)



Isolated as a minor component in the IBX oxidation of mixtures of (\pm)-**195** and (\pm)-**194**. (\pm)-**197** was not detected when pure (\pm)-**194** was used.

IR ν_{max} : 1734 cm^{-1} .


^1H NMR (500 MHz, CDCl_3): δ 4.59 (1H, ddd, $J = 2, 6, 11.5$ Hz, HC-4), 4.43 (1H, d, $J = 11.5$ Hz, HC-4), 4.06-3.93 (4H, m, $\text{H}_2\text{CO} \times 2$), 3.34 (1H, ddd, $J = 2, 2, 13.5$ Hz, HC-6), 3.32 (1H, dd, $J = 2.5, 13$ Hz, HC-8), 2.94 (1H, ddd, $J = 2, 2.5, 4$ Hz, HC-1), 2.78 (1H, ddd, $J = 2.5, 4, 13$ Hz, HC-8), 2.54 (1H, ddd, $J = 2.5, 4, 13.5$ Hz, HC-6), 2.26-2.21 (1H, m, HC-5).

^{13}C NMR (125 MHz, CDCl_3): δ 171.0 (s, C-2), 105.1 (s, C-9), 71.1 (t, C-4), 65.4 (t, CH_2O), 64.9 (t, CH_2O), 47.8 (d, C-1), 36.4 (d, C-5), 32.3 (t, C-6), 30.5 (t, C-8).

LRMS: m/z (relative intensity) 216 ($[\text{M}]^+$, 65), 183 (24), 169 (7), 144 (80), 131 (8), 115 (18), 99 (100) (EI).

HRMS: m/z calcd. for $\text{C}_9\text{H}_{12}\text{O}_4\text{S}$ 216.0456, found 216.0460 (EI).

(1*S*,2*R*,4*RS*,5*R*)-2-((*S*)-4-Oxotetrahydro-2*H*-thiopyran-3-yl)-3-oxa-7-thiaspiro[bicyclo [3.3.1]nonane-9,2'-[1,3]dioxolan]-4-yl Pivalate (198**)**



Trimethylacetyl chloride (1.5 mL, 1.5 g, 12 mmol), DMAP (1.3 g, 10 mmol), and Et₃N (4 mL, 2.9 g, 29 mmol) were added to a stirred solution of **190** (3.5 g, 10 mmol) in CH₂Cl₂ (100 mL) at rt. After ca. 16 h, the mixture was diluted with ethyl acetate and washed sequentially with 1N aq. HCl, sat. NaHCO₃, and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by FCC (40% ethyl acetate in hexanes) to give the titled compound as a ca. 1:1 mixture of anomers (3.56 g, 81%).

IR ν_{max} : 1737, 1715 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 6.08 (1H, s, HC-4 (4*R*)), 6.05 (1H, br s, HC-4 (4*S*)), 5.19 (1H, br d, J = 10 Hz, HC-2 (4*R*)), 4.90 (1H, br d, J = 10 Hz, HC-2 (4*S*)), 4.19-3.92 (8H, m, H₂CO \times 4), 3.48 (1H, dd, J = 3, 13 Hz, HC-6 (4*R*)), 3.45 (1H, m, J = 4. 14 Hz, HC-8 (4*S*)), 3.41 (1H, dd, J = 2.5, 14 Hz, HC-8 (4*R*)), 3.31 (1H, dd, J = 3, 13.5 Hz, HC-6 (4*S*)), 3.17-3.11 (2H, m, HC-3' (4*R* & 4*S*)), 3.08-2.80 (10H, m), 2.75-2.49 (8H, m), 2.11 (1H, br s, HC-5 (4*R*)), 2.01 (1H, br s, HC-5 (4*R*)), 1.78 (2H, br s, HC-1 (4*R* & 4*S*)), 1.26 (9H, s, (H₃C)₃C), 1.20 (9H, s, (H₃C)₃C).

^{13}C NMR (125 MHz, CDCl_3): δ 207.8 (s, C-4'), 207.7 (s, C-4'), 177.0 (s, Piv), 176.7 (s, OC=O), 107.1 (s, C-9), 105.7 (s, C-9), 96.6 (d, C-4 (4*R*)), 94.1 (d, C-4 (4*S*)), 72.9 (d, C-2 (4*S*)), 72.1 (d, C-2 (4*R*)), 64.9 (t, CH_2O), 64.7 (t, CH_2O), 64.6 (t, CH_2O), 64.2 (t, CH_2O), 53.9 (d, C-3' (4*R*)), 53.3 (d, C-3' (4*S*)), 43.0 (t, C-5'), 42.3 (t, C-5'), 40.7 (d, C-5 (4*S*)), 39.1 (s $\times 2$, $\text{C}(\text{CH}_3)_3$), 39.0 (d, C-5 (4*R*)), 36.9 (d, C-1), 36.8 (d, C-1), 32.9 (t, C-2' or C-6'), 32.7 (t, C-2' or C-6'), 32.2 (t, C-2' or C-6'), 32.0 (t, C-2' or C-6'), 29.7 (t, C-6 (4*R*)), 27.2 (q $\times 6$, $(\text{CH}_3)_3\text{C} \times 2$), 25.9 (t, C-8 (4*S*)), 25.6 (t, C-8 (4*R*)), 25.0 (t, C-6 (4*S*)).

LRMS: m/z (relative intensity) 416 ($[\text{M}]^+$, 10), 314 (18), 226 (6), 199 (10), 131 (12), 99 (100) (EI).

HRMS: m/z calcd for $\text{C}_{19}\text{H}_{28}\text{O}_6\text{S}_2$ 416.1327, found 416.1348 (EI).

(6*R*,7*RS*,9*R*,10*S*)-6,10-Dimethyl-9-((*S*)-3-oxopent-2-yl)-1,4,8-trioxaspiro[4.5]decan-7-yl Pivalate (199**)**




199

Raney Nickel (W2; 60 mL settled volume) was washed with THF (x3) and THF (150 mL) and **198** (2.76 g, 6.6 mmol) were added. The resulting suspension was heated under reflux with vigorous stirring. After 3 h, the mixture was allowed to settle and then was decanted. The solid was suspended in ethyl acetate, heated under reflux for 10 min, and decanted. This washing procedure was repeated with ethyl acetate and then acetone. The combined organic layers were filtered through Celite® and concentrated to give the crude desulfurized product

that contained a variable amount (up to 10% by ^1H NMR) of alcohol (from hydrogenation of the ketone). IBX (1.73 g, 6.2 mmol) was added to a stirred solution of the crude reaction mixture in DMSO (30 mL) at rt. After 15 h, the mixture was diluted with ethyl acetate and washed sequentially with sat. NaHCO_3 , water, and brine. The aqueous layers were back extracted with ethyl acetate. The organic layers were combined, dried over Na_2SO_4 , concentrated, and fractionated by FCC (30% diethyl ether in hexanes) to give the titled compounds as a 1:1 mixture of anomers (2.02 g, 86%). Pure samples of the individual anomers could be obtained by fractionation of the mixture by PTLC (30% diethyl ether in hexanes).

(6*R*,7*S*,9*R*,10*S*)-6,10-Dimethyl-9-((*S*)-3-oxopent-2-yl)-1,4,8-trioxaspiro[4.5]decan-7-yl Pivalate (α -199)



$[\alpha]_{\text{D}} \sim 0$ (c 0.9, CHCl_3).

IR ν_{max} : 1735, 1718 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ 5.70 (1H, d, $J = 3$ Hz, HC-7), 3.98-3.92 (4H, m, $\text{H}_2\text{CO} \times 2$), 3.90 (1H, dd, $J = 2, 10.5$ Hz, HC-9), 2.73 (1H, dq, $J = 10.5, 7$ Hz, HC-1'), 2.59-2.43 (2H, m, HC-3'), 1.95 (1H, dq, $J = 1.5, 7.5$ Hz, HC-6), 1.68 (1H, br q, $J = 7.5$ Hz, HC-10), 1.17 (9H, s), 1.06 (3H, d, $J = 7.5$ Hz, H_3CC -6), 1.03 (3H, d, $J = 7.5$ Hz, H_3CC -10), 1.00 (3H, t, $J = 7$ Hz, HC-4'), 0.93 (3H, d, $J = 7$ Hz, H_3CC -1').


^{13}C NMR (125 MHz, CDCl_3): δ 213.9 (s, C-3'), 176.5 (s, $\text{OC}=\text{O}$), 110.8 (s, C-5), 94.7 (d, C-7), 77.9 (d, C-9), 64.7 (t, CH_2O), 64.5 (t, CH_2O), 47.4 (d, C-1'), 41.4 (d, C-6), 39.1 (s, $\text{C}(\text{CH}_3)_3$), 38.6 (d, C-10), 35.0 (t, C-4'), 27.2 (q $\times 3$, $(\text{CH}_3)_3\text{C}$), 12.6 (q, C-1'), 9.1 (q, $\text{CH}_3\text{C}-10$), 8.9 (q, $\text{CH}_3\text{C}-6$), 7.5 (q, C-5').

LRMS: m/z (relative intensity) 374 ($[\text{M}+18]^+$, 47), 272 (11), 255 (100), 185 (5), 129 (19), 100 (8) (CI, NH_3).

HRMS: m/z calcd for $\text{C}_{19}\text{H}_{32}\text{O}_6$ 356.2199 (374.2543 for $\text{M}+\text{NH}_4$), found 374.2454 (CI, NH_3).

(6*R*,7*R*,9*R*,10*S*)-6,10-Dimethyl-9-((*S*)-3-oxopentan-2-yl)-1,4,8-trioxaspiro[4.5]decan-7-yl

Pivalate (β -199)



β -199

$[\alpha]_{\text{D}} +67$ (c 0.9, CHCl_3).

IR ν_{max} : 1735, 1718 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ 5.74 (1H, br s, HC-7), 4.35 (1H, dd, $J = 2, 10.5$ Hz, HC-9), 3.99-3.87 (4H, m, $\text{H}_2\text{CO} \times 2$), 2.73 (1H, dq, $J = 10.5, 7$ Hz, HC-2'), 2.56 (1H, dq, $J = 18, 7$ Hz, HC-4'), 2.46 (1H, dq, $J = 18, 7$ Hz, HC-4'), 1.91 (1H, br q, $J = 7.5$ Hz, HC-6), 1.80 (1H, br q, $J = 7.5$ Hz, HC-10), 1.22 (9H, s, $(\text{H}_3\text{C})_3\text{C}$), 1.11 (3H, d, $J = 7.5$ Hz, $\text{H}_3\text{CC}-6$), 1.03 (3H, d, $J = 7.5$ Hz, $\text{H}_3\text{CC}-10$), 0.99 (3H, t, $J = 7$ Hz, $\text{H}_3\text{C}-5'$), 0.92 (3H, d, $J = 7$ Hz, $\text{H}_3\text{C}-1'$).


^{13}C NMR (125 MHz, CDCl_3): δ 213.8 (s, C-3'), 177.4 (s, $\text{OC}=\text{O}$), 109.3 (s, C-5), 96.8 (d, C-7), 74.4 (d, C-9), 64.7 (t, CH_2O), 64.5 (t, CH_2O), 46.9 (d, C-2'), 39.9 (d, C-6), 39.1 (s,

C(CH₃)₃), 38.7 (d, C-10), 36.3 (t, C-3'), 27.2 (q ×3, (CH₃)₃C), 14.2 (q, CH₃C-6), 12.5 (q, C-1'), 8.8 (q, CH₃C-10), 7.5 (q, C-5').

LRMS: *m/z* (relative intensity) 374 ([M+18]⁺, 19), 272 (22), 255 (100), 197 (6), 129 (12). (CI, NH₃).

HRMS: *m/z* calcd for C₁₉H₃₂O₆ 356.2199 (374.2543 for M+NH₄), found 374.2543 (CI, NH₃).

2-((*S*)-1-((2*R*,3*S*)-3,5-Dimethyl-4-oxo-3,4-dihydro-2*H*-pyran-2-yl)ethyl)-6-ethyl-3,5-dimethyl-4*H*-pyran-4-one (202)



202

A solution of **199** (ca. 1:1 mixture of anomers; 2.04 g, 5.7 mmol) in THF (20 mL plus 2x10 mL rinses) was added to a stirred solution of LDA [freshly prepared from DIPA (1.0 mL, 0.74 g, 7.3 mmol) and n-BuLi (2.2 M in hexanes, 2.9 mL, 6.3 mmol)] in THF (100 mL) at -78 °C under Ar. After 30 min, neat **179** (3.3 g, 17.4 mmol) was added dropwise over 3 - 5 min. After 30 min, the mixture was diluted with ethyl acetate and washed sequentially with 1M HCl (x2), sat. NaHCO₃, and brine. The organic layer was dried over Na₂SO₄, concentrated, and fractionated by FCC (30-80% diethyl ether in hexanes) to give a complex mixture of aldol diastereomers (**200**) (2.84 g, 91%) and recovered aldehyde (2.2 g, 67%).

IBX (2.8 g, 10 mmol) was added to a stirred solution of the above aldol mixture (**200**) (2.67 g, 4.9 mmol) in dry DMSO (100 mL) at rt. After 24 h, the mixture was diluted with ethyl acetate and washed sequentially with sat. NaHCO₃, water, and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by FCC (25% ethyl acetate in hexanes) to give a mixture of diketones (**201**) (keto and enol forms) (2.53 g, 95%).

IBX (2.5 g, 8.9 mmol) and CF₃SO₃H (0.39 mL, 660 mg, 4.4 mmol) were added to a stirred solution of the above **201** (2.41 g, 4.4 mmol) in MeCN (120 mL) at rt. After 17 h, the mixture was diluted with ethyl acetate and washed with sat. NaHCO₃ (x2) and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by FCC (40% acetone in hexanes) to give the titled compound (961 mg, 71%; 62% from **199** over 3 steps): [α]_D -35 (*c* 0.7, CH₂Cl₂).

IR ν_{max} : 1659, 1611 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 7.09 (1H, s, HC-6"), 4.45 (1H, br d, *J* = 10 Hz, HC-2"), 3.39 (1H, dq, *J* = 10, 7 Hz, HC-1'), 2.59 (2H, q, *J* = 7.5 Hz, H₂CCH₃), 2.52 (1H, dq, *J* = 1.5, 7 Hz, HC-3"), 1.99 (3H, s, H₃CC-3 or H₃CC-5), 1.94 (3H, s, H₃CC-5 or H₃CC-3), 1.64 (3H, s, H₃CC-5"), 1.17 (3H, t, *J* = 7.5 Hz, H₃CCH₂), 1.16 (3H, d, *J* = 7 Hz, H₃CC-1'), 1.13 (3H, d, *J* = 7 Hz, H₃CC-3").


¹³C NMR (125 MHz, CDCl₃): δ 197.2 (s, C-4"), 179.9 (s, C-4), 164.4 (s, C-6), 162.2 (s, C-2), 159.0 (d, C-6"), 120.0 (s, C-3), 118.3 (s, C-5), 112.7 (s, C-5"), 82.4 (d, C-2"), 41.2 (d, C-7"),

36.2 (d, C-1'), 24.9 (t, CH₂C-6), 13.6 (q, CH₃-C1'), 11.5 (q, CH₃CH₂), 10.7 (q, CH₃C-5''), 9.7 (q ×2, CH₃C-3, CH₃C-5), 9.4 (q, CH₃C-3').

LRMS: m/z (relative intensity) 304 ($[M]^+$, 41), 256 (50), 180 (100), 129 (29), 73 (75) (EI).

HRMS: m/z calcd for C₁₈H₂₄O₄ 304.1675, found 304.1682 (EI).

(2R,3S)-3,5-dimethyl-2-((S)-3-oxopentan-2-yl)-2H-pyran-4(3H)-one (208)



IBX (24 mg, 0.086 mmol) and ethanedithiol (6 μ L, 6 mg, 0.07 mmol) were added to a stirred solution of **199** (ca. 1:1 mixture of anomers; 24 mg, 0.7 mmol) in MeCN (4 mL) at 80 °C (oil bath temperature). After 1 d, the solution was diluted with ethyl acetate and washed with sat. NaHCO₃ (x2) and brine, dried over Na₂SO₄, concentrated, and fractionated by PTLC (50% ethyl acetate in hexanes) to give the titled compound (8 mg, 56%, unoptimized).

IR ν_{max} : 1718, 1672, 1623 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 7.12 (1H, s, HC-6), 4.49 (1H, dd, J = 3, 10.5 Hz, HC-2), 3.03 (1H, dq, J = 10.5, 7 Hz, HC-2'), 2.64-2.49 (2H, m, H₂C-4'), 2.40 (1H, dq, J = 3, 7.5 Hz, HC-3), 1.64 (3H, s, H₃CC-5), 1.08 (3H, t, J = 7 Hz, H₃C-5'), 1.07 (3H, d, J = 7.5 Hz, H₃CC-3), 0.99 (3H, d, J = 7 Hz, H₃C-1').

^{13}C NMR (125 MHz, CDCl_3): δ 212.4 (s, C-3'), 197.2 (s, C-4), 159.0 (d, C-6), 112.8 (s, C-5), 83.2 (d, C-2), 56.0 (d, C-2'), 41.0 (d, C-3'), 36.8 (t, C-4'), 12.6 (q, C-1'), 10.7 (q, $\text{CH}_3\text{C-5}$), 9.7 (q, $\text{CH}_3\text{C-3}$), 7.6 (q, C-5').

LRMS: m/z (relative intensity) 210 ($[\text{M}]^+$, 15), 195 (12), 153 (12), 141 (9), 125 (19), 85 (52), 69 (13), 57 (100) (EI).

HRMS: m/z calcd. for $\text{C}_{12}\text{H}_{18}\text{O}_3$ 210.1256, found 210.1248 (EI).

2-((*S*)-1-((2*S*,3*R*,4*S*)-4-Hydroxy-3,5-dimethyl-3,4-dihydro-2*H*-pyran-2-yl)ethyl)-6-ethyl-3,5-dimethyl-4*H*-pyran-4-one (209)



209

$\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (2.3 g, 6.1 mmol) was added to a stirred solution of **202** (460 mg, 1.5 mmol) in EtOH (50 mL) at 0 °C. After 20 min, NaBH_4 (150 mg, 3.9 mmol) was added and the suspension stirred at 0 °C for 3 h. The cooling bath was removed and after 3 h, the mixture was diluted with ethyl acetate and washed sequentially with sat. NaHCO_3 and brine. The organic layer was dried over Na_2SO_4 and concentrated to give the titled compound (437 mg, 94%): $[\alpha]_{\text{D}} -29$ (c 0.5, CHCl_3).

IR ν_{max} : 3364, 1720, 1655, 1610 cm^{-1} .


¹H NMR (500 MHz, CDCl₃): δ 5.96 (br s, 1H, HC-6''), 4.50 (br d, 1H, *J* = 6 Hz, HC-4''), 4.04 (br d, 1H, *J* = 10.5 Hz, HC-2''), 3.27 (dq, 1H, *J* = 10.5, 7 Hz, HC-1'), 2.60 (q, 2H, *J* = 7.5 Hz, H₂CC-6), 2.25 (dq, 1H, *J* = 6, 7 Hz, HC-3''), 1.96 (s, 3H, H₃CC-3), 1.94 (s, 3H, H₃CC-5), 1.57 (s, 3H, H₃CC-5''), 1.20 (t, 3H, *J* = 7.5 Hz, H₃CCH₂), 1.15 (d, 3H, *J* = 7 Hz, H₃CC-1'), 0.98 (d, 3H, *J* = 7 Hz, H₃CC-3'').

¹³C NMR (125 MHz, CDCl₃): δ 180.1 (s, C-4), 164.3 (s, C-6), 164.0 (s, C-2), 139.7 (d, C-6''), 119.6 (s, C-3), 118.0 (s, C-5), 109.7 (s, C-5''), 79.4 (d, C-2''), 69.4 (d, C-4''), 36.9 (d, C-1'), 33.2 (d, C-3''), 25.0 (t, CH₂C-6), 14.1 (q, CH₃C-1'), 13.6 (q, CH₃C-5''), 11.6 (q, CH₃CH₂), 9.7 (q ×2, CH₃C-3, CH₃C-5), 5.0 (q, CH₃C-3'').

LRMS: *m/z* (relative intensity) 306 ([M]⁺, 55), 221 (24), 205 (15), 180 (100), 109 (7) (EI).

HRMS: *m/z* calcd for C₁₈H₂₆O₄ 306.1831, found 306.1828 (EI).

2-((*S*)-1-((2*S*,3*S*,4*S*)-4-(Benzyloxy)-3,5-dimethyl-3,4-dihydro-2*H*-pyran-2-yl)ethyl)-6-ethyl-3,5-dimethyl-4*H*-pyran-4-one (210)



210

KHMDS (0.5 M in toluene; 3 mL, 1.5 mmol) was added portion-wise (1 mL every 10 min) to a stirred solution of **209** (170 mg, 0.56 mmol), HMPA (2 mL), BnBr (0.4 mL, 0.57 g, 3.3 mmol), and *t*-BuOH (130 mg, 1.8 mmol) in THF (20 mL) at 0 °C under Ar. After 10 min, the mixture was diluted with ethyl acetate and washed sequentially with water, sat. NaHCO₃ and

brine, dried over Na₂SO₄, concentrated, and fractionated by FCC (40% ethyl acetate in hexanes) to give the titled compound (183 mg, 83%): [α]_D -10 (*c* 1.7, C₆H₆).

IR ν_{max} : 1658, 1610 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 7.42-7.28 (5H, m, ArH), 5.96 (1H, s, HC-6"), 4.70 (1H, d, *J* = 12 Hz, H₂CO), 4.47 (1H, d, *J* = 12 Hz, H₂CO), 4.22 (1H, br d, *J* = 6 Hz, HC-4"), 4.00 (1H, d, *J* = 10.5 Hz, HC-2"), 3.27 (1H, dq, *J* = 10.5, 7 Hz, HC-1'), 2.59 (2H, q, *J* = 7.5 Hz, H₂CC-6), 2.36 (1H, dq, *J* = 6, 7 Hz, HC-3"), 1.97 (3H, s, H₃CC-3), 1.94 (3H, s, H₃CC-5), 1.58 (3H, s, H₃CC-5'), 1.19 (3H, t, *J* = 7.5 Hz, H₃CCH₂), 1.16 (3H, d, *J* = 7 Hz, H₃CC-1'), 0.99 (3H, d, *J* = 7 Hz, H₃CC-3").

¹³C NMR (125 MHz, CDCl₃): δ 180.1 (s, C-4), 164.2 (s, C-6), 163.9 (s, C-2), 139.8 (d, C-6"), 138.8 (s, Ph), 128.6 (d \times 2, Ph), 127.8 (d, Ph), 127.7 (d \times 2, Ph), 119.7 (s, C-3), 118.0 (s, C-5), 109.4 (s, C-5"), 79.0 (d, C-2"), 76.2 (d, C-4"), 70.9 (t, CH₂O), 37.0 (d, C-1'), 29.8 (d, C-4"), 25.0 (t, CH₂C-6), 14.2 (q, CH₃C-1' or CH₃C-5"), 14.1 (q, CH₃C-1' or CH₃C-5"), 11.6 (q, CH₃CH₂), 9.7 (q \times 2, CH₃C-3, CH₃C-5), 5.2 (q, CH₃C-4").

LRMS: *m/z* (relative intensity): 396 ([M]⁺, 8), 305 (17), 221 (41), 180 (69), 91 (100) (EI).

HRMS: *m/z* calcd for C₂₅H₃₂O₄ 396.2301, found 396.2293 (EI).

(2*S*,3*S*,4*S*)-2-((*S*)-1-(6-ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)ethyl)-3,5-dimethyl-3,4-dihydro-2*H*-pyran-4-yl acetate (211**)**



211

Ac₂O (ca. 50 μ L, 46 mg, 0.45 mmol) and DMAP (10 mg, 0.08 mmol) were added to a stirred solution of **209** (16 mg, 0.05 mmol) in CH₂Cl₂ (1 mL) at room temperature. After 1 h, the mixture was concentrated and fractionated by PTLC (80% ethyl acetate in hexanes) to give the titled compound (19 mg, 100%): [α]_D -15 (*c* 0.6, C₆H₆).

IR ν_{max} : 1735, 1659, 1610 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 6.12 (1H, s, HC-6), 5.62 (1H, br d, *J* = 6.5 Hz, HC-4), 4.16 (1H, br d, *J* = 10 Hz, HC-2), 3.12 (1H, dq, *J* = 10, 7 Hz, HC-1'), 2.67 (2H, q, *J* = 7.5 Hz, H₂CCH₃), 2.52 (1H, dq, *J* = 6.5, 7.5 Hz, HC-3), 2.20 (3H, s, H₃CC(O)), 2.03 (3H, s, H₃CC-3"), 2.01 (3H, s, H₃CC-5"), 1.56 (3H, s, H₃CC-5), 1.27 (3H, t, *J* = 7.5 Hz, H₃CCH₂), 1.21 (3H, d, *J* = 7 Hz, H₃CC-1'), 1.00 (3H, d, *J* = 7 Hz, H₃CC-3).


¹³C NMR (125 MHz, CDCl₃): δ 180.1 (s, C-4"), 171.2 (s, COO), 164.3 (s, C-6"), 163.6 (s, C-2"), 141.2 (d, C-6), 119.7 (s, C-5"), 118.0 (s, C-3"), 106.7 (s, C-5), 78.8 (d, C-2), 71.7 (d, C-4), 36.8 (d, C-1'), 30.1 (d, C-3), 25.0 (t, CH₂CH₃), 21.2 (q, CH₃C(O)), 14.0 (q, CH₃C-1'), 13.6

(q, CH₃C-5'), 11.5 (q, CH₃CH₂), 9.7 (q, CH₃C-3"or CH₃C-5"), 9.7 (q, CH₃C-3"or CH₃C-5"), 5.7 (q, CH₃C-3).

LRMS: m/z (relative intensity) 348 ($[M]^+$, 38), 289 (16), 221 (13), 180 (100), 109 (82) (EI).

HRMS: m/z calcd. for C₂₀H₂₈O₅ 348.1937, found 348.1933 (EI).

2-ethyl-6-((*S*)-1-((2*S*,3*R*,6*S*)-6-methoxy-3,5-dimethyl-3,6-dihydro-2*H*-pyran-2-yl)ethyl)-3,5-dimethyl-4*H*-pyran-4-one (212)



212

Triphenylphosphine hydrobromide (ca. 1 mg) and MeOH (20 μ L) were added to a stirred solution of **211** (6 mg, 0.17 mmol) in CH₂Cl₂ (1 mL). The solution was stirred for 1 day and added to ethyl acetate. The organic layer was washed with sat. NaHCO₃ and brine, dried over Na₂SO₄, concentrated, and fractionated by PTLC (30% acetone in hexanes; 2 elutions) to give the titled compound (4 mg, 73%).

IR ν_{\max} : 1657, 1613 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 5.69 (1H, d, J = 5.5 Hz, HC-4''), 4.44 (1H, s, HC-6''), 4.08 (1H, dd, J = 2, 10.5 Hz, HC-2''), 3.12 (1H, dq, J = 10.5, 7 Hz, HC-1'), 2.97 (3H, s, H₃CO), 2.68-2.55 (2H, m, H₂CCH₃), 2.17-2.09 (1H, m, HC-3''), 2.01 (3H, s, H₃C-5), 1.95 (3H, s,


H₃C-3), 1.66 (3H, s, H₃C-5''), 1.23 (3H, t, *J* = 7.5 Hz, H₃CCH₂), 1.15 (3H, d, *J* = 5 Hz, H₃C-1'), 0.98 (3H, d, *J* = 5 Hz, H₃C-3'').

¹³C NMR (125 MHz, CDCl₃): δ 180.1, 164.8, 164.3, 131.6, 129.7, 119.8, 118.0, 99.3, 71.1, 55.2, 37.0, 30.3, 25.0, 25.0, 13.8, 12.1, 11.6, 9.9, 9.8.

LRMS: *m/z* (relative intensity): 320 ([M]⁺, 31), 289 (28), 180 (100), 141 (9), 113 (62), 83 (35) (EI).

HRMS: *m/z* calcd. for C₁₉H₂₈O₄ 320.1988, found 320.1979 (EI).

2-((2*S*,3*S*,4*S*,5*R*,6*R*)-5-(Benzyloxy)-3,7-dihydroxy-4,6-dimethylheptan-2-yl)-6-ethyl-3,5-dimethyl-4*H*-pyran-4-one (213)



213

A solution of Hg(OAc)₂ (130 mg, 0.41 mmol) in water (14 mL) was added to a stirred solution of **210** (139 mg, 0.35 mmol) in THF (14 mL) at rt. The resulting yellow suspension was stirred at this temperature for 2 h and then a solution of Na₂CO₃ (120 mg, 1.1 mmol) in water (10 mL) was added in one portion. After 10 min, a solution of NaBH₄ (32 mg, 0.84 mmol) in water (2 mL) was added. After 1 min, the mixture was diluted with water and extracted with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄, concentrated, and the residue taken up in ethanol (10 mL), and then NaBH₄ (105 mg, 2.8 mmol) was added

to the stirred solution at rt. After ca. 16 h, the mixture was diluted with water and extracted with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by FCC (100% ethyl acetate) to give **214** (24 mg, 16%) and the titled compound (91 mg, 62%): [α]_D -9 (c 0.6, CHCl₃).

IR ν_{max} : 3401, 1652, 1589 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 7.33-7.26 (5H, m, ArH), 4.72-4.66 (2H, m, H₂CPh), 4.22 (1H, br d, J = 10 Hz, HC-3'), 3.84-3.77 (1H, m, HC-7'), 3.75-3.68 (1H, m, HC-7'), 3.59 (1H, dd, J = 4, 7.5 Hz, HC-5'), 3.13 (1H, br s, HOC-3'), 3.11 (1H, dq, J = 10, 7 Hz, HC-2'), 2.64-2.51 (2H, m, H₂CC-6), 2.22 (1H, br s, HOC-7'), 2.09-2.03 (1H, m, HC-6'), 2.03-1.97 (1H, m, HC-4'), 1.98 (3H, s, H₃CC-3), 1.90 (3H, s, H₃CC-5), 1.17 (3H, t, J = 7.5 Hz, H₃CCH₂), 1.14 (3H, d, J = 7 Hz, H₃CC-4'), 1.10 (3H, d, J = 7 Hz, H₃C-1'), 1.07 (3H, d, J = 7 Hz, H₃CC-6').

¹³C NMR (125 MHz, CDCl₃): δ 180.0 (s, C-4), 164.8 (s, C-2), 164.2 (s, C-6), 137.8 (s, Ph), 128.8 (d \times 2, Ph), 128.3 (d, Ph), 128.0 (d \times 2, Ph), 119.6 (s, C-3), 118.0 (s, C-5), 88.2 (d, C-5'), 76.6 (t, CH₂Ph), 72.1 (s, C-3'), 65.3 (d, C-7'), 39.1 (d, C-2'), 38.0 (d, C-6'), 35.6 (d, C-4'), 25.0 (t, CH₂C-6), 15.2 (q, CH₃C-6'), 14.7 (q, C-1'), 11.4 (q, CH₃CH₂), 11.0 (q, CH₃C-4'), 9.9 (q, CH₃C-3 or CH₃C-5), 9.7 (q, CH₃C-3 or CH₃C-5).

LRMS: m/z (relative intensity) 416 ([M]⁺, 0.4), 357 (2), 270 (3), 180 (100), 91 (56) (EI).

HRMS: m/z calcd for C₂₅H₃₆O₅ 416.2563, found 416.2559 (EI).

2-((2*S*,3*S*,4*S*,5*R*,6*S*)-5-(Benzyloxy)-3,7-dihydroxy-4,6-dimethylheptan-2-yl)-6-ethyl-3,5-dimethyl-4*H*-pyran-4-one (214)



214

Isolated as a minor compound in the preceding reaction.

$[\alpha]_D -19$ (c 1.0, CHCl_3).

IR ν_{max} (Thin Film): 3399, 1653, 1592, 1557 cm^{-1} .


^1H NMR (500 MHz, CDCl_3): δ 7.25-7.26 (5H, m, ArH), 4.67 (1H, d, $J = 11$ Hz, CHPh), 4.63 (1H, d, $J = 11$ Hz, CHPh), 4.22 (1H, br d, $J = 10$ Hz, HC-3'), 3.70-3.61 (3H, m, HC-5', $\text{H}_2\text{C}-7'$), 3.11 (1H, dq, $J = 10, 7$ Hz, HC-2'), 2.64-2.49 (2H, m, $\text{H}_2\text{CC}-6$), 2.10-2.03 (2H, m, HC-6'), 2.03-1.96 (1H, m, HC-4'), 1.98 (3H, s, $\text{H}_3\text{CC}-3$), 1.91 (3H, s, $J = 7.5$ Hz, $\text{H}_3\text{CC}-5$), 1.14 (3H, t, $J = 7$ Hz, H_3CCH_2), 1.11 (3H, d, $J = 7$ Hz, $\text{H}_3\text{C}-1'$), 1.03 (3H, d, $J = 7$ Hz, $\text{H}_3\text{CC}-6'$), 1.02 (3H, d, $\text{H}_3\text{CC}-4'$).

^{13}C NMR (125 MHz, CDCl_3): δ 180.0 (s, C-4), 164.9 (s, C-2), 164.3 (s, C-6), 138.5 (s, Ph), 128.0 (d $\times 2$, Ph), 127.9 (d, Ph), 127.9 (d $\times 2$, Ph), 119.7 (s, C-3), 118.1 (s, C-5), 83.8 (d, C-5'), 75.6 (t, CH_2Ph), 72.4 (d, C-3'), 66.2 (t, C-7'), 39.5 (d, C-2'), 38.5 (d, C-6'), 35.6 (d, C-4'), 25.0 (t, $\text{CH}_2\text{C}-6$), 14.8 (q, C-1'), 12.0 (q, $\text{CH}_3\text{C}-6'$), 11.4 (q, CH_3CH_2), 10.2 (q, $\text{CH}_3\text{C}-4'$), 9.9 (q, $\text{CH}_3\text{C}-3$ or $\text{CH}_3\text{C}-5$), 9.7 (q, $\text{CH}_3\text{C}-3$ or $\text{CH}_3\text{C}-5$).

LRMS: m/z (relative intensity) 417 ($[\text{M}+1]^+$, 100), 236 (7), 209 (10), 181 (31) (CI, NH_3).

HRMS: m/z calcd for $C_{25}H_{36}O_5$ 416.2563 (417.2641 for $M+H$), found 417.2636 (CI, NH_3).

6-Ethyl-2-((*S*)-1-((2*S*,3*S*,4*S*)-4-((4-methoxybenzyl)oxy)-3,5-dimethyl-3,4-dihydro-2*H*-pyran-2-yl)ethyl)-3,5-dimethyl-4*H*-pyran-4-one (215)



215

KHMDS (0.40 mL, 0.20 mmol; 0.5 M in toluene) was added in 3 portions (0.16, 0.16 and 0.08 mL) over 20 min to a solution of **210** (24 mg, 0.08 mmol), HMPA (0.5 mL), PMBCl (50 μ L, 56 mg, 0.36 mmol), and *t*-BuOH (20 mg, 0.27 mmol) in THF (5 mL) at rt under Ar. After 10 min, the mixture was diluted with ethyl acetate, washed sequentially with sat. $NaHCO_3$, water, and brine, dried over Na_2SO_4 , concentrated, and fractionated by PTLC (80% ethyl acetate in hexanes) to give the titled compound (24 mg, 74%; unoptimized): $[\alpha]_D -14$ (*c* 1.5, C_6H_6).

IR ν_{max} : 1656, 1610 cm^{-1} .

1H NMR (500 MHz, $CDCl_3$): δ 7.31 (2H, ap d, $J = 8.5$ Hz, ArH), 6.90 (2H, ap d, $J = 8.5$ Hz, ArH), 5.94 (1H, s, HC-6''), 4.62 (1H, d, $J = 11.5$ Hz, H_2CO), 4.39 (1H, d, $J = 11.5$ Hz, H_2CO), 4.19 (1H, d, $J = 6$ Hz, HC-4''), 3.99 (1H, br d, $J = 10.5$ Hz, HC-2''), 3.80 (3H, s, H_3CO), 3.26 (1H, dq, $J = 10.5, 7$ Hz, HC-1'), 2.59 (2H, q, $J = 7.5$ Hz, H_2CC -6), 2.34 (1H, ddq, $J = 1.5, 6, 7$ Hz, HC-3''), 1.96 (3H, s, H_3CC -3), 1.93 (3H, s, H_3CC -5), 1.54 (3H, s,


H₃CC-5"), 1.18 (3H, t, $J = 7.5$ Hz, H₃CCH₂), 1.15 (3H, d, $J = 7$ Hz, H₃CC-1'), 0.97 (3H, d, $J = 7$ Hz, H₃CC-3").

¹³C NMR (125 MHz, CDCl₃): δ 180.1 (s, C-4), 164.2 (s, C-6), 164.0 (s, C-2), 159.4 (s, Ar), 139.7 (d, C-6"), 130.9 (s, Ar), 129.3 (d \times 2, Ar), 119.6 (s, C-3), 118.0 (s, C-5), 114.0 (d \times 2, Ar), 109.4 (s, C-5"), 79.1 (d, C-2"), 75.8 (d, C-4"), 70.6 (t, CH₂O), 55.5 (q, CH₃O), 37.0 (d, C-1'), 29.8 (d, C-3"), 25.0 (t, CH₂C-6), 14.2 (q, CH₃C-1' or CH₃C-5'), 14.1 (q, CH₃C-1' or CH₃C-5'), 11.6 (q, CH₃CH₂), 9.7 (q \times 2, CH₃C-3, CH₃C-5), 5.2 (q, CH₃C-3").

LRMS: m/z (relative intensity) 426 ([M]⁺, 6), 290 (50), 221 (26), 180 (39), 121 (100) (EI).

HRMS: m/z calcd for C₂₆H₃₄O₅ 426.2406, found 426.2391 (EI).

2-((2*S*,3*S*,4*S*,5*R*,6*S*)-3,7-Dihydroxy-5-((4-methoxybenzyl)oxy)-4,6-dimethylheptan-2-yl)-6-ethyl-3,5-dimethyl-4*H*-pyran-4-one (216)



216

Further fractionation of **80** by PTLC (10% MeOH in CH₂Cl₂) gave a pure sample (2.5 mg, 16%).

IR ν_{max} : 3397, 1651, 1588 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 7.24 (2H, ap d, $J = 8.5$ Hz, ArH), 6.84 (2H, ap d, $J = 8.5$ Hz, ArH), 4.60 (1H, d, $J = 11$ Hz, CHAr), 4.55 (1H, d, $J = 11$ Hz, CHAr), 4.21 (1H, br d, $J = 10$


Hz, HC-3'), 3.78 (3H, s, H₃CO), 3.64-3.61 (3H, m, HC-5', H₂C-7'), 3.15-3.07 (1H, m, HC-2'), 2.65-2.53 (2H, m, H₂CC-6), 2.41 (1H, br s, HOC-3'), 2.10-2.03 (1H, m, HC-6'), 2.01-1.91 (1H, m, HC-4'), 1.99 (3H, s, H₃CC-3), 1.93 (3H, s, H₃CC-5), 1.17 (3H, t, *J* = 7.5 Hz, H₃CCH₂), 1.11 (3H, d, *J* = 7 Hz, H₃C-1'), 1.03 (3H, d, *J* = 7 Hz, H₃CC-6'), 1.01 (3H, d, *J* = 7 Hz, H₃CC-4').

¹³C NMR (125 MHz, CDCl₃): δ 180.0 (s, C-4), 164.8 (s, C-2), 164.2 (s, C-6), 159.6 (s, Ar), 130.5 (s, Ar), 129.6 (d x 2, Ar), 119.7 (s, C-3), 118.1 (s, C-5), 114.1 (d x 2, Ar), 83.8 (d, C-5'), 75.2 (t, CH₂Ar), 72.4 (d, C-3'), 66.2 (t, C-7'), 55.5 (q, CH₃O), 39.4 (d, C-2'), 38.5 (d, C-6'), 36.4 (d, C-4'), 25.0 (t, CH₂C-6), 14.8 (q, C-1'), 12.2 (q, CH₃C-6'), 11.5 (q, CH₃CH₂), 10.4 (q, CH₃C-4'), 9.9 (q, CH₃C-3 or CH₃C-5), 9.8 (q, CH₃C-3 or CH₃C-5).

LRMS: *m/z* (relative intensity) 446 ([M]⁺, 1), 310 (7), 209 (12), 180 (55), 121 (100) (EI).

HRMS: *m/z* calcd for C₂₆H₃₈O₆ 446.2668, found 446.2672 (EI).

2-((2*S*,3*S*,4*R*,5*R*,6*R*)-5-(Benzyloxy)-7-hydroxy-3-(methoxymethoxy)-4,6-dimethylheptan-2-yl)-6-ethyl-3,5-dimethyl-4*H*-pyran-4-one (217)



217

2,6-Lutidine (35 μL, 38 mg, 0.36 mmol) and Et₃SiOTf (57 μL, 67 mg, 0.25 mmol) were sequentially added to a stirred solution of **216** (100 mg, 0.24 mmol) in CH₂Cl₂ (2 mL) at room temperature under Ar. After 1 h, DIPEA (0.42 mL, 0.31 g, 2.4 mmol),

tetrabutylammonium iodide (95 mg, 0.26 mmol) and MOMCl (0.2 mL, 0.2 g, 2.4 mmol) were sequentially added and then the flask was fitted with a stopper. After 4 d, MeOH (2 mL) and tetrabutylammonium fluoride (100 mg, 0.38 mmol) were sequentially added. After 3 h, the mixture was diluted with ethyl acetate and washed sequentially with HCl (1 M), sat. NaHCO₃, and brine. The organic layer was dried over Na₂SO₄, concentrated, and fractionated by FCC (80% ethyl acetate) to give the titled compound (102 mg, 92%): [α]_D -77 (*c* 1.5, CH₂Cl₂).

IR ν_{max} : 3419, 1654, 1609, 1593 cm⁻¹.


¹H NMR (500 MHz, CDCl₃): δ 7.36-7.23 (5H, m, ArH), 4.82 (1H, d, *J* = 11 Hz, HCPh), 4.73 (1H, d, *J* = 11 Hz, HCPh), 4.29 (1H, d, *J* = 7 Hz, OCHO), 4.26 (1H, d, *J* = 7 Hz, OCHO), 4.03 (1H, br d, *J* = 9.5 Hz, HC-3'), 3.89 (1H, dd, *J* = 3, 11 Hz, HC-7'), 3.67-3.61 (1H, m, HC-7'), 3.53 (1H, br d, *J* = 8 Hz, HC-5'), 3.22-3.16 (1H, m, HC-2'), 3.21 (3H, s, H₃CO), 2.89 (1H, br s, HO), 2.55-2.40 (2H, m, H₂CCH₃), 2.07-1.95 (2H, m, HC-4', HC-6'), 1.97 (3H, s, H₃CC-3), 1.91 (3H, s, H₃CC-5), 1.25 (3H, d, *J* = 7 Hz, H₃CC-6'), 1.12 (3H, d, *J* = 7 Hz, H₃C-1'), 1.06 (3H, t, *J* = 7.5 Hz, H₃CCH₂), 0.94 (3H, d, *J* = 7 Hz, H₃CC-4').

¹³C NMR (125 MHz, CDCl₃): δ 180.0 (s, C-4), 164.7 (s, C-2), 164.2 (s, C-6), 138.8 (s, Ph), 128.6 (d \times 2, Ph), 127.8 (d, Ph), 127.3 (d \times 2, Ph), 119.7 (s, C-3), 118.1 (s, C-5), 98.0 (t, OCH₂O), 86.5 (d, C-5'), 82.0 (d, C-3'), 75.4 (t, CH₂Ph), 64.7 (t, C-7'), 55.7 (q, CH₃O), 39.2 (d, C-2'), 38.8 (d, C-4'), 36.5 (d, C-6'), 24.9 (t, CH₂C-6), 16.8 (q, CH₃C-6'), 15.1 (q, C-1'), 11.5 (q, CH₃CH₂), 10.5 (q, CH₃C-4'), 9.8 (q, CH₃C-3 or CH₃C-5), 9.7 (q, CH₃C-3 or CH₃C-5).

LRMS: *m/z* (relative intensity) 461 ([M+1]⁺, 100), 224 (43), 180 (37), 91 (15) (CI, NH₃).

HRMS: m/z calcd for $C_{27}H_{40}O_6$ 460.2903 (461.2903 for $M+H$), found 461.2918 (CI, NH_3).

(2*S*,3*S*,4*R*,5*S*,6*S*)-3-(Benzyloxy)-6-(6-ethyl-3,5-dimethyl-4-oxo-4*H*pyran-2-yl)-5-(methoxymethoxy)-2,4-dimethylheptanal (218)



218

IBX (50 mg, 0.14 mmol) was added to a stirred solution of **217** (56 mg, 0.12 mmol) in dry DMSO (2 mL) at room temperature under Ar. After 3 h, the mixture was diluted with ethyl acetate and washed sequentially with sat. $NaHCO_3$, water and brine, dried over Na_2SO_4 , and concentrated to give the titled compound (56 mg, 100%): $[\alpha]_D -52$ (c 0.8, C_6H_6).

IR ν_{max} : 1721, 1655, 1609 cm^{-1} .


1H NMR (500 MHz, C_6D_6): δ 9.64 (1H, s, HC-1), 7.32 (2H, ap d, $J = 7.5$ Hz, ArH), 7.20 (2H, ap t, $J = 7.5$ Hz, ArH), 7.15-7.10 (1H, ap t, $J = 7.5$ Hz, ArH), 4.47 (1H, d, $J = 11$ Hz, HCPh), 4.43 (1H, d, $J = 11$ Hz, HCPh), 4.19 (1H, br d, $J = 9.5$ Hz, HC-5), 4.19 (1H, d, $J = 7$ Hz, OCHO), 4.14 (1H, d, $J = 7$ Hz, OCHO), 3.84 (1H, dd, $J = 3.5, 10$ Hz, HC-3), 3.00 (3H, s, H_3CO), 2.98 (1H, dq, $J = 10, 7$ Hz, HC-6), 2.50 (1H, ap dq, $J = 2, 7$ Hz, HC-2), 2.11 (3H, s, H_3CC-3'), 2.10-2.00 (2H, m, H_2CCH_3), 1.95 (3H, s, H_3CC-5'), 1.94-1.82 (1H, m, HC-4), 1.11 (3H, d, $J = 7$ Hz, H_3CC-2), 0.84 (3H, d, $J = 7$ Hz, H_3C-7), 0.83 (3H, t, $J = 7.5$ Hz, H_3CCH_2), 0.73 (3H, d, $J = 7$ Hz, H_3CC-4).

^{13}C NMR (125 MHz, C_6D_6): δ 202.5 (d, C-1), 179.3 (s, C-4'), 164.2 (s, C-2'), 163.5 (s, C-6'), 139.4 (s, Ph), 129.0 (d $\times 2$, Ph), 128.7 (d, Ph), 128.1 (d $\times 2$, Ph), 120.1 (s, C-3'), 118.4 (s, C-5'), 98.6 (t, OCH_2O), 82.3 (d, C-5), 81.6 (d, C-3), 72.8 (t, CH_2Ph), 55.9 (q, CH_3O), 48.6 (d, C-2), 39.3 (d, C-6), 38.2 (d, C-4), 24.9 (t, $\text{CH}_2\text{C-6'}$), 15.0 (q, C-7), 11.7 (q, CH_3CH_2), 10.2 (q, CH_3), 10.1 (q $\times 2$, $\text{CH}_3 \times 2$), 9.6 (q, $\text{CH}_3\text{C-2}$).

LRMS: m/z (relative intensity) 459 ($[\text{M}+1]^+$, 100), 351 (51), 224 (76), 180 (16), 91 (14) (CI, NH_3).

HRMS: m/z calcd for $\text{C}_{27}\text{H}_{38}\text{O}_6$ 458.2668 (459.2747 for $\text{M}+\text{H}$), found 459.2741 (CI, NH_3).

(2*R*,3*R*,4*R*,5*S*,6*S*)-3-(Benzyloxy)-6-(6-ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)-2,4-dimethylheptane-1,5-diyl Diacetate (219)



Acetic anhydride (0.2 mL, 0.2 g, 2 mmol) and DMAP (70 mg, 0.57 mmol) were added to a stirred solution of **216** (67 mg, 0.16 mmol) in CH_2Cl_2 (5 mL) at room temperature. After 3 h, the mixture was concentrated and the residue fractionated by FCC (80% ethyl acetate in hexanes) to give the titled compound (78 mg, 97%).

IR ν_{max} : 1737, 1656, 1610 cm^{-1} .


¹H NMR (500 MHz, CDCl₃): δ 7.38-7.34 (2H, m, Ph), 7.32 (2H, m, Ph), 7.29-7.24 (1H, m, Ph), 5.50 (1H, br d, *J* = 10 Hz, HC-5), 4.60-4.54 (2H, m, H₂CPh), 4.29 (1H, dd, *J* = 5, 11 Hz, HC-1), 4.04 (1H, dd, *J* = 8, 11 Hz, HC-1), 3.23 (1H, dq, *J* = 10, 7 Hz, HC-6), 3.16 (1H, dd, *J* = 3.5, 8.5 Hz, HC-3), 2.61-2.47 (2H, m, H₂CCH₃), 2.24 (1H, dddq, *J* = 3.5, 5, 8, 7 Hz, HC-2), 2.09 (1H, ddq, *J* = 8.5, 10, 7 Hz, HC-4), 2.05 (3H, s, H₃CCOOC-5), 1.96 (3H, s, H₃CC-3'), 1.91 (3H, s, H₃CC-5'), 1.76 (3H, s, H₃CCOOC-1), 1.17 (3H, d, *J* = 7 Hz, H₃CC-2), 1.15 (3H, t, *J* = 7.5 Hz, H₃CCH₂), 1.14 (3H, d, *J* = 7 Hz, H₃CC-6), 1.05 (3H, d, *J* = 7 Hz, H₃CC-4).

¹³C NMR (125 MHz, CDCl₃): δ 179.9 (s, C-4'), 171.3 (s, COOC-5), 169.9 (s, COOC-1), 164.9 (s, C-6'), 163.1 (s, C-2'), 138.9 (s, Ph), 128.4 (d x2, Ph), 127.8 (d x2, Ph), 127.7 (d, Ph), 119.5 (d, C-3'), 117.9 (d, C-5'), 83.9 (d, C-3), 75.6 (t, CH₂Ph), 74.3 (d, C-5), 66.0 (t, C-1), 37.7 (d, C-6), 37.1 (d, C-4), 35.3 (d, C-2), 24.9 (t, CH₂CH₃), 21.2 (q, CH₃COOC-5), 20.8 (q, CH₃COOC-1), 16.3 (q, CH₃C-6), 14.5 (q, CH₃C-2), 11.2 (q, CH₃CH₂), 10.4 (q, CH₃C-4), 9.8 (q, CH₃C-3' or CH₃C-5'), 9.7 (q, CH₃C-3' or CH₃C-5').

LRMS: *m/z* (relative intensity) 500 ([M]⁺, 4), 394 (19), 335 (34), 251 (13), 180 (86), 91 (100) (EI)

HRMS: *m/z* calcd. for C₂₉H₄₀O₇ 500.2774, found 500.2774 (EI).

(2*S*,3*S*,4*R*,5*R*,6*R*)-5-(Benzyloxy)-2-(6-ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)-7-hydroxy-4,6-dimethylheptan-3-yl Acetate (220)



220

K₂CO₃ (109 mg, 0.79 mmol) was added to a stirred solution of **219** (78 mg, 0.16 mmol) in MeOH (8 mL) and water (0.4 mL). After 3 h at rt, the mixture was diluted with water and extracted with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄, and concentrated to give the titled compound (71 mg, 99%): [α]_D -84 (*c* 1.5, C₆H₆).

IR ν_{max} : 3432, 1737, 1653, 1609, 1593 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 7.38 (2H, ap d, *J* = 7 Hz, Ph), 7.35-7.27 (3H, m, Ph), 5.53 (1H, br d, *J* = 10 Hz, HC-3), 4.65 (1H, d, *J* = 10 Hz, HCPh), 4.58 (1H, d, *J* = 10 Hz, HCPh), 3.86 (1H, dd, *J* = 4, 11 Hz, HC-7), 3.64 (1H, dd, *J* = 4, 11 Hz, HC-7), 3.28-3.20 (2H, m, HC-2, HC-4), 2.71 (1H, br s, HO), 2.62-2.49 (2H, m, H₂CCH₃), 2.12 (1H, dq, *J* = 8.5, 7 Hz, HC-4), 2.05-2.12 (1H, m, HC-6), 1.96 (3H, s, H₃CC-3'), 1.92 (3H, s, H₃CC-5'), 1.77 (3H, s, H₃CCO), 1.23 (3H, d, *J* = 7 Hz, H₃CC-6), 1.17 (3H, d, *J* = 7 Hz, H₃CC-2), 1.17 (3H, t, *J* = 7.5 Hz, H₃CCH₂), 1.02 (3H, d, *J* = 7 Hz, H₃CC-4).


¹³C NMR (125 MHz, CDCl₃): δ 179.9 (s, C-4'), 169.9 (s, COOC-3), 164.9 (s, C-6'), 163.0 (s, C-2'), 138.4 (s, Ph), 128.6 (d x2, Ph), 128.1 (d x2, Ph), 128.0 (d, Ph), 119.5 (s, C-3'), 117.9 (s,

C-5'), 86.1 (d, C-5), 76.1 (t, CH₂Ph), 74.2 (d, C-3), 64.6 (t, C-7), 37.7 (d, C-2), 37.5 (d, C-4), 36.8 (d, C-6), 24.9 (t, CH₂CH₃), 20.8 (q, CH₃COOC-3), 16.5 (q, CH₃C-6), 14.5 (q, CH₃C-2), 11.3 (q, CH₃CH₂), 10.6 (q, CH₃C-4), 9.8 (q, CH₃C-3' or CH₃C-5'), 9.7 (q, CH₃C-3' or CH₃C-5').

LRMS: *m/z* (relative intensity) 458 ([M]⁺, 5), 399 (12), 352 (19), 293 (17), 251 (10), 180 (100), 91 (90) (EI).

HRMS: *m/z* calcd. for C₂₇H₃₈O₆ 458.2668, found 458.2669 (EI).

(2*S*,3*S*,4*R*,5*S*,6*S*)-5-(Benzyloxy)-2-(6-ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)-4,6-dimethyl-7-oxoheptan-3-yl Acetate (221)



221

IBX (30 mg, 0.11 mmol) was added to a stirred solution of **220** (30 mg, 0.066 mmol) in dry DMSO (2 mL) at rt. The solution was stirred for 5 hours at rt and added to ethyl acetate. The organic layer was washed with sat. NaHCO₃, water, and brine, dried over Na₂SO₄, and concentrated to give the titled compound (26 mg, 87%).

¹H NMR (500 MHz, CDCl₃): δ 9.81 (1H, br s, HC-7), 7.38 (2H, ap d, *J* = 7.5 Hz, Ph), 7.35-7.27 (3H, m, Ph), 5.62 (1H, br d, *J* = 10 Hz, HC-3), 4.56-4.49 (2H, m, H₂CPh), 3.57 (1H, dd,


$J = 3, 9$ Hz, HC-5), 3.27 (1H, dq, $J = 10, 7$ Hz, HC-2), 2.84 (1H, ddq, $J = <1, 3, 7$ Hz, HC-6), 2.65-2.49 (2H, m, H_2CCH_3), 2.08 (1H, dq, $J = 9, 7$ Hz, HC-4), 1.95 (3H, s), 1.93 (3H, s), 1.81 (3H, s), 1.25 (3H, d, $J = 7$ Hz), 1.18 (3H, t, $J = 7.5$ Hz, H_3CCH_2), 1.16 (3H, d, $J = 7$ Hz), 0.91 (3H, d, $J = 7$ Hz).

^{13}C NMR (125 MHz, CDCl_3): δ 203.9, 180.0, 169.9, 165.0, 163.0, 138.2, 128.5, 128.2, 128.0, 119.5, 117.9, 81.7, 74.0, 73.9, 48.6, 37.5, 37.0, 24.9, 20.8, 14.4, 11.2, 10.1, 9.9, 9.8, 9.7.

LRMS: m/z (relative intensity) 456 ($[\text{M}]^+$, 1), 321 (8), 180 (100), 91 (58) (EI).

HRMS: m/z calcd. for $\text{C}_{27}\text{H}_{36}\text{O}_6$ 456.2512, found 456.2491 (EI).

2-((2*S*,3*S*,4*R*,5*R*,6*R*,7*R*)-5-(Benzyloxy)-7-hydroxy-3-(methoxymethoxy)-7-((3*S*,5*S*)-5-((*R*)-(methoxymethoxy))((*S*)-1,4-dioxo-8-thiaspiro[4.5]decan-6-yl)methyl)-4-oxotetrahydro-2*H*-thiopyran-3-yl)-4,6-dimethylheptan-2-yl)-6-ethyl-3,5-dimethyl-4*H*-pyran-4-one (223)



A solution of TiCl_4 (30 μL , 52 mg, 0.27 mmol) in CH_2Cl_2 (0.3 mL) was added to a stirred solution of **222** (88 mg, 0.25 mmol) in CH_2Cl_2 (6 mL) at -78°C under Ar. The resulting yellow suspension was stirred for 2 min and then DIPEA (130 μL , 96 mg, 0.74 mmol) was

added. The resulting red solution was stirred for 1.5 hrs and then a solution of **218** (56 mg, 0.12 mmol) in CH₂Cl₂ (0.5 mL plus 2 x 0.5 mL rinses) was added dropwise via syringe. Over the course of 3 h, the red color faded to orange. The mixture was diluted with ethyl acetate and washed sequentially with sat. NH₄Cl (x2), sat. NaHCO₃, water, and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by FCC (50-70% ethyl acetate in hexanes) to give recovered ketone (46 mg, 52%) and the titled compound essentially as a single diastereomer (dr>20:1 by ¹H NMR) (78 mg, 79%): [α]_D -69 (*c* 0.7, C₆H₆).

IR ν_{max} : 3456, 1706, 1654, 1609 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 7.35-7.26 (5H, m, ArH), 4.85 (1H, d, *J* = 11 Hz, HCPh), 4.81 (1H, d, *J* = 11 Hz, HCPh), 4.68 (1H, d, *J* = 5.5 Hz, HCOC-1'''), 4.57 (1H, d, *J* = 5.5 Hz, HCOC-1'''), 4.47 (1H, br d, *J* = 9.5 Hz, HC-7'), 4.29-4.23 (2H, m, HC-1'', HCOC-3'), 4.15 (1H, d, *J* = 7 Hz, HCOC-3'), 4.14-3.92 (5H, m, HC-3', H₂CO \times 2), 4.12 (1H, s, HO), 3.60 (1H, br d, *J* = 10 Hz, HC-5'), 3.35 (3H, s, H₃CO), 3.25 (3H, s, H₃CO), 3.27-3.17 (2H, m, HC-2', HC-2''), 3.11-3.00 (2H, m, HC-3'', HC-6''), 2.92-2.81 (3H, m, HC-2'', HC-5'', HC-6''), 2.81-2.71 (3H, m, H₂C-7''', HC-9'''), 2.56-2.37 (3H, m, H₂CC-6. HC-9'''), 2.22-2.09 (3H, m, HC-4', HC-6''', HC-10'''), 2.02-1.94 (1H, m, HC-6'), 1.97 (3H, s, H₃CC-3), 1.91 (3H, s, H₃CC-5), 1.65 (1H, ddd, *J* = 3, 12, 13.5 Hz, HC-10'''), 1.24 (3H, d, *J* = 7 Hz, H₃CC-6'), 1.15 (3H, d, *J* = 7 Hz, H₃C-1'), 1.04 (3H, t, *J* = 7.5 Hz, H₃CCH₂), 1.00 (3H, d, *J* = 7 Hz, H₃CC 4').


¹³C NMR (125 MHz, CDCl₃): δ 210.1 (d, C-4''), 180.0 (s, C-4), 164.7 (s, C-2), 164.1 (s, C-6), 138.4 (s, Ph), 128.7 (d \times 2, Ph), 127.9 (d, Ph), 127.2 (d \times 2, Ph), 119.8 (s, C-3), 118.2 (s, C-5), 108.7 (s, C-5'''), 97.8 (t, CH₂OC-3'), 97.4 (t, CH₂OC-1'''), 88.4 (d, C-5'), 82.3 (d, C-3'),

75.9 (t, CH₂Ph), 74.2 (d, C-1'''), 68.5 (d, C-7''), 64.9 (t, CH₂O), 64.7 (t, CH₂O), 59.1 (d, C-5''), 56.3 (q, CH₃O), 55.7 (q, CH₃O), 53.7 (d, C-3''), 50.2 (d, C-6'''), 39.2 (d, C-2'), 38.4 (d, C-4'), 36.1 (t, C-10'''), 35.6 (d, C-6'), 32.0 (t, C-6''), 31.9 (t, C-2''), 28.4 (t, C-7'''), 26.8 (t, C-9'''), 24.9 (t, CH₂C-6), 15.3 (q, C-1'), 13.0 (q, CH₃C-6'), 11.6 (q, CH₃CH₂), 10.2 (q, CH₃C-4'), 9.8 (q, CH₃C-3 or CH₃C-5), 9.7 (q, CH₃C-3 or CH₃C-5).

LRMS: m/z (relative intensity) 829 ([M+23]⁺, 35), 807 ([M+1]⁺, 100), 459 (4), 351 (6) (ESI).

HRMS: m/z calcd for C₄₂H₆₂O₁₁S₂ 806.3634 (807.3812 for [M+H]⁺), found 807.3816 (ESI).

2-((*S*)-1-((2*S*,3*R*,4*S*,5*S*,6*S*)-4-(Benzyloxy)-6-methoxy-3,5-dimethyltetrahydro-2*H*-pyran-2-yl)ethyl)-6-ethyl-3,5-dimethyl-4*H*-pyran-4-one (226)



226

FeCl₃•6H₂O (34 mg, 0.13 mmol) was added to a stirred solution of **223** (34 mg, 0.042 mmol) in acetone (12 mL) and methanol (0.6 mL) and the resulting yellow solution was heated under reflux. After 3.5 h, the mixture was diluted with CH₂Cl₂ and washed sequentially with water and brine. The aqueous layers were back extracted with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by PTLC (90% ethyl acetate in hexanes) to give the putative deprotected compound (12 mg, crude) that was insufficiently pure for characterization (and could not be purified further) and the titled compound (7 mg, 39%): [α]_D 34 (*c* 0.4, C₆H₆).

IR ν_{max} : 1656, 1612 cm^{-1} .


^1H NMR (500 MHz, C_6D_6): δ 7.31 (2H, ap d, $J = 7.5$ Hz, Ph), 7.19 (2H, ap d, $J = 7.5$ Hz, Ph), 7.10 (1H, ap t, $J = 7.5$ Hz, Ph), 4.32-4.16 (3H, m, HC-6', H_2CPh), 3.97 (1H, dd, $J = 2.5$, 10.5 Hz, HC-2'), 3.89 (1H, dd, $J = 5.5$, 5.5 Hz, HC-4'), 3.12 (1H, dq, $J = 10.5$, 7 Hz, HC-1'), 2.81 (3H, s, H_3CO), 2.24 (3H, s, H_3CC -3), 2.26-2.05 (4H, m, HC-5', 3', H_2CCH_3), 1.99 (3H, s, H_3CC -5), 1.06 (3H, d, $J = 7$ Hz, H_3CC -5'), 1.06 (3H, d, $J = 7$ Hz, H_3CC -3'), 0.92 (3H, t, $J = 7.5$ Hz, H_3CCH_2), 0.88 (3H, d, $J = 7$ Hz, H_3CC -1').

^{13}C NMR (125 MHz, C_6D_6): δ 179.3 (s, C-4), 164.1 (s, C-2), 163.2 (s, C-6), 139.8 (s, Ph), 128.9 (d x2, Ph (DEPT)), 128.0 (d, Ph), 127.9 (d x2, Ph (DEPT)), 120.5 (s, C-3), 118.6 (s, C-5), 104.7 (d, C-6'), 76.0 (d, C-4'), 71.9 (d, C-2'), 70.1 (t, CH_2Ph), 54.5 (q, CH_3O), 37.3 (d, C-1'), 37.1 (d, C-5'), 34.0 (d, C-3'), 25.0 (t, CH_2CH_3), 13.7 (q, CH_3C -5'), 13.5 (q, CH_3C -1'), 11.8 (q, CH_3CH_2), 10.5 (q, CH_3C -3), 10.2 (q, CH_3C -5), 8.1 (q, CH_3C -3').

LRMS: m/z (relative intensity): 429 ($[\text{M}+1]^+$, 100) (ESI).

HRMS: m/z calcd. for $\text{C}_{26}\text{H}_{36}\text{O}_5$ 428.2563 (429.2635 for $[\text{M}+\text{H}]^+$), found 429.2635 (ESI).

(4*S*,5*S*,6*S*,8*S*,9*R*,10*R*,11*S*,12*S*,13*S*,14*S*)-11-(Benzyloxy)-14-(6-ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)-5,9,13-trihydroxy-4,6,8,10,12-pentamethylpentadecane-3,7-dione (227)



227

From aldol 223. Raney nickel (W2; 0.5 mL settled volume) was washed with THF (x3) and then transferred to a solution of **223** (42 mg, 0.052 mmol) in THF (5 mL) and the resulting suspension was heated under reflux with vigorous stirring. After 3 h, the mixture was allowed to settle and then decanted. The solid was suspended in THF (10 mL), heated under reflux for 10 min, and decanted. This washing procedure was repeated with ethyl acetate and then acetone. The combined organic layers were filtered through Celite® and concentrated to give the crude desulfurized product (40 mg). A solution of FeCl₃•6H₂O (40 mg, 0.15 mmol) in acetone (1 mL) was added to a solution of the residue (40 mg) in acetone (5 mL) and methanol (0.3 mL) and the resulting yellow solution was heated under flux reflux. After 5 h, the mixture was diluted with ethyl acetate and washed sequentially with sat. NH₄Cl (x2), sat. NaHCO₃, and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by PTLC (80% ethyl acetate in hexanes) to give the titled compound (27 mg, 84%): [α]_D -33 (*c* 1, C₆H₆).

From bisTES 229. HF•pyridine (0.13 mL) was added to a stirred solution of **229** (20 mg, 0.024 mmol) in THF (2 mL), pyridine (0.4 mL), and water (50 μ L) at room temperature.

After 24 h, the mixture was diluted with ethyl acetate and washed sequentially with 0.2 M aq. citric acid (x2), sat. NaHCO₃, and brine. The organic layer was concentrated and fractionated by PTLC (80% ethyl acetate in hexanes) to give the titled compound (14 mg, 96%).

IR ν_{max} : 3450, 1708, 1652, 1588 cm⁻¹.


¹H NMR (500 MHz, C₆D₆): δ 7.52 (2H, ap d, J = 7.5 Hz, ArH), 7.22-7.12 (3H, m, ArH), 5.14 (1H, d, J = 11 Hz, HCPh), 4.75 (1H, d, J = 11 Hz, HCPh), 4.60 (1H, br d, J = 9.5 Hz, HC-9), 4.46 (1H, br d, J = 9.5 Hz, HC-13), 4.19 (1H, dd, J = 4, 8 Hz, HC-5), 3.92 (1H, br d, J = 9 Hz, HC-11), 3.11 (1H, dq, J = 9.5, 7 Hz, HC-14), 2.88 (1H, dq, J = 9.5, 7 Hz, HC-8), 2.67 (1H, dq, J = 8, 7 Hz, HC-6), 2.39 (1H, br dq, J = 9, 7 Hz, HC-12), 2.22 (1H, dq, J = 4, 7 Hz, HC-4), 2.18-1.87 (8H, m, H₂C-2, HC-10, H₂CC-6), 2.09 (3H, s, H₃CC-3'), 1.60 (3H, s, H₃CC-5'), 1.45 (3H, d, J = 7 Hz, H₃CC-8), 1.23 (3H, d, J = 7 Hz, H₃CC-10), 1.22 (3H, d, J = 7 Hz, H₃CC-12), 0.96 (3H, d, J = 7 Hz, H₃CC-4), 0.91 (3H, d, J = 7 Hz, H₃CC-14), 0.90 (3H, t, J = 7.5 Hz, H₃C-1), 0.85 (3H, t, J = 7.5 Hz, H₃CCH₂), 0.80 (3H, d, J = 7 Hz, H₃CC-6).

¹³C NMR (125 MHz, C₆D₆): δ 217.5 (s, C-7), 214.1 (s, C-3), 180.3 (s, C-4'), 166.3, 164.4 (s, C-6'), 139.7 (s, Ph), 129.1 (d \times 2, Ph), 128.6 (d \times 2), 128.2 (d, Ph), 120.3 (s, C-3'), 117.9 (s, C-5'), 88.2 (d, C-11), 77.0 (t, CH₂Ph), 73.3 (d, C-5), 72.1 (d, C-13), 71.4 (d, C-9), 50.6 (d, C-8), 48.5 (d, C-6), 48.0 (d, C-4), 40.8 (d, C-14), 38.1 (d, C-12), 36.8 (d, C-10), 34.7 (t, C-2), 25.2 (t, CH₂C-6'), 14.9 (q, H₃CC-8), 14.4 (q, H₃CC-14), 14.0 (q, H₃CC-6), 12.9 (q, H₃CC-10), 11.5 (q, H₃CCH₂), 10.7 (q, H₃CC-3'), 10.5 (q, H₃CC-4), 9.9 (q, H₃CC-5'), 9.3 (q, H₃CC-12), 8.1 (q, H₃C-1).

LRMS: m/z (relative intensity) 637 ([M+23]⁺, 25), 615 ([M+1]⁺, 100), 599 (15), 501 (20) (ESI).

HRMS: m/z calcd for $C_{36}H_{54}O_8$ 614.3819 (615.3897 for $[M+H]^+$), found 615.3883 (ESI).

(4*S*,5*S*,6*S*,8*S*,9*R*,10*R*,11*S*,12*S*,13*S*,14*S*)-11-(Benzyloxy)-14-(6-ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)-9,13-dihydroxy-4,6,8,10,12-pentamethyl-5-((triethylsilyl)oxy)pentadecane-3,7-dione (228)



228

Triethylsilyltriflate (25 μ L, 29 mg, 0.11 mmol) was added to a stirred solution of 2,6-lutidine (50 μ L, 50 mg, 0.47 mmol) and **227** (33 mg, 0.054 mmol) in dry CH_2Cl_2 (3 mL) at 0 $^{\circ}C$ under Ar. After 1 h, the mixture was diluted with ethyl acetate and washed with 0.2 M citric acid (x2), sat. $NaHCO_3$, and brine. The organic layer was dried over Na_2SO_4 , concentrated, and fractionated by PTLC (80% ethyl acetate in hexanes) to give the **229** (20 mg, 44%) and the titled compound (18 mg, 46% [80% BORSM]): $[\alpha]_D$ 1.0 (c 1.3, C_6H_6).

IR ν_{max} : 3422, 1711, 1652, 1590 cm^{-1} .

1H NMR (500 MHz, C_6D_6): δ 7.49 (2H, ap d, J = 7 Hz, ArH), 7.22-7.10 (3H, m, ArH), 5.08 (1H, d, J = 11 Hz, CHPh), 4.71 (1H, d, J = 11 Hz, CHPh), 4.64 (1H, dd, J = 4, 7 Hz, HC-5), 4.54 (1H, br d, J = 9 Hz, HC-9), 4.42 (1H, br d, J = 10 Hz, HC-13), 3.89-3.81 (2H, m, HC-11, HOC-11), 3.11-3.08 (1H, m, HC-14), 2.93 (1H, dq, J = 9, 7 Hz, HC-8), 2.88 (1H, dq,


$J = 7, 7$ Hz, HC-6), 2.47 (1H, dq, $J = 4, 7$ Hz, HC-4), 2.41-2.29 (2H, m, HC-2, HC-12), 2.16-2.06 (3H, m, HC-2, H₂CC-6'), 2.08 (3H, s, H₃CC-3'), 2.00 (1H, br q, $J = 7$ Hz, HC-10), 1.63 (3H, s, H₃CC-5'), 1.46 (3H, d, $J = 7$ Hz, H₃CC-8), 1.20 (3H, d, $J = 7$ Hz, H₃CC-10), 1.15 (3H, d, $J = 7$ Hz, H₃CC-12), 1.08-1.04 (6H, m, H₃C-1, H₃C-4), 1.05 (9H, t, $J = 8$ Hz, H₃CCSi $\times 3$), 0.94 (3H, d, $J = 7$ Hz, H₃CC-6), 0.87 (3H, d, $J = 7.5$ Hz, H₃CC-14), 0.84 (3H, t, H₃CCH₂), 0.76-0.70 (6H, m, H₂CSi $\times 3$).

¹³C NMR (125 MHz, C₆D₆): δ 214.5 (s, C-7), 211.8 (s, C-3), 180.1 (s, C-4'), 166.0 (s, C-2'), 164.2 (s, C-6'), 139.6 (s, Ph), 129.1 (d $\times 2$, Ph), 128.7 (d $\times 2$, Ph), 128.6 (d, Ph), 120.3 (s, C-3), 117.9 (s, C-5), 88.2 (d, C-11), 77.0 (t, CH₂Ph), 73.3 (d, C-5), 72.1 (d, C-13), 71.8 (d, C-9), 52.1 (d, C-6), 50.1 (d, C-8), 49.1 (d, C-4), 40.7 (d, C-14), 38.0 (d, C-12), 36.6 (d, C-10), 35.3 (t, C-2), 25.1 (t, CH₂C-6'), 14.7 (q, CH₃C-8), 14.4 (q, CH₃C-14), 13.00 (q, CH₃C-6 or CH₃C-10), 12.96 (q, CH₃C-6 or CH₃C-10), 12.4 (q, CH₃C-4), 11.5 (q, CH₃CH₂), 10.7 (q, CH₃C-3'), 9.9 (q, CH₃C-5'), 9.3 (q, CH₃C-12), 8.2 (q, C-1), 7.7 (q $\times 3$, (CH₃CH₂)₃Si), 5.9 (t $\times 3$, (CH₃CH₂)₃Si).

LRMS: m/z (relative intensity) 751 ([M+23]⁺, 10), 729 ([M+1]⁺, 100) (ESI).

HRMS: m/z calcd for C₄₂H₆₈O₈Si 728.4883 (729.4756 for [M+H]⁺), found 729.4762 (ESI).

(4*S*,5*S*,6*S*,8*S*,9*R*,10*S*,11*S*,12*S*,13*S*,14*S*)-11-(Benzyloxy)-14-(6-ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)-13-hydroxy-4,6,8,10,12-pentamethyl-5,9-bis((triethylsilyl)oxy)pentadecane-3,7-dione (229)



229

$[\alpha]_D^{20}$ 30 (*c* 1.3, C₆H₆).

IR ν_{max} : 3374, 1713, 1655, 1610, 1593 cm⁻¹.

¹H NMR (500 MHz, C₆D₆): δ 7.41 (2H, ap d, *J* = 7.5 Hz, ArH), 7.20-7.10 (2H, m, ArH), 7.05 (1H, ap t, *J* = 7 Hz, ArH), 4.74-4.66 (2H, m, H₂CPh), 4.61 (1H, dd, *J* = 5, 6 Hz, HC-5), 4.44 (1H, br d, *J* = 6.5 Hz, HC-9), 4.32 (1H, br d, *J* = 10 Hz, HC-13), 3.52 (1H, br d, *J* = 8.5 Hz, HC-11), 3.40 (1H, br s, HO), 3.07 (1H, dq, *J* = 6, 7 Hz, HC-14), 2.96-2.89 (2H, m, HC-6, HC-8), 2.53 (1H, dq, *J* = 5, 7 Hz, HC-4), 2.33 (1H, dq, *J* = 18, 7.5 Hz, HC-2), 2.24 (3H, s, H₃CC-16), 2.17 (2H, ap q, *J* = 7.5 Hz, H₂CC-6'), 2.15-2.03 (2H, m, HC-2, HC-10), 2.01-1.94 (1H, m, HC-12), 1.97 (3H, s, H₃CC-5'), 1.25 (3H, d, *J* = 7 Hz, H₃CC-8), 1.15 (3H, d, *J* = 7 Hz, H₃CC-12), 1.09-0.95 (27H, m, H₃C-1, H₃C-4, H₃C-6, H₃CCSi \times 6), 1.00-0.95 (9H, m, H₃C-10, H₃C-14, H₃CCH₂C-6'), 1.76-0.68 (12H, m, H₂CSi \times 6).


¹³C NMR (125 MHz, C₆D₆): δ 213.6 (s, C-7), 212.0 (s, C-3), 179.4 (s, C-4'), 164.4 (s, C-2'), 163.2 (s, C-6'), 138.4 (s, Ph), 129.2 (d \times 2, Ph), 128.7 (d, Ph), 128.1 (d \times 2, Ph), 120.1 (s, C-3'), 118.4 (s, C-5'), 88.4 (d, C-11), 76.8 (t, CH₂Ph), 74.4 (d, C-9), 73.0 (d, C-5), 72.5 (d, C-13), 53.1 (d, C-6), 52.2 (d, C-8), 48.9 (d, C-4), 41.7 (d, C-10), 39.5 (d, C-14), 35.5 (d, C-

12), 35.4 (t, C-2), 25.0 (t, CH₂C-6'), 14.6 (q, CH₃C-8 or CH₃C-14), 14.5 (q, CH₃C-8 or CH₃C-14), 13.1 (q, CH₃C-4), 12.4 (q ×2, CH₃C-6, CH₃C-10 or CH₃C-12), 11.9 (q, CH₃C-10 or CH₃C-12), 11.6 (q, CH₃CH₂), 10.5 (q, CH₃C-3'), 10.2 (q, CH₃C-5'), 8.2 (q, C-1), 7.8 (q ×3, (CH₃CH₂)₃Si), 7.7 (q ×3, (CH₃CH₂)₃Si), 6.7 (t ×3, (CH₃CH₂)₃Si), 5.9 (t ×3, (CH₃CH₂)₃Si).

LRMS: m/z (relative intensity) 865 ([M+23]⁺, 25), 843 ([M+1]⁺, 100) (ESI).

HRMS: m/z calcd for C₄₈H₈₂O₈Si₂ 842.5548 (843.5626 for [M+H]⁺), found 843.5630 (ESI).

(4*S*,5*S*,6*S*,10*S*,11*S*,12*R*,14*R*)-11-(Benzyloxy)-14-(6-ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)-4,6,8,10,12-pentamethyl-5-((triethylsilyl)oxy)pentadecane-3,7,9,13-tetraone (230)



230 (enol and keto forms)

IBX (70 mg, 0.25 mmol) was added to a solution of **228** (22 mg, 0.03 mmol) in anhydrous DMSO (4 mL) at rt. After 2 d, the mixture was diluted with ethyl acetate and washed sequentially with sat. NaHCO₃, water, and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by PTLC (60% ethyl acetate in hexanes) to give the titled compound (18 mg, 82%) as a 25:65:10 mixture of enol and 2 keto forms (by ¹H NMR), respectively.

Only partial data reported.


¹H NMR (500 MHz, CDCl₃): δ 17.22 (0.25H, s), 7.39-7.12 (5H, m), 4.57-4.28 (3H, m), 4.20-3.84 (2.7H, m), 3.38-2.78 (3H, m), 2.78-2.40 (5H, m), 2.03 (3H, s), 1.96 (3H, s), 1.90 (0.7H, s), 1.32-0.85 (33H, m), 0.65-0.45 (6H, m).

¹³C NMR (125 MHz, CDCl₃) partial data: δ 195.8 & 194.5 (enol form), 84.5 & 84.3 & 83.7 (C-11, 3 major forms), 60.8 & 60.6 (C-8 of β-diketone form, 2 diastereomers).

LRMS: *m/z* (relative intensity) 747 ([M+23]⁺, 100), 725 ([M+1]⁺, 40), 543 (5), 521 (2), 255 (4) (ESI).

HRMS: *m/z* calcd for C₄₂H₆₄O₈Si 724.4371 (725.4443 for [M+H]⁺), found 725.4454 (ESI).

(4*S*,5*S*,6*S*,8*RS*,10*S*,11*S*,12*R*,14*R*)-14-(6-Ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)-5,11-dihydroxy-4,6,8,10,12-pentamethylpentadecane-3,7,9,13-tetraone (14/15)



14/15

Raney nickel (W2; 0.2 mL settled volume) was added to a solution of **230** (8 mg, 0.011 mmol) in EtOH (2 mL) at rt and the resulting suspension was heated under reflux with vigorous stirring. After 50 min, the mixture was allowed to settle and then was decanted. The solid was suspended in ethyl acetate, heated under reflux for 10 min, and decanted. This washing procedure was repeated with ethyl acetate and then acetone. The organic layers were filtered over Celite® and the combined filtrates were concentrated. The residue was taken up

in THF (2 mL) and pyridine (0.4 mL, 0.4 g, 5 mmol), water (50 μ L, 50 mg, 3 mmol), and HF•pyridine (0.13 mL) were sequentially added to the stirred solution at rt. After 4 h, the mixture was diluted with ethyl acetate and washed with 0.2 M citric acid (x2), sat. NaHCO₃, and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, concentrated and fractionated by PTLC (40% acetone in hexanes) to give the titled compound (5 mg, 87%) that was a complicated 8: 3: 1: 16 mixture of hemiacetals along with small amounts of keto-enol tautomers and a trace of siphonarin B (**4**) (by NMR).

The ratio of isomers present remained essentially unchanged on standing in CDCl₃ solution at ambient temperature; however, after 28 days the ratio of the major hemiacetals was 3:2:1 and the amount of siphonarin B (**4**) present had increased to ca. 9%.

Only partial data reported.


¹H NMR (500 MHz, CDCl₃): δ 17.05 (0.02H, s, HO-enol), 6.46 (0.2H, s, HO-hemiacetal), 6.39 (0.1H, s, HO-hemiacetal), 6.19 (0.4H, s, HO-hemiacetal), 5.12 (0.02, s, HO-4), 4.6-3.6 (4H, m), 3.00-2.25 (8H, m), 2.15-1.95 (6H, several s), 1.50-0.58 (24H, m).

¹³C NMR (125 MHz, CDCl₃): δ numerous tautomers.

LRMS: m/z (relative intensity) 543 ([M+23]⁺, 25), 521 ([M+1]⁺, 100), 139 (7) (ESI).

HRMS: m/z calcd for C₂₉H₄₄O₈ 520.3036 (521.3108 for [M+H]⁺), found 521.3096 (ESI).

14-*epi*-Baconipyrrone C (**235**)



From **14/15:** DBU (ca. 1 μ L) was added to a solution of **14/15** (5 mg, 0.01 mmol) in C_6D_6 (0.4 mL) at rt. After 1 h, **14/15** was consumed (by 1H NMR). The mixture was diluted with ethyl acetate and washed sequentially with 0.2 M citric acid, sat. $NaHCO_3$, and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na_2SO_4 , concentrated, and fractionated by PTLC (40% acetone in hexanes) to give the baconipyrrone C (**8**) (2.5 mg, 50%) and 14-*epi*-baconipyrrone C (**235**) (1.5 mg, 30%).

From baconipyrrone C (8**):** DBU (1 μ L) was added to a solution of baconipyrrone C (**8**) (6.2 mg) in C_6D_6 (0.4 mL). After 45 min, the presence of a 1.3:1 mixture of **8** and **235** was detected by 1H NMR. The mixture was concentrated and fractionated by PTLC (40% acetone in hexanes) to give baconipyrrone C (**8**) (3.4 mg, 55%) and 14-*epi*-baconipyrrone C (**235**) (2.4 mg, 39%): $[\alpha]_D -6$ (c 0.1, $CHCl_3$).

IR ν_{max} : 3412, 1716, 1653, 1608 cm^{-1} .

1H NMR (500 MHz, $CDCl_3$): δ 5.48 (1H, dd, $J = 3.5, 9$ Hz, HC-5), 4.20 (1H, q, $J = 7$ Hz, HC-14), 3.64 (1H, ddd, $J = 4.5, 8, 10$ Hz, HC-11), 3.14 (1H, d, $J = 10$ Hz, HO), 2.93-2.86 (2H, m, HC-4 or HC-6, HC-12), 2.83 (1H, dq, $J = 3.5, 7$ Hz, HC-6 or HC-4), 2.78 (1H, dq, J


= 18, 7.5 Hz, HC-2 or HC-8), 2.65-2.48 (4H, m, HC-2 or HC-8, HC-10, H₂CC-19), 2.47-2.36 (2H, m, HC-2, HC-8), 2.03 (3H, s, H₃C-16), 1.94 (3H, s, H₃C-18), 1.45 (3H, d, *J* = 7 Hz, H₃C-14), 1.20 (3H, t, *J* = 7.5 Hz, H₃CCH₂C-19), 1.11 (3H, d, *J* = 7 Hz, H₃C-4), 1.09 (3H, d, *J* = 7 Hz, H₃C-10), 1.06 (3H, d, *J* = 7 Hz, H₃C-12), 1.03 (3H, t, *J* = 7.5 Hz, H₃C-2 or H₃C-8), 1.02 (3H, d, *J* = 7 Hz, H₃C-6), 1.01 (3H, t, *J* = 7.5 Hz, H₃C-2 or H₃C-8).

¹³C NMR (125 MHz, CDCl₃): δ 212.3 (s, C-7 or C-3), 211.6 (s, C-3 or C-7), 210.6 (s, C-13), 179.9 (s, C-17), 173.8 (s, C-9), 165.0 (s, C-19), 160.0 (s, C-15), 120.4 (s, C-16), 118.4 (s, C-18), 76.6 (d, C-11), 74.1 (d, C-5), 48.7 (d, C-14), 47.8 (d, C-12), 47.6 (d, C-4 or C-6), 46.1 (d, C-6 or C-4), 42.4 (d, C-10), 35.5 (t, C-2 or C-8), 35.4 (t, C-2 or C-8), 25.0 (t, CH₂C-19), 15.1 (q, CH₃C-10 or CH₃C-12), 14.9 (q, CH₃C-10 or CH₃C-12), 13.7 (q, CH₃C-4 or CH₃C-6), 13.5 (q, C-14), 11.5 (q, CH₃CH₂C-19), 10.03 (q, CH₃C-16), 9.99 (q, CH₃C-6 or CH₃C-4), 9.7 (q, CH₃C-18), 7.9 (q, CH₃C-8 or CH₃C-2), 7.7 (q, CH₃C-2 or CH₃C-8).

LRMS: *m/z* (relative intensity) 543 ([M+23]⁺, 30), 521 ([M+1]⁺, 100), 503 (3), 485 (3), 242 (3), 132 (2) (ESI).

HRMS: *m/z* calcd for C₂₉H₄₄O₈ 520.3036 (521.3108 for [M+H]⁺), found 521.3098 (ESI).

(2*S*,3*S*,4*S*)-(2*R*,4*R*,5*R*,6*S*)-2-(6-Ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)-4,6-dimethyl-3,7-dioxononan-5-yl-3-hydroxy-2,4-dimethyl-5-oxoheptanoate (237**)**



237

Activated neutral aluminum oxide (50 mg; Brockmann I, standard grade, ca. 150 mesh, 58 Å) was added to a solution of **14/15** (5 mg, 0.01 mmol) in EtOH (2 mL) and the resulting suspension was heated under reflux. After 1 h, the suspension was filtered through Celite® washing with ethyl acetate. The combined filtrate and washings were concentrated. ¹H NMR of the residue indicated the presence of a 10:7:5:3 mixture of **237**, baconipyronone C (**8**), siphonarin B (**4**), and baconipyronone A (**6**), respectively. Fractionation of the residue by PTLC (80% ethyl acetate in hexanes) gave a 1:1 mixture of siphonarin B (**4**) and baconipyronone C (**8**), respectively (2 mg), and a 4:1 mixture of **237** and baconipyronone A (**6**), respectively (2.5 mg). Further fractionation of the latter mixture by PTLC (50% ethyl ether in CH₂Cl₂) gave baconipyronone A (**6**) (0.5 mg) and the titled compound (2 mg, 40%): [α]_D -92 (*c* 0.1, CHCl₃).

IR ν_{max} : 3401, 1712, 1653, 1610 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 5.37 (1H, dd, *J* = 5, 7.5 Hz, HC-5'), 4.03 (1H, q, HC-2'), 4.01 (1H, ddd, *J* = 4, 4.5, 7.5 Hz, HC-3), 3.15 (1H, d, *J* = 4.5 Hz, HO), 3.06 (1H, dq, *J* = 7.5, 7 Hz, HC-4'), 2.89 (1H, dq, *J* = 5, 7 Hz, HC-6'), 2.66 (1H, dq, *J* = 4, 7 Hz, HC-4), 2.62-2.49


(6H, m, H₂C-6, H₂C-8', H₂C-6''), 2.46 (1H, dq, $J = 7.5, 7$ Hz, HC-2), 2.08 (3H, s, H₃CC-3''), 1.95 (3H, s, H₃CC-5''), 1.37 (3H, d, $J = 7$ Hz, H₃CC-2'), 1.15 (3H, t, $J = 7.5$ Hz, H₃CCH₂C-6''), 1.14 (3H, d, $J = 7$ Hz, H₃CC-4), 1.10 (3H, d, $J = 7$ Hz, H₃CC-6'), 1.07 (3H, d, $J = 7$ Hz, H₃CC-2), 1.06 (3H, t, $J = 7.5$ Hz, H₃C-7), 1.02 (3H, t, $J = 7.5$ Hz, H₃C-9'), 0.89 (3H, d, $J = 7$ Hz, H₃CC-4').

¹³C NMR (125 MHz, CDCl₃) δ : 215.4 (s, C-5), 211.4 (s, C-7'), 207.6 (s, C-3'), 179.8 (s, C-4''), 174.3 (s, C-1), 165.0 (s, C-6''), 159.9 (s, C-2''), 120.5 (s, C-3''), 118.7 (s, C-5''), 76.1 (d, C-5'), 73.1 (d, C-3), 50.2 (d, C-2'), 48.1 (d, C-6'), 47.4 (d, C-4), 45.8 (d, C-4'), 43.4 (d, C-2), 35.0 (d, C-6 or 8'), 35.0 (t, C-6 or 8'), 24.9 (t, CH₂C-6''), 14.3 (q, C-1), 13.7 (q, CH₃C-4'), 13.5 (q, CH₃C-2'), 12.4 (q, CH₃C-6'), 11.5 (q, CH₃CH₂C-6''), 10.3 (q, CH₃C-3'' or CH₃C-4), 10.2 (q, CH₃C-3'' or CH₃C-4), 9.8 (q, CH₃C-5''), 7.8 (q $\times 2$, C-7, C-9').

LRMS: m/z (relative intensity) 543 ([M+23]⁺, 100), 521 ([M+1]⁺, 20), 355 (6), 333 (6) (ESI).

HRMS: m/z calcd for C₂₉H₄₄O₈ 520.3036 (521.3108 for [M+H]⁺), found 531.3127 (ESI).

(4*S*,5*S*,6*S*,10*S*,11*S*,12*R*,14*R*)-11-(Benzyloxy)-14-(6-ethyl-3,5-dimethyl-4-oxo-4*H*-pyran-2-yl)-4,6,8,10,12-pentamethyl-5-hydroxy-4,6,8,10,12-pentamethylpentadecane-3,7,9,13-tetraone (238)



IBX (50 mg, 0.18 mmol) was added to a solution of **228** (15 mg, 0.021 mmol) in anhydrous DMSO (2 mL) at rt. After 2 d, the mixture was diluted with ethyl acetate and washed sequentially with sat. NaHCO₃, water, and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄ and concentrated. The residue that was taken up in THF (2 mL) and pyridine (0.4 mL, 0.4 g, 5 mmol), water (50 µL, 50 mg, 3 mmol), and HF•pyridine (0.13 mL) were added sequentially to the stirred solution at rt. After 4 h, the mixture was diluted with ethyl acetate and washed sequentially with 0.2 M citric acid (0.2 M; ×2), sat. NaHCO₃, and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by PTLC (60% ethyl acetate in hexanes) to give the titled compound (11 mg, 88%) as a complicated mixture consisting of enol (ca. 5%), hemiacetal (one diastereomer, ca. 40%), and β-diketone (ca. 55% as a 4:3 mixture of diastereomers) forms (by NMR).

Only partial data reported.


¹H NMR (500 MHz, CDCl₃). δ 17.14 (0.05H, s, HO (enol)), 7.42-7.12 (5H, m, ArH), 6.13 (0.4H, br s, hemiacetal OH), 4.60-3.70 (4H, m), 3.20-2.30 (8H, m), 2.17-1.80 (6H, several s, pyrone CH₃'s), 1.35-0.80 (24H, m).

¹³C NMR (125 MHz, CDCl₃) (partial data): δ 104.6 (C-9 hemiacetal), 85.3 & 84.8 & 84.3 (C-11, 3 major forms), 61.8 & 61.4 (C-8 keto form, 2 diastereomers).

LRMS: *m/z* (relative intensity) 633 ([M+23]⁺, 45), 611 ([M+1]⁺, 100), 593 (10) (ESI).

HRMS: *m/z* calcd for C₃₆H₅₀O₈ 610.3506 (611.3578 for [M+H]⁺), found 611.3597 (ESI).

Siphonarin B (4)



siphonarin B (4)


From 238: Raney nickel (W2; 0.2 mL settled volume in EtOH) was transferred to a solution of **238** (6 mg, 0.01 mmol) in EtOH (3 mL) at rt and the resulting suspension was heated under reflux with vigorous stirring. After 45 min, the mixture was allowed to settle and then was decanted. The solid was suspended in EtOH (10 mL), heated under reflux for 10 min, and decanted. This washing procedure was repeated with ethyl acetate. The organic layers were passed over Celite®, combined, concentrated, and fractionated by PTLC (70% ether in CH₂Cl₂) to give baconipyron C (**8**) (1 mg, 20%) and siphonarin B (**4**) (1.5 mg, 27%).

From 14/15: Imidazole (10 mg, 0.15 mmol) was added to a solution of **14/15** (3.5 mg, 6.7 μ mol) in CDCl_3 (0.4 mL) at rt. After 24 hr, the mixture was diluted with ethyl acetate and washed with 0.2 M citric acid, sat. NaHCO_3 , and brine. The aqueous layers were back extracted with ethyl acetate. The combined organic layers were dried over Na_2SO_4 , and concentrated to give the crude product that, by ^1H NMR, contained a mixture of **4** (δ_{H} 5.12) and hemiacetals (δ_{H} 6.46, 6.39, 6.19 in a 0.1:1.5:1 ratio). [Note: similar mixtures were also obtained from similar reactions starting from **14/15** and from **4** after 48 h.] Fractionation of the residue by PTLC (50% ether in CH_2Cl_2) gave the titled compound containing ca. 10% of a δ_{H} 5.01 impurity (3 mg, 85%). Further fractionation by PTLC (7% i PrOH in CH_2Cl_2) gave the titled compound (2.5 mg, 70%): $[\alpha]_{\text{D}} +12$ (c 0.1, CHCl_3).

^1H NMR (500 MHz, CDCl_3): δ 5.12 (1H, s), 3.91 (1H, d, J = 10.5 Hz), 3.81 (1H, br s), 3.27 (1H, q, J = 7 Hz), 3.08 (1H, br s), 2.77 (2H, ap q, J = 7 Hz), 2.66 (1H, q, J = 7 Hz), 2.61 (1H, q, J = 6.5 Hz), 2.48 (1H, dq, J = 18.5, 7 Hz), 2.32-2.18 (2H, m), 2.05 (1H, dq, J = 2.5, 7.5 Hz), 1.97 (3H, s), 1.96 (3H, s), 1.86 (1H, dq, J = 2, 7 Hz), 1.25 (3H, d, J = 7 Hz), 1.21 (3H, d, J = 7 Hz), 1.20 (3H, t, J = 7.5 Hz), 1.19 (3H, d, J = 7 Hz), 1.07 (3H, d, J = 6.5 Hz), 1.07 (3H, d, J = 7 Hz), 0.94 (3H, t, J = 7 Hz), 0.77 (3H, d, J = 6.5 Hz).

^{13}C NMR (125 MHz, CDCl_3): δ 213.5, 206.7, 180.1, 165.7, 161.8, 121.8, 117.5, 105.4, 103.4, 74.82, 74.80, 50.2, 46.8, 45.5, 42.7, 38.9, 38.6, 35.9, 24.9, 13.2, 12.8, 12.1, 11.6, 11.1, 9.6, 9.5, 8.8, 8.4, 7.6.

Baconipyrrone A (6)



baconipyrrone A (6)

Activated basic aluminum oxide (50 mg; Brockmann I, standard grade, 58 Å) was added to a stirred solution of **238** (10 mg, 0.016 mmol) in EtOH (2 mL) and the resulting suspension was heated under reflux. After 7 h, the cooled mixture was filtered through Celite®, washing with ethyl acetate. The combined filtrate and washings were concentrated and the residue taken up in EtOH (2 mL) and 5% Pd-C (10 mg) was added. The resulting black suspension was stirred under a H₂ atmosphere 24 h and then was filtered through Celite®, washing with ethyl acetate. The combined filtrate and washings were concentrated and fractionated by PTLC (80% ethyl acetate in hexanes) to give baconipyrrone A (**6**) (1.5 mg, 18%) and baconipyrrone C (**8**) (6 mg, 70%): $[\alpha]_D -96$ (*c* 0.13, CHCl₃).

IR ν_{max} : 1718, 1652, 1597 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ 5.00 (1H, dd, *J* = 4.5, 6 Hz, HC-5), 4.04 (1H, q, *J* = 7 Hz, HC-14), 3.62 (1H, ddd, *J* = 3.5, 8.5, 9.5 Hz, HC-11), 3.35 (1H, d, *J* = 9.5 Hz, HOC-11), 2.96 (1H, dq, *J* = 4.5, 7 Hz, HC-6), 2.79 (1H, dq, *J* = 8.5, 7 Hz, HC-12), 2.64 (1H, dq, *J* = 3.5, 7 Hz, HC-10), 2.62-2.51 (2H, m, HC-8. H₂CC-19), 2.13 (1H, dq, *J* = 6.5, 7 Hz, HC-4), 2.05 (3H, s, H₃CC-16), 1.95 (3H, s, H₃CC-18), 1.66 (1H, dq, *J* = 14.5, 7 Hz, HC-2), 1.52 (1H, dq, *J* = 14.5, 7 Hz, HC-2), 1.38 (3H, d, *J* = 7 Hz, H₃CC-14), 1.29 (3H, d, *J* = 7 Hz, H₃CC-10),


1.16 (3H, t, $J = 7.5$ Hz, $\text{H}_3\text{CCH}_2\text{C-19}$), 1.07 (3H, d, $J = 7$ Hz, $\text{H}_3\text{CC-4}$ or $\text{H}_3\text{CC-8}$), 1.06 (3H, d, $J = 7$ Hz, $\text{H}_3\text{CC-4}$ or $\text{H}_3\text{CC-8}$), 1.00 (3H, d, $J = 7$ Hz, $\text{H}_3\text{CC-6}$), 0.90 (3H, d, $J = 7$ Hz, $\text{H}_3\text{CC-12}$), 0.86 (3H, d, $J = 7$ Hz, $\text{H}_3\text{C-1}$).

^{13}C NMR (125 MHz, CDCl_3): δ 211.5 (s, C-7), 210.5 (s, C-13), 179.8 (s, C-17), 175.0 (s, C-9), 165.0 (s, C-19), 160.5 (s, C-15), 120.5 (s, C-16), 118.7 (s, C-18), 77.5 (d, C-5 or C-11), 77.4 (d, C-5 or C-11), 76.6 (s, C-3), 51.4 (d, C-14), 48.3 (d, C-12), 46.4 (d, C-8), 44.8 (d, C-6), 41.6 (d, C-10), 38.0 (d, C-4), 30.5 (t, C-2), 25.0 (t, $\text{CH}_2\text{C-19}$), 15.4 (q, $\text{CH}_3\text{C-10}$), 14.5 (q, $\text{CH}_3\text{C-12}$), 13.2 (q, $\text{CH}_3\text{C-14}$), 12.1 (q, $\text{CH}_3\text{C-4}$ or $\text{CH}_3\text{C-6}$), 11.8 (q, $\text{CH}_3\text{C-4}$ or $\text{CH}_3\text{C-6}$), 11.5 (q, $\text{CH}_3\text{CH}_2\text{C-19}$), 10.2 (q, $\text{CH}_3\text{C-18}$), 9.8 (q, $\text{CH}_3\text{C-18}$), 9.0 (q, C-1), 7.6 (q, $\text{CH}_3\text{C-8}$).

LRMS: m/z (relative intensity) 543 ($[\text{M}+23]^+$, 90), 521 ($[\text{M}+1]^+$, 100) (ESI).

HRMS: m/z calcd for $\text{C}_{29}\text{H}_{44}\text{O}_8$ 520.3036 (521.3108 for $[\text{M}+\text{H}]^+$), found 521.3104 (ESI).

Baconipyrrone C (8)



From 238: Activated basic aluminum oxide (Brockmann I, standard grade, 58 Å; 50 mg) was added to a stirred solution of **238** (10 mg, 0.016 mmol) in EtOH (2 mL) and the resulting suspension was heated under reflux. After 7 h, the cooled mixture was filtered through Celite®, washing with ethyl acetate. The combined filtrate and washings were concentrated

and the residue taken up in EtOH (2 mL) and 5% Pd-C (10 mg) was added. The resulting black suspension was stirred under a H₂ atmosphere 24 h and then was filtered through Celite®, washing with ethyl acetate. The combined filtrate and washings were concentrated and fractionated by PTLC (80% ethyl acetate in hexanes) to give baconipyronone A (**6**) (1.5 mg, 18%) and baconipyronone C (**8**) (6 mg, 70%): [α]_D -81 (*c* 0.1, MeOH).

From 14/15: DBU (ca. 1 μ L) was added to a solution of **14/15** (5 mg, 0.01 mmol) in C₆D₆ (0.4 mL) at rt. After 1 h, the mixture was diluted with ethyl acetate and washed with 0.2 M citric acid, sat. NaHCO₃, and brine. Each aq. layer was sequentially back extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, concentrated, and fractionated by PTLC (40% acetone in hexanes) to give the titled compound (2.5 mg, 50%) and 14-*epi*-baconipyronone C (**235**) (1.5 mg, 30%).

¹H NMR (500 MHz, CDCl₃): δ 5.47 (1H, dd, *J* = 3.5, 9 Hz, HC-5), 4.15 (1H, q, *J* = 7 Hz, HC-4), 3.55 (1H, ddd, *J* = 3, 9, 10 Hz, HC-11), 3.38 (1H, d, *J* = 10 Hz, HO), 2.89-2.19 (3H, m, HC-4, HC-6, HC-12), 2.75 (1H, dq, *J* = 18, 7 Hz, HC-8 or HC-2), 2.60-2.45 (4H, m, HC-2 or HC-8, HC-10, H₂CC-19), 2.44-2.29 (2H, m, HC-2, HC-8), 2.09 (3H, s, H₃CC-16), 1.93 (3H, s, H₃CC-18), 1.38 (3H, d, *J* = 7 Hz, H₃CC-14), 1.22 (3H, d, *J* = 7 Hz, H₃CC-10), 1.16 (3H, t, *J* = 7.5 Hz, H₃CCH₂C-19), 1.09 (3H, d, *J* = 7 Hz, H₃CC-4 or H₃CC-6), 1.02 (3H, d, *J* = 7 Hz, H₃CC-6 or H₃CC-4), 1.01 (3H, t, *J* = 7.5 Hz, H₃CC-8 or H₃CC-2), 0.91 (3H, t, *J* = 7 Hz, H₃CC-2 or H₃CC-8), 0.86 (3H, d, *J* = 7 Hz, H₃CC-12).

¹³C NMR (125 MHz, CDCl₃): δ 212.1 (s, C-7 or C-3), 211.0 (s, C-3 or C-7), 210.7 (s, C-13), 179.9 (s, C-17), 174.3 (s, C-9), 164.8 (s, C-19), 160.8 (s, C-16), 120.6 (s, C-16), 118.5 (s, C-

18), 77.8 (d, C-11), 74.0 (d, C-5), 51.2 (d, C-14), 48.8 (d, C-12), 47.5 (d, C-4 or C-6), 46.0 (d, C-6 or C-4), 41.3 (d, C-10), 35.32 (t, C-2 or C-8), 35.28 (t, C-2 or C-8), 24.9 (t, CH₂C-19), 15.3 (q, CH₃C-10), 14.4 (q, CH₃C-12), 13.7 (q, CH₃C-4 or CH₃C-6), 13.4 (q, CH₃C-14), 11.5 (q, CH₃CH₂C-19), 10.4 (q, CH₃C-16), 9.9 (q, CH₃C-6 or CH₃C-4), 9.7 (q, CH₃C-18), 7.9 (q, CH₃C-8 or CH₃C-2), 7.5 (q, CH₃C-2 or CH₃C-8).

LRMS: m/z (relative intensity): 520 ($[M]^+$, 2), 339 (3), 236 (8), 209 (5), 180 (100), 151 (10), 121 (43), 57 (54) (EI).

HRMS: m/z calcd for C₂₉H₄₄O₈ 520.3036, found 520.3028 (EI).

REFERENCES

1. Garson, M. J. Marine mollusks from Australia and New Zealand: chemical and ecological studies. *Progress in Molecular and Subcellular Biology* **2006**, 43, 159-174.
2. Darias, J., Cueto, J., Diaz-Marrero, A. R. The chemistry of marine pulmonate gastropods. *Progress in Molecular and Subcellular Biology* **2006**, 43, 105-131.
3. Davies-Coleman, M. T., Garson, M. J. Marine polypropionates. *Natural Product Reports* **1998**, 15, 477-493.
4. Manker, D. C., Faulkner, D. J., Stout, T. J., Clardy, J. The baconipyrones. Novel polypropionates from the pulmonate Siphonaria baconi. *Journal of Organic Chemistry* **1989**, 54, 5371-5374.
5. Hochlowski, J. E., Faulkner, D. J., Matsumoto, G. K., Clardy, J. The denticulatins, two polypropionate metabolites from the pulmonate Siphonaria denticulata. *Journal of the American Chemical Society* **1983**, 105, 7413-7415.
6. Roll, D. M., Biskupiak, J. E., Mayne, C. L., Ireland, C. M. Muamvatin, a novel tricyclic spiro ketal from the Fijian mollusk Siphonaria normalis. *Journal of the American Chemical Society* **1986**, 108, 6680-6682.
7. Hochlowski, J. E., Faulkner, D. J. Antibiotics from the marine pulmonate Siphonaria diemenensis. *Tetrahedron Letters* **1983**, 24, 1917-20.
8. Hochlowski, J., Coll, J., Faulkner, D. J., Clardy, J. Novel metabolites of four Siphonaria species. *Journal of the American Chemical Society* **1984**, 106, 6748-6750.
9. Blanchfield, J. T., Brecknell, D. J., Brereton, I. M., Garson, M. J., Jones, D. D. Caloundrin B and funiculatin A: new polypropionates from siphonariid limpets. *Australian Journal of Chemistry* **1994**, 47, 2255-2269.
10. Socorro, I. M., Taylor, K., Goodman, J. M. ROBIA: A Reaction Prediction Program. *Organic Letters* **2005**, 7, 3541-3544.
11. Garson, M. J., Goodman, J. M., Paterson, I. A configuration model for siphonariid polypropionates derived from structural and biosynthetic considerations. *Tetrahedron Letters* **1994**, 35, 6929-6932.
12. Brecknell, D. J., Collett, L. A., Davies-Coleman, M. T., Garson, M. J., Jones, D. D. New non-contiguous polypropionates from marine molluscs: a comment on their natural product status. *Tetrahedron* **2000**, 56, 2497-2502.
13. Jenkins, B. W. Redescriptions and relationships of Siphonaria zelandica Quoy & Gaimard to S. australia Quoy and Gaimard with a description of S. propria sp. nov.

(Mollusca: Pulmonata: Siphonariidae). *Journal of the Malacological Society of Australia* **1983**, 6, 1-35.

14. Sundram, U. N., Albizati, K. F. Synthesis and absolute configuration of polypropionate metabolites of *Siphonaria australis*. *Tetrahedron Letters* **1992**, 33, 437-440.
15. Paterson, I., Chen, D. Y.-K., Franklin, A. S. Total Synthesis of Siphonarin B and Dihydrosiphonarin B. *Organic Letters* **2002**, 4, 391-394.
16. Lister, T., Perkins, M. V. A Retro-Claisen Approach to Dolabriferol. *Organic Letters* **2006**, 8, 1827-1830.
17. Lister, T., Perkins, M. V. Total Synthesis of a Hemiacetal Polypropionate from *Siphonaria australis*. *Australian Journal of Chemistry* **2004**, 57, 787-797.
18. Manker, D. C., Garson, M. J., Faulkner, D. J. De novo biosynthesis of polypropionate metabolites in the marine pulmonate *Siphonaria denticulata*. *Chemical Communications* **1988**, 1061-1062.
19. Garson, M. J., Jones, D. D., Small, C. J., Liang, J.; Clardy, J. Biosynthetic studies on polypropionates: a stereochemical model for siphonarins A and B from the pulmonate limpet *Siphonaria zelandica*. *Tetrahedron Letters* **1994**, 35, 6921-6924.
20. Cane, D. E., Celmer, W. D., Westley, J. W. Unified stereochemical model of polyether antibiotic structure and biogenesis. *Journal of the American Chemical Society* **1983**, 105, 3594-3600.
21. Paterson, I., Franklin, A. S. Assignment of the absolute configuration of the siphonarins and baconipyrones. Enantiocontrolled synthesis of a γ -pyrone subunit. *Tetrahedron Letters* **1994**, 35, 6925-6928.
22. Paterson, I., Yeung, K.-S., Watson, C., Ward, R. A., Wallace, P. A. The total synthesis of scytophycin C. Part 1: stereocontrolled synthesis of the C-1 - C-32 protected seco acid. *Tetrahedron* **1998**, 54, 11935-11954.
23. Arimoto, H., Nishiyama, S., Yamamura, S. Mild conditions for cyclization of β -triketides to the corresponding γ -pyrones carrying adjacent chiral centers toward biomimetic synthesis of fully substituted γ -pyrone-containing natural products. *Tetrahedron Letters* **1990**, 31, 5619-5620.
24. Yamamura, S., Nishiyama, S. Synthetic Studies on Polypropionate-Derived 4-Pyrone-Containing Marine Natural Products. *Bulletin of the Chemical Society of Japan* **1997**, 70, 2025-2037.
25. Paterson, I., Tillyer, R. D. Studies in polypropionate synthesis: high π -face selectivity in syn aldol reactions of tin(II) enolates from (*R*)- and (*S*)-1-benzyloxy-2-methylpentan-3-one. *Tetrahedron Letters* **1992**, 33, 4233-4236.

26. Evans, D. A., Hoveyda, A. H. Samarium-catalyzed intramolecular Tishchenko reduction of β -hydroxy ketones. A stereoselective approach to the synthesis of differentiated anti 1,3-diol monoesters. *Journal of the American Chemical Society* **1990**, 112, 6447-6449.
27. Bode, S. E., Wolberg, M., Mueller, M. Stereoselective synthesis of 1,3-diols. *Synthesis* **2006**, 557-588.
28. Paterson, I., Chen, D. Y.-K., Acena, J. L., Franklin, A. S. Studies in Marine Polypropionate Synthesis: Total Synthesis of (-)-Baconipyrone C. *Organic Letters* **2000**, 2, 1513-1516.
29. Yadav, J. S., Sathaiah, K., Srinivas, R. Total synthesis of (-)-baconipyrone C. *Tetrahedron* **2009**, 65, 3545-3552.
30. Gillingham, D. G., Hoveyda, A. H. Chiral N-heterocyclic carbenes in natural product synthesis: application of Ru-catalyzed asymmetric ring-opening/cross-metathesis and Cu-catalyzed allylic alkylation to total synthesis of baconipyrone C. *Angewandte Chemie, International Edition* **2007**, 46, 3860-3864.
31. Paterson, I., Goodman, J. M., Lister, M. A., Schumann, R. C., McClure, C. K., Norcross, R. D. Enantio- and diastereoselective aldol reactions of achiral ethyl and methyl ketones with aldehydes. The use of enol diisopinocampheylborinates. *Tetrahedron* **1990**, 46, 4663-4684.
32. Still, W. C., Barrish, J. C. A stereoselective synthesis of 1,3-diol derivatives and application to the ansa bridge of rifamycin S. *Journal of the American Chemical Society* **1983**, 105, 2487-2489.
33. Ito, H., Taguchi, T., Hanzawa, Y. Practical zirconium-mediated deprotective method of allyl groups. *Journal of Organic Chemistry* **1993**, 58, 774-775.
34. Lautens, M., Bouchain, G. [4 + 3]-Cycloaddition in water. Synthesis of 2,4-endo,endo-dimethyl-8-oxabicyclo[3.2.1]oct-6-en-3-one. *Organic Syntheses* **2002**, 79, 251-256.
35. Yadav, J. S., Samad Hossain, S., Madhu, M., Mohapatra, D. K. Formal Total Synthesis of (-)-Saliniketals. *Journal of Organic Chemistry* **2009**, 74, 8822-8825.
36. Gillingham, D. G., Kataoka, O., Garber, S. B., Hoveyda, A. H. Efficient Enantioselective Synthesis of Functionalized Tetrahydropyrans by Ru-Catalyzed Asymmetric Ring-Opening Metathesis/Cross-Metathesis (AROM/CM). *Journal of the American Chemical Society* **2004**, 126, 12288-12290.
37. Evans, P. A., Cui, J., Gharpure, S. J., Polosukhin, A., Zhang, H.-R. Enantioselective Total Synthesis of the Potent Antitumor Agent (-)-Mucocin Using a Temporary Silicon-Tethered Ring-Closing Metathesis Cross-Coupling Reaction. *Journal of the American Chemical Society* **2003**, 125, 14702-14703.

38. Hoye, T. R., Eklov, B. M., Jeon, J., Khoroosi, M. Sequencing of Three-Component Olefin Metatheses: Total Synthesis of Either (+)-Gigantecin or (+)-14-Deoxy-9-oxygigantecin. *Organic Letters* **2006**, 8, 3383-3386.
39. Lister, T., Perkins, M. V. Total synthesis of auriopyrone A. *Angewandte Chemie, International Edition* **2006**, 45, 2560-2564.
40. Yadav, J. S., Rao, C. S., Chandrasekhar, S., Rama Roa, A. V. Asymmetric synthesis of C-19 to C-27 fragment of rifamycin-S. *Tetrahedron Letters* **1995**, 36, 7717-7720.
41. Yadav, J. S., Abraham, S., Reddy, M. M., Sabitha, G., Sankar, A. R., Kunwar, A. C. Corrigendum to "Towards the synthesis of (+)-discodermolide" [*Tetrahedron Letters* **2001**, 42, 4713-4716]. *Tetrahedron Letters* **2002**, 43, 3453.
42. Yadav, J. S., Abraham, S., Reddy, M. M., Sabitha, G., Sankar, A. R., Kunwar, A. C. Towards the synthesis of (+)-discodermolide. *Tetrahedron Letters* **2001**, 42, 4713-4716.
43. Yadav, J. S., Ahmed, M. M. A stereoconvergent synthesis of the C-19 - C-31 fragment of scytophycin C. *Tetrahedron Letters* **2002**, 43, 7147-7150.
44. Yadav, J. S., Srinivas, R., Sathaiah, K. Total synthesis of natural (+)-membrenone C and its 7-epimer. *Tetrahedron Letters* **2006**, 47, 1603-1606.
45. Yadav, J. S., Reddy, K. B., Sabitha, G. An efficient synthesis of (+)-prelactone B. *Tetrahedron Letters* **2004**, 45, 6475-6476.
46. Yadav, J. S., Reddy, K. B., Sabitha, G. Stereoconvergent synthesis of C-1 - C-17 and C-18 - C-25 fragments of bafilomycin A1. *Tetrahedron* **2008**, 64, 1971-1982.
47. Yadav, J. S., Satyanarayana, M., Srinivasulu, G., Kunwar, A. C. A stereoselective synthesis of the C-20 - C-32 fragment of the phorboxazoles. *Synlett* **2007**, 1577-1580.
48. Yadav, J. S., Pratap, T. V., Rajender, V. Stereoselective Formal Total Synthesis of (+)-Methynolide. *Journal of Organic Chemistry* **2007**, 72, 5882-5885.
49. Paterson, I. New methods and strategies for the stereocontrolled synthesis of polypropionate-derived natural products. *Pure and Applied Chemistry* **1992**, 64, 1821-1830.
50. Arjona, O., Menchaca, R., Plumet, J. Synthesis of the Cyclohexan Subunit of Baconipyrones A and B from Furan. *Organic Letters* **2001**, 3, 107-109.
51. Turks, M., Murcia, M. C., Scopelliti, R., Vogel, P. First Asymmetric Synthesis of the Cyclohexanone Subunit of Baconipyrones A and B. Revision of Its Structure. *Organic Letters* **2004**, 6, 3031-3034.

52. Turks, M., Fonquerne, F., Vogel, P. Synthesis of Long-Chain Polyketide Fragments by Reaction of 1,3-Dioxy-1,3-dienes with Allylsilanes: Umpolung with Sulfur Dioxide. *Organic Letters* **2004**, 6, 1053-1056.
53. Pereyre, M., Bellegarde, B., Mendelsohn, J., Valade, J. Action of alkoxytrialkyl tins on enolic esters. Problem of obtaining C- or O-tin compounds. *Journal of Organometallic Chemistry* **1968**, 11, 97-110.
54. Labadie, S. S., Stille, J. K. Stereoselective aldol condensations of organotin reagents with aldehydes. *Tetrahedron* **1984**, 40, 2329-2336.
55. Paterson, I., Lister, M. A. Aldol condensations of chiral ethyl ketones: control by chiral boron reagents. *Tetrahedron Letters* **1988**, 29, 585-588.
56. Takai, K., Tagashira, M., Kuroda, T., Oshima, K., Utimoto, K., Nozaki, H. Reactions of alkenylchromium reagents prepared from alkenyl trifluoromethanesulfonates (triflates) with chromium(II) chloride under nickel catalysis. *Journal of the American Chemical Society* **1986**, 108, 6048-6050.
57. Jin, H., Uenishi, J., Christ, W. J., Kishi, Y. Catalytic effect of nickel(II) chloride and palladium(II) acetate on chromium(II)-mediated coupling reaction of iodo olefins with aldehydes. *Journal of the American Chemical Society* **1986**, 108, 5644-5646.
58. Paterson, I., Goodman, J. M., Isaka, M. Aldol reactions in polypropionate synthesis: high π -face selectivity of enol borinates from α -chiral methyl and ethyl ketones under substrate control. *Tetrahedron Letters* **1989**, 30, 7121-7124.
59. Paterson, I., Perkins, M. V. Total synthesis of the marine polypropionate (+)-muamvatin. A configurational model for siphonariid metabolites. *Journal of the American Chemical Society* **1993**, 115, 1608-1610.
60. Hoffmann, R. W., Dahmann, G. The absolute and relative configuration of muamvatin. *Tetrahedron Letters* **1993**, 34, 1115-1118.
61. Hoffmann, R. W., Dahmann, G. Synthesis of a hydroxytrioxaadamantane, a model for the trioxaadamantane moiety of muamvatin. *Chemische Berichte* **1994**, 127, 1317-1322.
62. Dahmann, G., Hoffmann, R. W. The absolute configuration of muamvatin. *Liebigs Annalen der Chemie* **1994**, 837-845.
63. Ward, D. E., Man, C. C., Guo, C. The thiopyran route to polypropionates revisited: selective syn and anti aldol reaction via 3,6-dihydro-4-trimethylsilyloxy-2H-thiopyran. *Tetrahedron Letters* **1997**, 38, 2201-2202.
64. Ward, D. E., Guo, C., Sasmal, P. K., Man, C. C., Sales, M. Thiopyran route to polypropionates: aldol diastereoselectivity of linear and two-directional iterative homologations. *Organic Letters* **2000**, 2, 1325-1328.

65. Ward, D. E., Sales, M., Sasmal, P. K. Syn-anti isomerization of aldols by enolization. *Organic Letters* **2001**, 3, 3671-3673.
66. Ward, D. E., Sales, M., Man, C. C., Shen, J., Sasmal, P. K., Guo, C. Influence of the β -Alkoxy Group on the Diastereoselectivity of Aldol Reactions of Tetrahydro-4*H*-thiopyran-4-one with 4-Alkoxytetrahydro-2*H*-thiopyran-3-carboxaldehydes. *Journal of Organic Chemistry* **2002**, 67, 1618-1629.
67. Ward, D. E., Akinnusi, O. T., Alarcon, I. Q., Jheengut, V., Shen, J., Quail, J. W. The thiopyran route to polypropionates. Asymmetric synthesis of the building blocks by enantioselective protonation. *Tetrahedron: Asymmetry* **2004**, 15, 2425-2430.
68. Ward, D. E., Jheengut, V. Proline-catalyzed asymmetric aldol reactions of tetrahydro-4*H*-thiopyran-4-one with aldehydes. *Tetrahedron Letters* **2004**, 45, 8347-8350.
69. Ward, D. E., Sales, M., Sasmal, P. K. Syn-Anti Isomerization of Aldols by Enolization. *Journal of Organic Chemistry* **2004**, 69, 4808-4815.
70. Ward, D. E., Jheengut, V., Akinnusi, O.T. Enantioselective direct intermolecular aldol reactions with enantiotopic group selectivity and dynamic kinetic resolution. *Organic letters* **2005**, 7, 1181-1184.
71. Ward, D. E., Gillis, H. M., Akinnusi, O. T., Rasheed, M. A., Saravanan, K., Sasmal, P. K. Asymmetric Synthesis of Hexapropionate Synthons by Sequential Enantiotopic Group Selective Enolization of Meso Diketones. *Organic Letters* **2006**, 8, 2631-2634.
72. Ward, D. E., Jheengut, V., Beye, G. E. Thiopyran Route to Polypropionates: An Efficient Synthesis of Serricornin. *Journal of Organic Chemistry* **2006**, 71, 8989-8992.
73. Ward, D. E., Beye, G. E., Sales, M., Alarcon, I. Q., Gillis, H. M., Jheengut, V. Thiopyran Route to Polypropionates: Exploiting and Overcoming Double Stereodifferentiation and Mutual Kinetic Enantioselection in Aldol Couplings of Chiral Fragments. *Journal of Organic Chemistry* **2007**, 72, 1667-1674.
74. Ward, D. E., Rasheed, M. A., Gillis, H. M., Beye, G. E., Jheengut, V., Achonduh, G. T. Simple and efficient preparation of reagents for thiopyran introduction. Methyl tetrahydro-4-oxo-2*H*-thiopyran-3-carboxylate, tetrahydro-4*H*-thiopyran-4-one, and 3,6-dihydro-4-trimethylsilyloxy-2*H*-thiopyran. *Synthesis* **2007**, 1584-1586.
75. Beye, G. E., Goodman, J. M., Ward, D. E. Synthetic Studies on Siphonariid Polypropionates: Synthesis and Isomerization of the Caloundrin B Trioxaadamantane Ring System. *Organic Letters* **2009**, 11, 1373-1376.
76. Ward, D. E., Becerril-Jimenez, F., Zahedi, M. M. Rational Design of Aldol Reactions That Proceed via Kinetic Resolution with Switchable Enantioselectivity. *Journal of Organic Chemistry* **2009**, 74, 4447-4454.

77. Jheengut, V., Ward, D. E. The Thiopyran Route to Polypropionates: Enantioselective Synthesis of Membrenone B from Racemic Fragments. *Journal of Organic Chemistry* **2007**, 72, 7805-7808.
78. More, J. D., Finney, N. S. A Simple and Advantageous Protocol for the Oxidation of Alcohols with o-Iodoxybenzoic Acid (IBX). *Organic Letters* **2002**, 4, 3001-3003.
79. Gillis, H. M. Ph. D. Thesis. University of Saskatchewan, Saskatoon, Saskatchewan, **2007**.
80. Willis, M. C. Enantioselective desymmetrization. *Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry* **1999**, 1765-1784.
81. Pellissier, H. Dynamic kinetic resolution. *Tetrahedron* **2003**, 59, 8291-8327.
82. Cobb, A. J. A., Shaw, D. M., Ley, S. V. 5-pyrrolidin-2-yltetrazole: A new, catalytic, more soluble alternative to proline in an organocatalytic asymmetric Mannich-type reaction. *Synlett* **2004**, 558-560.
83. Torii, H., Nakadai, M., Ishihara, K., Saito, S., Yamamoto, H. Asymmetric direct aldol reaction assisted by water and a proline-derived tetrazole catalyst. *Angewandte Chemie, International Edition* **2004**, 43, 1983-1986.
84. Hartikka, A., Arvidsson, P. I. Rational design of asymmetric organocatalysts--increased reactivity and solvent scope with a tetrazolic acid. *Tetrahedron: Asymmetry* **2004**, 15, 1831-1834.
85. Hartikka, A., Arvidsson, P. I. 5-(Pyrrolidine-2-yl)tetrazole: rationale for the increased reactivity of the tetrazole analogue of proline in organo-catalyzed Aldol reactions. *European Journal of Organic Chemistry* **2005**, 4287-4295.
86. Theaker, N. E. M.Sc. Thesis. University of Saskatchewan Saskatoon, Saskatchewan, **2009**.
87. Fawcett, F. S. Bredt's rule of double bonds in atomic bridged-ring structures. *Chemical Reviews* **1950**, 47, 219-274.
88. Buchanan, G. L. Bredt's rule. *Chemical Society Reviews* **1974**, 3, 41-63.
89. Sen, S. E., Roach, S. L., Boggs, J. K., Ewing, G. J., Magrath, J. Ferric Chloride Hexahydrate: A Mild Hydrolytic Agent for the Deprotection of Acetals. *Journal of Organic Chemistry* **1997**, 62, 6684-6686.
90. Kim, K. S., Song, Y. H., Lee, B. H., Hahn, C. S. Efficient and selective cleavage of acetals and ketals using ferric chloride adsorbed on silica gel. *Journal of Organic Chemistry* **1986**, 51, 404-406.

91. Crossman, J. S., Perkins, M. V. Total Synthesis and Structural Elucidation of (-)-Maurenone. *Journal of Organic Chemistry* **2006**, 71, 117-124.
92. Afarinkia, K., Vinader, V. Product class 3: pyranones and pyranthiones. In *Science of Synthesis*, Thomas, J., Ed. Georg Thieme Verlag: Stuttgart, **2003**, 275-346.
93. Jung, M. E., Salehi-Rad, R. Total Synthesis of Auripyrone A Using a Tandem Non-Aldol Aldol/Paterson Aldol Process as a Key Step. *Angewandte Chemie, International Edition* **2009**, 48, 8766-8769.
94. Sakakura, A., Watanabe, H., Ishihara, K. Rate-Accelerating Effect by the Neighboring-Group Participation of Protecting Groups in the Dehydrative Cyclization of 1,3,5-Triketones. *Organic Letters* **2008**, 10, 2569-2572.
95. Sakakura, A., Watanabe, H., Nakagawa, S., Ishihara, K. Unusual rate acceleration in bronsted acid catalyzed dehydration reactions: local hydrophobic environment in aggregated N-(2,6-diphenylphenyl)-N-mesitylammonium pentafluorobenzenesulfonates. *Chemistry--An Asian Journal* **2007**, 2, 477-483.
96. Dorman, L. C. Synthesis of 2-methyl-4*H*-pyran-4-one. *Journal of Organic Chemistry* **1967**, 32, 4105-4107.
97. Mullock, E. B., Suschitzky, H. A simple preparation of γ -pyrones. *Journal of the Chemical Society (C): Organic* **1967**, 828-830.
98. Brown, C. A. Saline hydrides and superbases in organic reactions. X. Rapid, high yield condensations of esters and nitriles via kationation. *Synthesis* **1975**, 326-327.
99. Zhdankin, V. V. Benziodoxole-Based Hypervalent Iodine Reagents in Organic Synthesis. *Current Organic Synthesis* **2005**, 2, 121-145.
100. Uyanik, M., Ishihara, K. Hypervalent iodine-mediated oxidation of alcohols. *Chemical Communications* **2009**, 2086-2099.
101. Wu, Y., Shen, X., Huang, J.-H., Tang, C.-J., Liu, H.-H., Hu, Q. Preferential hydrolysis of benzylic/allylic dithianes and dithiolanes using o-iodoxybenzoic acid (IBX) in DMSO containing traces of water. *Tetrahedron Letters* **2002**, 43, 6443-6445.
102. Krishnaveni, N. S., Surendra, K., Nageswar, Y. V. D., Rao, K. R. Mild and efficient hydrolysis of aromatic thioacetals/thioketals using o-iodoxybenzoic acid (IBX) in the presence of β -cyclodextrin in water. *Synthesis* **2003**, 2295-2297.
103. Nicolaou, K. C., Mathison, C. J. N., Montagnon, T. New reactions of IBX: oxidation of nitrogen- and sulfur-containing substrates to afford useful synthetic intermediates. *Angewandte Chemie, International Edition* **2003**, 42, 4077-4082.
104. Nicolaou, K. C., Mathison, C. J. N., Montagnon, T. o-Iodoxybenzoic Acid (IBX) as a Viable Reagent in the Manipulation of Nitrogen- and Sulfur-Containing Substrates:

Scope, Generality, and Mechanism of IBX-Mediated Amine Oxidations and Dithiane Deprotections. *Journal of the American Chemical Society* **2004**, 126, 5192-5201.

105. Eckert, F., Leito, I., Kaljurand, I., Kuett, A., Klamt, A., Diedenhofen, M. Prediction of acidity in acetonitrile solution with COSMO-RS. *Journal of Computational Chemistry* **2009**, 30, 799-810.
106. Danishefsky, S. J., Selnick, H. G., DeNinno, M. P., Zelle, R. E. The total synthesis of zincophorin. *Journal of the American Chemical Society* **1987**, 109, 1572-1574.
107. Danishefsky, S. J., Myles, D. C., Harvey, D. F. Expeditious synthesis of the polypropionate sector of rifamycin S by reiterative Diene-Aldehyde cyclocondensation reactions. *Journal of the American Chemical Society* **1987**, 109, 862-867.
108. Danishefsky, S. J., Selnick, H. G., Zelle, R. E., DeNinno, M. P. Total synthesis of zincophorin. *Journal of the American Chemical Society* **1988**, 110, 4368-4378.
109. Myles, D. C., Danishefsky, S. J., Schulte, G. Development of a fully synthetic stereoselective route to 6-deoxyerythronolide B by reiterative applications of the Lewis acid catalyzed diene aldehyde cyclocondensation reaction: a remarkable instance of diastereofacial selectivity. *Journal of Organic Chemistry* **1990**, 55, 1636-1648.
110. Luche, J. L. Lanthanides in organic chemistry. 1. Selective 1,2 reductions of conjugated ketones. *Journal of the American Chemical Society* **1978**, 100, 2226-2227.
111. Luche, J. L., Rodriguez-Hahn, L., Crabbe, P. Reduction of natural enones in the presence of cerium trichloride. *Journal of the Chemical Society, Chemical Communications* **1978**, 601-602.
112. Gemal, A. L., Luche, J. L. Lanthanoids in organic synthesis. 6. Reduction of α -enones by sodium borohydride in the presence of lanthanoid chlorides: synthetic and mechanistic aspects. *Journal of the American Chemical Society* **1981**, 103, 5454-5459.
113. Mullins, R. J., Gregg, J. J., Hamilton, G. A. Luche reduction. In *Name Reactions for Functional Group Transformations*, Li, J. J., Corey, E. J., Ed. John Wiley & Sons: Hoboken, **2007**, 112-122.
114. Demchenko, A. V. *Handbook of Chemical Glycosylation*. Wiley-VCH, 2008.
115. Danishefsky, S., Harvey, D. F. A new approach to polypropionates: routes to subunits of monensin and tirandamycin. *Journal of the American Chemical Society* **1985**, 107, 6647-6652.
116. Danishefsky, S. J., Larson, E., Askin, D., Kato, N. On the Scope, Mechanism, and Stereochemistry of the Lewis Acid-Catalyzed Cyclocondensation of Activated Dienes with Aldehydes - an Application to the Erythronolide Problem. *Journal of the American Chemical Society* **1985**, 107, 1246-1255.

117. Danishefsky, S. J., Deninno, S., Lartey, P. A Concise and Stereoselective Route to the Predominant Stereochemical Pattern of the Tetrahydropyranoid Antibiotics - an Application to Indanomycin. *Journal of the American Chemical Society* **1987**, 109, 2082-2089.
118. Myles, D. C., Danishefsky, S. J. The Synthesis of Polyoxygenated Natural-Products Via Fully Synthetic Branched Pyranose Derivatives - Application to the Erythronolide Problem. *Pure and Applied Chemistry* **1989**, 61, 1235-1242.
119. Krauss, I. J., Mandal, M., Danishefsky, S. J. Total synthesis of (+)-isomigrastatin. *Angewandte Chemie, International Edition* **2007**, 46, 5576-5579.
120. Yadav, J. S., Reddy, B. V. S., Reddy, K. B., and Satyanarayana, M. $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$: a novel reagent for the synthesis of 2-deoxysugars from D-glycals. *Tetrahedron Letters* **2002**, 43, 7009-7012.
121. Yadav, J. S. R., B. V. S. Bhasker, E. V., Raghavendra S., and Narsaiah, A. V. GaCl_3 -Catalyzed addition of thiols to glycals: a facile synthesis of 2-deoxy thioglycosides. *Tetrahedron Letters* **2007**, 48, 677-680.
122. Rani, S., Agarwal, A., and Vankar Y. D., $\text{LaCl}_3 \cdot 7\text{H}_2\text{O}/\text{NaI}$ /benzyl alcohol: a novel reagent system for regioselective hydration of glycals: application in the synthesis of 1,6-dideoxynojirimycin. *Tetrahedron Letters* **2003**, 44, 5001-5004.
123. Sherry, B. D., Loy, R. N., and Toste, F. D., Rhenium(V)-Catalyzed Synthesis of 2-Deoxy- α -glycosides. *Journal of the American Chemical Society* **2004**, 126, 4510-4511.
124. Costantino, V., Imperatore, C., Fattorusso, E., and Mangoni, A. A mild and easy one-pot procedure for the synthesis of 2-deoxysugars from glycals. *Tetrahedron Letters* **2000**, 41, 9177-9180.
125. Sabesan, S., Neira, S., Synthesis of 2-Deoxy Sugars from Glycals. *Journal of Organic Chemistry* **1991**, 56, 5468-5472.
126. Bolitt, V., Mioskowski, C., Lee, S. G., Falck, J. R. Direct preparation of 2-deoxy-D-glucopyranosides from glucals without Ferrier rearrangement. *Journal of Organic Chemistry* **1990**, 55, 5812-5813.
127. Lin, H.-C., Du, W.-P., Chang, C.-C., Lin, C.-H. Different reaction routes found in acid-catalyzed glycosylation of endo- and exo-glycals: competition between Ferrier rearrangement and protonation. *Tetrahedron Letters* **2005**, 46, 5071-5076.
128. McDonald, F. E., and Wu, M. Stereoselective Synthesis of l-Oliose Trisaccharide via Iterative Alkynol Cycloisomerization and Acid-Catalyzed Glycosylation. *Organic Letters* **2002**, 4, 3979-3981.
129. Kaila, N., Blumenstein, M., Bielawska, H., and Franck, R. W. Face selectivity of the protonation of glycals. *Journal of Organic Chemistry* **1992**, 57, 4576-4578.

130. Rauter, A. P., Almeida, T., Vicente, A. I., Ribeiro, V., Bordado, J. C., Marques, J. P., Ribeiro, F. R., Ferreira, M. J., Oliveira, C., and Guisnet, M. Reactions of N-, S- and O-Nucleophiles with 3,4,6-Tri-O-benzyl-D-glucal Mediated by Triphenylphosphane Hydrobromide versus Those with HY Zeolite. *European Journal of Organic Chemistry* **2006**, 2429–2439.
131. Bettelli, E., Cherubini, P. D'Andrea, P., Passacantilli, P., Piancatelli, G. Mercuration-reductive demercuration of glycals: A mild and convenient entry to 2-deoxy-sugars. *Tetrahedron* **1998**, 54, 6011-6018.
132. Passacantilli, P., Centore, C., Ciliberti, E., Leonelli, F., Piancatelli, G. A highly efficient and stereocontrolled synthesis of 2-deoxy-1,5-thioanhydro-L-hexitols from D-glycals in a tandem nucleophilic displacement reaction. *European Journal of Organic Chemistry* **2006**, 3097-3104.
133. Ciliberti, E., Galvani, R., Gramazio, F., Haddas, S., Leonelli, F., Passacantilli, P., Piancatelli, G. Glycals in organic synthesis: a systematic strategy for the preparation of uncommon piperidine 1,2-dideoxy-L-azasugars and 2-deoxy-1,5-anhydro-L-hexitols. *European Journal of Organic Chemistry* **2007**, 1463-1473.
134. Huang, H., and Panek, J. S. Total Synthesis of Callipeltoside A. *Organic Letters* **2004**, 6, 4383-4385.
135. Engers, D. W., Bassindale, M. J., and Pagenkopf, B. L. Synthesis of the C-1 - C-12 Segment of Peloruside A by an α -Benzyloxymethyl Ketone Aldol Strategy. *Organic Letters* **2004**, 6, 663-666.
136. Larock, R. C. *Solvomercuration/demercuration reactions in organic synthesis*. Springer-Verlag: Berlin, 1986.
137. Brown, H. C., Lynch, G. J. Solvomercuration-demercuration. 8. Oxymercuration-demercuration of methoxy-, hydroxy- and acetoxy-substituted alkenes. *Journal of Organic Chemistry* **1981**, 46, 531-538.
138. Barluenga, J., and Yus, M. Free Radical Reactions of Organomercurials. *Chemical Reviews* **1988**, 88, 487-509.
139. Jensen, F. R., Miller, J. J., Cristol, S. J., and Beckley, R. S. Bridged polycyclic of University of Colorado group. LXXV. Reduction of organomercurials. Stereospecific replacement of mercury by deuterium. *Journal of Organic Chemistry* **1972**, 37, 4341-4349.
140. Nishimura, S. *Handbook of Heterogenous Catalytic Hydrogenation for Organic Synthesis*. John Wiley & Sons: New York, 2001.
141. Evans, D. A., Dart, M. J., Duffy, J. L., Yang, M. G. A Stereochemical Model for Merged 1,2- and 1,3-Asymmetric Induction in Diastereoselective Mukaiyama Aldol

Addition Reactions and Related Processes. *Journal of the American Chemical Society* **1996**, 118, 4322-4343.

142. Chen, D. Y.-K., Ph. D. Thesis. University of Cambridge, Cambridge, U.K., 2002.
143. Still, W. C., Kahn, M., and Mitra, A. Rapid chromatographic technique for preparative separations with moderate resolution. *Journal of Organic Chemistry* **1978**, 43, 2923-2925.
144. Reynolds, W. F., and Enríquez, R. G. Choosing the Best Pulse Sequences, Acquisition Parameters, Postacquisition Processing Strategies, and Probes for Natural Product Structure Elucidation by NMR Spectroscopy. *Journal of Natural Products* **2002**, 65, 221-244.
145. Frigerio, M., Santagostino, M., and Sputore, S. A User-Friendly Entry to 2-Iodoxybenzoic Acid (IBX). *Journal of Organic Chemistry* **1999**, 64, 4537-4538.
146. Mozingo, R. Catalyst, Raney nickel *Organic Syntheses* **1941**, 21, 15-17.
147. Halgren, T. A. Merck molecular force field.1. Basis, form, scope, parameterization, and performance of MMFF94 *Journal of Computational Chemistry* **1996**, 17, 490-519.
148. *Batchmin v9.6, Jaguar v7.5*, Schrödinger Inc.: New York, 2007.
149. Gill, P. M. W., Johnson, B. G., Pople, J. A., Frisch, M. The Performance of the Beckle-Lee-Yand-Parr (B-LYP) Density Functional Theory With Various Basis-Sets. *Chemical Physics Letters* **1992**, 197, 499-505.
150. Krishnan, R., Binkley, J. S., Seeger, R., Pople, J. A. Self-Consistent Molecular-Orbital Methods. 20. Basis Set For Correlated Wave-Functions *Journal of Chemical Physics* **1980**, 72, 650-654.
151. Clark, T., Chandrasekhar, J., Schleyer, P. V. R. Efficient Diffuse Function-Augmented Basis-Sets For Anion Calculations. 3. The 3-21+G Basis Set For 1st-Row Elements, Li-F *Journal of Computational Chemistry* **1983**, 4, 294-301.
152. Becke, A. D. Density-Functional Thermochemistry. 3. The Role of Exact Exchange *Journal of Chemical Physics* **1993**, 98, 5648-5652.